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Abstract  
 
Glutathione peroxidase (GPx) and superoxide dismutase (SOD) are among the primary 
antioxidant enzymes that scavenge reactive oxygen species in the blood (ROS), thereby 
protecting against high levels of oxidative stress.  The consequences of oxidative stress 
include cellular injury and tissue damage.  High levels of oxidative stress have been 
implicated in the pathogenesis of acute coronary syndromes (ACS), however large 
clinical trials involving dietary antioxidant supplements have not shown a reduction in 
the rate of major adverse cardiovascular events (MACE). 
 
In a cohort of 262 ACS patients we examined the relationship between GPx activity, SOD 
activity and MACE.  Patients with MACE were found to have significantly lower levels of 
GPx activity than those without MACE, whereas SOD activity did not differ between the 
groups.  Furthermore, dividing the patients into quartiles corresponding to levels of GPx 
activity demonstrated significantly higher rates of MACE in the lower quartile of GPx 
activity compared to the highest quartile. 
 
Previous studies have demonstrated that deficiencies in GPx activity are associated with 
vascular dysfunction and platelet-dependent thrombosis, leading to the hypothesis that 
low levels of GPx activity would be associated with increased levels of platelet reactivity.  
In 51 ACS patients we did not observe a significant relationship between these two 
parameters, however we did demonstrate that increasing levels of GPx activity was 
associated with lower levels of ROS.  ROS measures were based on the response of the 
platelets to addition of exogenous nitric oxide.  Such an inverse relationship between 
GPx activity and levels of ROS is consistent with the view that GPx activity may play an 
important role in an ACS by reducing ROS-mediated damage, thereby protecting against 
MACE. 
 
We examined levels of GPx activity, protein concentration and mRNA expression across 
populations of ACS patients, stable coronary disease patients and healthy subjects.  
Cardiovascular risk factors thought to influence levels of GPx activity were controlled for 
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in all three cohorts.  These studies demonstrated that GPx activity, protein and mRNA 
levels were significantly elevated in the ACS patients compared to the stable coronary 
disease patients and healthy subjects.  Oxidised low-density lipoprotein (oxLDL), a 
widely used marker of oxidative stress, was also significantly elevated in the ACS 
patients compared to the other two cohorts. 
 
In a study examining the temporal changes in GPx activity in the acute phase of an ACS, 
GPx activity was found to be highly dynamic, with no consistent single time point that 
identified when peak activity occurred.  In the majority of patients, levels of oxLDL were 
found to peak prior to, or at the same time, as peak GPx activity, suggesting that GPx 
activity was modulated by changes in oxidative stress. 
 
In conclusion, the elevated levels of GPx activity observed in ACS patients were found to 
be highly dynamic throughout an ACS event.  However those with lower levels of GPx 
activity have an increased risk of adverse clinical outcomes that may be due to an 
inadequate defence against levels of ROS.  Whether these patients can be accurately 
identified and targeted with an appropriate therapeutic intervention warrants further 
investigation.  
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Chapter 1 - Introduction 
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1.1 Oxidative stress overview 
Reactive oxygen species (ROS) are some of the most important free radicals in biological 
systems.  As derivatives of oxygen, they are normal by-products of the oxidative 
respiration process, and under normal circumstances physiological levels are necessary 
for cell signalling and growth, which are essential to almost all the body’s processes [1, 
2].  ROS are highly reactive and include free radicals containing one or more unpaired 
electrons, such as the superoxide radical (O2-) and the hydroxyl radical (-OH), as well as 
non-radical molecules such as hydrogen peroxide (H2O2) [3].  Primary sources of ROS in 
the vascular wall include the enzymatic systems of the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases, xanthine oxidases, enzymes of the 
mitochondrial respiratory chain, and an uncoupled endothelial nitric oxide synthase 
(eNOS) [4, 5].   
 
Under normal circumstances the physiological levels of intracellular ROS are maintained 
by various antioxidant systems participating in the in vivo redox homeostasis.  As 
humans, we produce endogenous antioxidants, and consume exogenous dietary 
antioxidants, that work to maintain homeostasis.  Endogenous antioxidants consist of 
enzymatic e.g glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase 
(CAT) and non-enzymatic (e.g. glutathione) compounds.  Dietary antioxidants include 
vitamin E (tocopherols), vitamin C (ascorbic acid), and vitamin A (β-carotene) among 
others.  Antioxidants function by slowing or preventing the oxidation of other molecules 
by either removing free radical intermediates or inhibiting other oxidation reactions by 
being oxidised themselves [6].   
 
Oxidative stress occurs when the homeostatic processes fail and ROS production 
exceeds the capacity of the antioxidant defence system, thus promoting cellular injury 
and tissue damage (Figure 1-1) [7].  Oxidative damage to DNA and protein content of 
cells, as well as lipid peroxidation of cellular membranes, calcium influx and 
mitochondrial swelling and lysis can all occur as a result of increased levels of ROS [8].  
This disturbance in homeostasis has been implicated in the pathogenesis of various 
human diseases including those of the cardiovascular system.  In particular, one disease 
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widely purported to be associated with elevated oxidative stress is atherosclerotic 
cardiovascular disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1 Schematic representation of in vivo redox homeostasis. 
ROS levels are maintained by enzymatic and non-enzymatic antioxidants for 
homeostatic processes.  ROS occurs from several different sources, and in oxidative 
stress conditions, the balance tips towards high levels of ROS, overwhelming the 
antioxidant defence system.  This can lead to detrimental effects implicated in the 
pathogenesis of various disease states.  GPx-glutathione peroxidase; SOD-superoxide 
dismutase; CAT-catalase.  Figure modified from Tsutsui et al. 2011 with permission from 
The American Physiological Society [9]. 
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1.2 Atherosclerosis 
1.2.1 Burden of coronary artery disease 
In New Zealand, Ministry of Health statistics show that cardiovascular disease (CVD) is 
the leading cause of death, accounting for 30% of all deaths annually [10].  Ischaemic 
heart disease, also known as coronary artery disease (CAD), is responsible for over 6000 
(22%) of these deaths [11].  A high mortality and economic burden still exists despite 
the development of effective treatment strategies and improvements in both medical 
and invasive therapies [12-14].  Following initial presentation, these patients have an 
increased risk of repeat CVD events such as heart failure, stroke, myocardial infarction 
(MI) and death [15, 16]. 
1.2.2 Pathophysiology of coronary artery disease 
Atherosclerosis is the underlying pathophysiology of CAD in the majority of cases [17].  
Coronary atherosclerotic lesions are characterised by the adaptive intimal thickening of 
the artery as a result of the accumulation of lipids, immune cells, connective tissue 
elements and endothelial and smooth muscle cells [18].  Simple lesions, known as fatty 
streaks, can develop in childhood and adolescence [19], with the influence of a 
combination of genetic and environmental factors responsible for the progression of 
coronary atherosclerosis throughout adulthood [20].  These fatty streaks are subclinical, 
however the evolution to complex vulnerable plaques can manifest into clinical events 
such as MI or stroke [21]. 
1.2.2.1 Progression of the atherosclerotic lesion 
The evolution of the fatty streak to a complex vulnerable plaque is depicted in Figure 1-
2.  The atherosclerotic lesion results from a complex interplay between circulating 
factors and various cell types in the vessel wall that create plaque which gradually 
impinges on the vessel lumen and impedes blood flow [3].  The atherosclerotic lesion 
core is formed through cholesterol deposits in macrophages creating a lipid-laden 
environment that attracts inflammatory and immunogenic cells.  The subsequent 
disruption to the endothelium leads to the proliferation of vascular smooth muscle cells 
(VSMC) and increased collagen production that creates the fibrous cap that separates 
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the necrotic core from the circulation [18, 22].  The thick fibrous cap formed by the 
collagen-producing VSMC keeps the lesion structurally stable.  The pro-inflammatory 
and pro-atherogenic environment surrounding the plaque promotes the release of 
cytokines and increases ROS generation, inducing the apoptotic death of VSMCs and 
stimulating the release of matrix-degrading enzymes that diminish the integrity of the 
fibrous cap [3].  Combined with the mechanical force of blood flow, plaque rupture can 
occur, exposing the core and activating platelet adhesion, thrombosis and vasospasm, 
manifesting into clinical coronary events such as an MI [23].  
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Figure 1-2 Progression of the atherosclerotic plaque. 
Diagrammatic depiction of the sequence involved in the progression of atherosclerosis.  
Development of the lesion is shown along with the main histology findings associated 
with the onset of each stage according to earliest onset (patients’ age), main growth 
mechanism and clinical manifestation.  Increased endothelial dysfunction and lesion 
complexity are other factors associated with the progression of the atherosclerosis (not 
shown).  Image reproduced with permission from Creative Commons Attribution-Share 
Alike 3.0 Unported. 
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1.2.3 Acute coronary syndromes 
An acute coronary syndrome (ACS) is an unstable and potentially life-threating 
presentation of CAD [24].  The presence of an atherosclerotic lesion may obstruct blood 
flow and cause symptoms of angina pectoris, but rarely does this alone cause a fatal 
clinical event.  Often ACS events are not accompanied by the preceding angina 
symptoms indicative of a high-grade stenosis.  Manifestation of ischemia and infarction 
is the activation of vulnerable plaques, and ACS is nearly always caused by the formation 
of an occluding thrombus on the culprit atherosclerotic plaque [23, 25].  Thrombosis on 
the surface of a plaque occurs due to plaque rupture – identifiable in 60-70% of cases - 
and less commonly, plaque erosion [26].  Vulnerable plaques susceptible to rupturing 
are often those with a thin fibrous cap that tear, exposing the lipid core to arterial blood 
flow.  The core area is highly thrombogenic, containing tissue factor (a potent pro-
coagulant found in the core), collagen fragments and crystalline surfaces to accelerate 
coagulation.  The thrombus initially forms in the plaque, distorting and expanding from 
within, and may extend into the arterial lumen [27].  The fibrous cap allows a barrier 
between the immuno- and thrombogenic rich lesion core and the coagulation factors 
found in the blood.  The collagen-producing smooth muscle cells provide the tensile 
strength of the cap.  The production of proteinases caused by the enhanced 
inflammatory environment local to the plaque breaks down collagen and inhibits 
replenishment from the VSMC.  These enzymes belong to the matrix-metalloproteinase 
(MMP) family, with 3 of the human isoforms over-produced by macrophages in 
atherosclerotic plaques [28].  Rupture of the fibrous cap allows blood to come into 
contact with the necrotic core, allowing the action of tissue factor to cause thrombin 
generation and platelet activation and aggregation [29].    
 
Autopsy studies show that the majority of deaths are caused by plaque rupture, with 
superficial plaque erosion accounting for 20-25% of fatal ACS cases [30, 31].  The 
mechanisms of plaque erosion have received much less attention and are less 
understood than those involved in plaque rupture.  Apoptosis of the endothelial cells, 
induced by oxidative stress mechanisms, could contribute to desquamation and the 
production of tissue factor [32].  Endothelial cell death and tissue factor production 
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could propagate local thrombosis in the coronary arteries.  From the growing body of 
evidence, it is now undisputed that plaque rupture or erosion in isolation is not enough 
to cause coronary events [33].  Indeed, rupture and erosion occur frequently, with 
subclinical symptoms, and are key factors in plaque progression, remodelling and 
subsequent luminal narrowing [30, 34].  Instead, it is not only the exposure of the plaque 
core to the blood, but the combination of other factors such as thrombogenicity of the 
plaque material, local flow dynamics and systemic thrombotic predisposition that lead 
to a perfect storm scenario resulting in ischemia and infarction [23].    
1.2.3.1 Clinical treatment of ACS 
ACS encompasses a spectrum of clinical conditions ranging from undifferentiated chest 
pain to unstable angina to non-ST-segment elevation myocardial infarction (NSTEMI) to 
ST-segment elevation myocardial infarction (STEMI) (Figure 1-3).  The severity of 
myocardial ischaemia increases from UA through to STEMI, dictating the degree of injury 
to the myocardial cells.  The subendocardial region is the first to be affected since this 
layer of the heart is farthest from the blood supply [35].  Injury to this area manifests 
itself on an electrocardiogram (ECG) as ST-segment depression and/or T-wave 
abnormalities (UA or NSTEMI) [13, 36].  Transmural injury manifests itself on an ECG as 
ST-segment elevation, and is generally considered to be a more severe event due to the 
larger area of infarction occurring (STEMI) [37, 38].  Management and treatment 
according to this spectrum dictates the appropriate treatment and allows for the best 
possible outcomes.  The main goal is to reduce the amount of myocardial necrosis thus 
preserving left ventricular function.  This allows for the prevention and management of 
major adverse cardiac events such as ventricular fibrillation, decompensated heart 
failure and cardiogenic shock [39].  Reperfusion therapy to restore coronary blood flow 
to the ischemic myocardium is the primary objective for ACS treatment to limit infarct 
size.  Percutaneous coronary intervention (PCI) with stents and balloons is the treatment 
of choice and can restore coronary artery flow in >90% of patients under optimal 
circumstances.  STEMI patients are advised to undergo PCI by a skilled provider in a well-
equipped facility within 90 minutes of presenting to hospital, with fibronolytic therapy 
recommended if this time frame cannot be achieved.  Adjunct therapies to manage both 
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the acute phase and chronic disease include: oxygen, nitroglycerin, analegesia, 
antiplatelet agents, hypertensive medications, anticoagulation and statin therapy [39]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 Spectrum of Acute Coronary Syndromes (ACS). 
Schematic table describing the clinical manifestation of ACS with arrows depicting the 
increase in the clinical severity of the ACS spectrum from UA to STEMI.  Adapted from 
Boateng et al. [40] with permission from Elsiever. 
 
 
 
 
Unstable angina (UA) Non-ST segment Elevation 
Myocardial Infarction (NSTEMI) 
ST segment Elevation 
Myocardial Infarction (STEMI) 
Angina pain with at 
least one of the 
following features: 
• Is of new 
onset and 
severe 
• Occurs at rest 
or with 
minimal 
exertion 
• Pain is 
worsening in 
the severity 
and length of 
each episode 
(crescendo 
angina) 
• New ischemic 
ST segment 
changes not 
including ST 
elevation 
Characterised by 
clinical features of 
unstable angina in 
addition to elevated 
cardiac markers:  
Troponin & CKMB.  
Cardiac markers are 
elevated as a result of 
myocardial necrosis. 
Characterised by clinical 
features of myocardial 
infarction in addition to ST-
segment elevation on a 12-
lead ECG 
 
 
10 
1.3 Oxidative stress in atherogenesis and thrombosis 
Atherogenesis is a complex, multifactorial process.  Several factors, such as 
dyslipidaemia, hypertension, diabetes, obesity, cigarette smoking and aging are 
established risk factors for CAD, with evidence that they are associated with high levels 
of oxidative stress [41]. As no single genetic marker or test accurately predicts 
cardiovascular death, research into the role of oxidative stress has highlighted its 
importance as a unifying mechanism across many vascular diseases [42].  ROS mediate 
various signalling pathways that underlie vascular inflammation in atherogenesis, from 
the initiation of fatty streak development through lesion progression to ultimate plaque 
rupture.  Animal and human studies corroborate on the oxidative stress hypothesis of 
atherosclerosis. A summary of these studies are described in the following section. 
 
1.3.1 The “oxidative modification hypothesis” of atherosclerosis     
A general consensus exists that atherosclerosis represents a heightened state of 
oxidative stress, that can be characterised by lipid and protein oxidation in the vascular 
wall [3].  The ability of low-density lipoproteins (LDL) to transverse the subendothelial 
space of the arterial wall via binding to proteoglycans, and subsequently undergoing 
oxidation, forms the basis of the “oxidative modification hypothesis” of atherosclerosis 
first described by Steinberg et al. [43].  Recruitment of macrophages and their 
subsequent uptake of cholesterol in the form of oxidised LDL (oxLDL) are the main 
cellular events driving the formation of fatty streaks in the arterial endothelium.  The 
formation of oxLDL renders it susceptible to macrophage uptake via the scavenger 
receptor pathway, transforming them into foam cells [44].  Foam cells are cytotoxic and 
promote the loss of endothelial integrity, a hallmark of atherosclerotic lesion formation.  
This concept is supported by considerable experimental evidence, demonstrated in 
multiple animal models, in which there is a defect in the scavenger receptor that 
protects against atherosclerosis, and results in a lower burden of disease [45, 46].  The 
oxidation process of LDL has a number of other pro-atherogenic properties, including 
the activation and recruitment of monocytes [47] and inflammatory/immune cells [48] 
into the arterial wall which sets the stage for the catalytic expansion of the 
atherosclerotic lesion and the full-blown spectrum of atherosclerosis [49].  OxLDL has 
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several biological effects: it is pro-inflammatory, it causes inhibition of endothelial nitric 
oxide synthase (eNOS), it promotes vasoconstriction and adhesion, it stimulates 
cytokines such as interleukin-1 and it increases platelet aggregation.  A schematic 
representation of the oxidative modification hypothesis is shown in Figure 1-4.   
 
The ability of LDL to transit the subendothelial space and arrive back into the circulation 
means that a certain fraction exhibits an enhanced oxidised lipid content [50], and 
human plasma has been found to contain immunoreactivity towards epitopes 
generated from oxLDL [51].  However, the existence of oxLDL in the circulation has been 
controversial on the basis of potential artifacts that may occur during the ex vivo 
handling of plasma [52].  Nevertheless, several studies have shown that circulating levels 
of oxLDL epitopes can be used to distinguish between patients with and without evident 
atherosclerosis [53, 54], with increased circulating levels being associated with ACS [55].  
No causal relation between oxLDL and atherosclerosis has been identified in the 
literature, and it remains unclear whether oxLDL levels are implicated in determining 
disease burden [52].     
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Figure 1-4 Oxidative modification hypothesis of atherosclerosis. 
LDL is protected from oxidative modification in systemic circulation by the abundant 
endogenous circulating antioxidants.  Once LDL passes into the subendothelial space 
and subsequently oxidised by reactive oxygen species (ROS) forming oxidised LDL 
(oxLDL).  OxLDL is a chemoattractant to circulating monocytes and is transcytosed by 
them via scavenger receptor pathways, leading to formation of foam cells.  
Accumulation of foam cells and subsequent vascular smooth muscle cell (VSMC) 
proliferation is the hallmark of atherogenesis.  The chain of events is amplified via a 
feed-forward mechanism, as oxLDL contributes to endothelial dysfunction, promoting 
further ROS formation via eNOS uncoupling and increased NADPH oxidase activity.  
Figure modified from Lee et al. 2012 Unported [56] with permission from Creative 
Commons Attribution-Share Alike 3.0 Unported. 
 
Other abbreviations in the figure: EC – endothelial cells; eNOS – endothelial nitric oxide 
synthase; NADPH – nicotinamide adenine dinucleotide phosphate.   
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1.3.2 Production of reactive oxygen species 
Oxidative modifications in the vessel wall are caused by several radical and non-radical 
oxidants, collectively called ROS.  Free radicals can be defined as any molecule capable 
of independent existence that contains one or more unpaired electrons [57].  In 
biological systems, a variety of free radicals exist, and, if two radicals meet, they can join 
their unpaired electrons, which lead to non-radical products.  ROS are a particularly 
destructive aspect of oxidative stress, and excess generation of ROS causes damage to 
proteins, lipids and DNA [41].  Consequences of this damage are associated with the 
pathological state of atherosclerosis, characterised by vascular remodelling, reperfusion 
injury, endothelial dysfunction, and plaque rupture [58].  Oxygen is the most abundant 
molecule in biological systems and can subsequently undergo enzymatic and non-
enzymatic reduction to form the superoxide anion (O2-).  An example of the detrimental 
effect this has in the vessel wall, is the fast reaction between superoxide anions with 
nitric oxide (NO) to form peroxynitrite (ONOO-), a compound that promotes endothelial 
dysfunction and VSMC growth [59].  Similarly superoxide anions have the ability to form 
hydrogen peroxide (H2O2), arguably the most abundant non-radical species found in the 
vasculature.  A chain of radical reactions produces highly reactive hydroxyl radicals 
capable of oxidative destruction of biomolecules.  Lipid oxidation initiated by ROS 
molecules to generate lipid hydroperoxides (LOOH) is also a frequent occurrence in the 
vasculature [59], and is intricately linked to the pathophysiological relevance of 
atherosclerosis. 
 
Under physiological conditions ROS can be generated in vivo by the NADPH oxidases, 
xanthine oxidase (XO), mitochondrial respiratory chain and nitric oxide synthases (NOS).  
A brief summary of the implications of dysregulation of these ROS sources on 
atherogenesis can be found below. 
 
1.3.2.1 NADPH oxidases 
NADPH oxidases are major sources of ROS in the vasculature, producing O2- from 
molecular oxygen using NADPH as the electron donor.  An upregulation of NADPH 
oxidase subunits has been associated with the development of human CAD [60].  ROS 
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production from the p22phox subunit of NADPH oxidise has been reported to mediate 
the formation of oxLDL in atherosclerotic coronary arteries [61], supporting the notion 
that ROS plays a role in the pathogenesis of CAD.  
1.3.2.2 Xanthine oxidase 
XO donates electrons to molecular oxygen, producing O2- and H2O2, making it another 
primary source of O2- in atherosclerotic coronary arteries, alongside the NADPH oxidases 
[60].  Activity of XO is increased in human plaque [62], supporting the contribution of 
XO-derived ROS in the pathogenesis of CAD.   
1.3.2.3 Mitochondria respiratory chain 
Continuous ROS production occurs as a result of the electron transport chain (ETC) 
located in the mitochondrial membrane and is essential for energy production inside the 
cell [63].  The ETC is of central importance to atherogenesis.  Dysfunctional 
mitochondrial ROS production has been linked to early atherosclerotic lesion 
development [64], and the site where electrons enter the ETC is reported to be critically 
involved in the oxidative burst observed during ischemia/reperfusion damage [65]. 
1.3.2.4 Nitric oxide synthases 
Under physiological conditions, endothelial NOS (eNOS) is responsible for the 
production of NO that has an important vasoprotective function in the endothelium 
[66].  The uncoupling of eNOS (i.e uncoupling of O2 reduction from NO synthesis) under 
pathological conditions associated with oxidative stress can render it dysfunctional such 
that it no longer produces NO, but produces superoxide instead.   The result is significant 
endothelial dysfunction that plays an important role in the progression of CAD [67].  
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1.4 The antioxidant defence system 
The vascular wall contains a variety of enzymes that can reduce the oxidative stress 
burden by acting as antioxidant defence systems.  The classic antioxidant enzymes are 
both cell-associated and found in the extracellular matrix, whose function is to maintain 
the redox potential.  Endogenous antioxidant systems protect against atherogenesis by 
virtue of their ability to scavenge ROS, facilitate endothelium-dependent vasorelaxation, 
inhibit inflammatory cell adhesion to endothelium, and alter vascular cellular responses, 
such as VSMC and endothelial cell apoptosis, VSMC proliferation, hypertrophy, and 
migration [68].  Enzymatic antioxidants principally include GPx, glutathione reductase 
and transferases, SOD, CAT and peroxiredoxins, with many of these antioxidants present 
in normal arteries.  Non-enzymatic antioxidants are another of the body’s defence 
systems against oxidative stress.  These are generally found in the forms of the 
antioxidant vitamins ascorbic acid (vitamin C), α-tocopherol (the principal constituent of 
vitamin E), and β-carotene (pro-vitamin A). Compared with the in-depth knowledge of 
lipid changes in atherosclerosis, little is known of the accompanying changes to vascular 
wall antioxidants.  Systematic studies on antioxidant changes at the various stages of 
CAD are not readily available.  It is worth noting that the interpretation of changes to 
antioxidant defences is complicated because the same material is not normally analysed 
for the presence of oxidised biomolecules and oxidative tissue damage.  For example, 
an increase in antioxidant defence is commonly interpreted as a biological response to 
increased oxidative stress without the knowledge of whether this is associated with an 
overall decrease or increase in oxidative tissue damage.  A brief summary of the 
common enzymatic and non-enzymatic antioxidant systems and their association with 
atherogenesis can be found below.  
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1.4.1 Enzymatic antioxidants 
1.4.1.1 Glutathione peroxidase  
GPxs are a family selenocysteine (Sec)-containing antioxidant enzymes that use 
glutathione (GSH) as an obligate co-substrate in the reduction of H2O2 to water (H2O): 
 
H2O2 + 2GSH    2H2O + GSSG 
 
Not all GPxs (defined by homology), use GSH, nor do they all contain Sec at the catalytic 
site.  Some of these enzymes are functionally identified as thioredoxin-dependent 
peroxidases containing a redox-active Cys in place of the Sec.  There is a growing body 
of evidence that GPx enzymes play an important role in protecting against 
atherosclerosis.  Mice deficient in GPx1 and GPx3 show anomalies in cardiac structure 
and function [69] and an increased pro-thrombotic state with vascular dysfunction [70].  
Selected clinical studies suggest GPx is protective against adverse cardiovascular events 
[71] and deficiencies in this enzyme are associated with arterial thrombosis in human 
subjects [72]. More detail on the individual GPxs and their respective characteristics and 
role in CAD can be found in Section 1.7. 
1.4.1.2 Superoxide dismutase  
Three isoforms of SOD exist in mammals.  Copper-zinc SOD (Cu-Zn-SOD, SOD1) is a 
soluble enzyme localised to the cytosol. Mitochondrial SOD (Mn-SOD, SOD2) is 
expressed in the mitochondrial matrix and extracellular SOD (EC-SOD, SOD3) is found in 
the extracellular space.  All three isoforms catalyse the dismutation of superoxide into 
oxygen and H2O2, thereby serving an important antioxidant function.   
 
2O2-+ 2H+    H2O2 +O2 
 
SOD3 is abundantly present in the vascular wall and is synthesised in atherosclerotic 
lesions by smooth muscle cells and macrophages [73].  Thus, in the vessel wall, SOD3 
expression may play a critical role in regulating the vascular redox state by preventing 
deleterious effects of superoxide and superoxide-mediated inactivation of NO.  
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However the functional significance of SOD3 activity in the development of 
atherosclerosis is still unclear.  Murine models show that SOD3 expression and activity 
is markedly increased in macrophage-rich atherosclerotic lesions [74], and that SOD 
inhibition increases lipid peroxidation [75], indicating a potential protective role.  
However, overexpression of SOD increases, rather than decrease, lesion formation [76].  
Studies carried out in a mouse model of atherosclerosis (apolipoprotein E knock-out 
mice) have demonstrated that a genetic deletion of SOD3 paradoxically causes a slight 
reduction in atherosclerotic lesions after a 1-month atherogenic diet, while having no 
effect after 3 months on the atherogenic diet, or after 8 months on a standard diet [77].  
Human studies have not been any more conclusive, with a large study conducted by 
Blankenberg et al. in 643 CAD patients showing no significant association with SOD 
activity and CAD progression [71].   
1.4.1.3 Catalase  
CAT functions by metabolising H2O2 produced from the dismutation of O2-.  It directly 
decomposes H2O2 to water and molecular oxygen: 
 
2H2O2    2H2O  + O2 
 
Overexpression of CAT reduces the vascular cell response to oxidised lipids [78, 79] and 
retards atherosclerosis in apoE-KO mice [80].  However a study in humans has shown 
that vascular and endothelial cells lack CAT activity [81], suggesting that CAT isn’t the 
most important antioxidant shield in atherosclerotic plaque in humans. 
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1.4.2 Non-enzymatic antioxidants  
1.4.2.1 Vitamin A 
Collectively, the three active forms of the fat-soluble vitamin A are called retinoids, with 
the most important one being β-carotene which has high antioxidant properties [82, 
83].  It plays a key role in quenching free radical reactions, particularly those involved in 
singlet oxygen species.  This prevents lipid peroxidation and potential oxidative damage 
to DNA, both key determinants in the atherosclerotic process.  β-carotene has been 
studied extensively in large clinical trials for its antioxidant effect in prevention of 
atherosclerosis [84].  For an in-depth review refer to Section 1.6. 
1.4.2.2 Vitamin C 
Vitamin C is a water-soluble substance, with ascorbic acid being one of the two 
biologically active forms.  Ascorbate’s biological role is related to its reducing capability, 
in which it is readily oxidised to dehydroascorbate.  As a hydrogen donor, vitamin C can 
inactivate free radicals before they exert damaging effects on lipids or proteins [85].  
Vitamin C has been used as an antioxidant agent in large clinical trials to determine its 
effect on atherosclerosis [86]. For an in-depth review refer to Section 1.6. 
1.4.2.3 Vitamin E 
Vitamin E plays an important protective role against free radical damage by being a 
hydrogen donor, preventing the oxidation of other molecules.  Importantly it prevents 
the oxidation of polyunsaturated fats in cell membranes.  When fatty acids are 
damaged, lipid peroxides are produced which can alter the function of cell membranes 
and causes damage to metabolic pathways [85].  It also has the ability to enhance the 
bioactivity of NO, inhibit smooth muscle proliferation and limit platelet aggregation [3].  
The form that accounts for 90% of the vitamin activity in tissues is α-tocopherol, and has 
been studied in large clinical trials for its antioxidant effect in prevention of 
atherosclerosis [84].  For an in-depth review refer to Section 1.6.  
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1.5 The antioxidant paradox 
There is an undeniable wealth of data demonstrating that atherosclerosis and 
subsequent cardiovascular events are associated with a number of oxidative events 
ranging from LDL oxidation to the production of ROS.  Increased levels of oxidative stress 
biomarkers have been shown to predict CVD diseases [87-89]; therefore targeting this 
system has been an obvious focus of investigation.  The ‘antioxidant paradox’ refers to 
the observation that despite this knowledge about oxidative stress being involved in 
CVD, giving large doses of dietary antioxidant supplements to human subjects to prevent 
or limit atherosclerosis and its clinical events, has, in most cases, demonstrated little or 
no therapeutic effect [90].  There remains today no consensus that antioxidant 
supplementation of patients at risk of, or suffering from, atherosclerosis is able to 
prevent or ameliorate the disease process.   
 
However, with the abundant pathophysiological, epidemiologic, and mechanistic data 
that support the value of antioxidant therapies, it is critical to evaluate both the 
information supporting the need for antioxidants, as well as examine the clinical trials 
to understand why they have not demonstrated the expected results.  This will allow for 
new research questions to be raised and strategies to be developed that could target 
potential biomarkers to help explain the antioxidant paradox.   
 
1.6 Antioxidant Clinical Trials 
1.6.1 Prospective cohort studies: 
Epidemiological and population studies have demonstrated that consumption of a diet 
rich in antioxidants is associated with a reduced mortality by CVD [91], and that plasma 
antioxidant levels reflect this benefit [92, 93].  A number of other observational studies 
that employed long-term follow-up evaluation on >100,000 individuals also support the 
observation that high levels of dietary antioxidants are cardioprotective.  In the Health 
Professionals Follow-Up Study involving 40,000 males with a 4-year follow-up, an 
inverse relationship was observed between vitamin A and vitamin E intake and risk of 
CAD [94].  Similarly, in the Nurse’s Health Study involving 87,000 female nurses with an 
8-year follow-up, vitamin E dietary supplements were found to beneficial in reducing 
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the risk of CAD [95].  Results from observational studies are not always so clear-cut; 
another population study of 35,000 postmenopausal women showed a significant 
reduction in CVD risk with an increase in dietary, but not supplemental vitamin E [96].  
In yet another study, the Scottish Heart Health Study, intake of dietary vitamin E was 
recorded in 8,000 men and women who were followed for 9 years found that higher 
levels of vitamin E intake had no benefit for lowering CAD risk.  However there was an 
inverse association between levels of vitamin A and vitamin C and risk of CAD in men 
but not women [97].  This is in contrast to the study that reported a similar inverse 
relationship with vitamin A and C with CAD risk, only it was in their woman’s group 
compared to their men [98]. 
 
With the data from the observational studies suggesting individuals who increase their 
levels of antioxidants via diet or supplements may benefit from a decreased risk of CVD, 
large-scale randomised controlled trials were carried out to determine whether the 
disease could be modulated via antioxidant therapy.  However when investigating the 
benefits of antioxidants used, such as vitamin E, C and β-carotene, the evidence for 
linking supplementation to prevent or reduce CVD is inconsistent. A discussion of the 
clinical trials can be found below, with a summary in Table 1-1 located at the end of 
Section 1.6.4. 
 
1.6.2 Randomized controlled studies: primary preventions 
A wide range of prospective studies have been undertaken that compare antioxidant 
treatment with placebo for the prevention of CVD.  Where the primary aim was 
prevention of CVD, the major clinical trials reported no significant benefit of vitamin E 
on the traditional end-points (MI, CVD and stroke).  Two such examples of these trials 
are the Finnish Alpha-Tocopherol Beta Carotene Cancer Prevention Study (ATBC) [99] 
and the Collaborative Primary Prevention Project (PPP) [100], with study populations of 
29,000 and 4,500 respectively.  Risk factors were reported for all subjects and these 
trials used a low-dose and high-dose vitamin E vs placebo regimen.  The ATBC reported 
no benefit on the prevalence of fatal or nonfatal MI, but a small, yet significant, increase 
in haemorrhagic stroke was observed.  The importance of this is yet to be determined, 
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as this correlation was not seen in several secondary prevention studies (Section 1.6.3).  
The PPP study similarly showed no effect on cardiovascular deaths by vitamin E, 
although this study was halted early as it confirmed a protective effect by aspirin that 
was considered the primary study end-point.  In addition to the traditional clinical end 
points, other studies have used carotid intima-to-media thickness as a marker of on-
going atherosclerotic disease, although a limitation of this parameter must be noted, in 
that it only correlates weakly when disease is measured by angiography [101].  Studies 
that used this measure reported no decrease by vitamin E or vitamin C supplementation 
after a follow-up of 3 years [86], although one study reported a borderline disease-
promoting effect from α-tocopherol supplements [102].  The conclusions from these 
studies were that vitamin E supplements failed to slow or inhibit the progression of 
intima-to-media thickness in healthy men and women at low risk for CVD.   
 
1.6.3 Randomised controlled studies: secondary preventions 
In the studies that investigate the effect of vitamin E supplementation in patients with 
pre-existing cardiovascular disease, there are two studies that appear to show 
favourable results.  In the Cambridge Heart Antioxidant Study (CHAOS), vitamin E 
supplementation was observed to decrease the risk of nonfatal acute MI (AMI), however 
they did report a non-significant small increase in total mortality in the treatment group 
[103].  Similarly, in a smaller study, the Secondary Prevention with Antioxidants of 
Cardiovascular Disease in Endstage renal disease (SPACE), reported that in 
haemodialysis patients, vitamin E supplementation resulted in a significant decrease in 
AMI [104].  This raises the question of whether vitamin E supplementation will only show 
a benefit in some populations, for example those with renal failure who may 
demonstrate increased oxidative stress, or those with a certain level of chronic coronary 
disease.  Both these studies had a relatively short follow-up of 1.4 years.  The positive 
results reported from these two studies are inconsistent with other studies that report 
no significant benefit with vitamin E supplementation.  In the sub-group of the ATBC 
trial, no benefit was reported in cardiovascular events of this secondary prevention 
study [105].  Similarly, in the large GISSI Prevenzione trial in which 11,000 patients with 
a recent history of MI were given vitamin E supplementation for 3 years, no decrease 
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was found in cardiovascular death, nonfatal MI or stroke [106].  The large Heart 
Outcomes Prevention Evaluation (HOPE) study investigated patients with CVD and 
diabetes and another risk factor, and showed no benefit with vitamin E supplementation 
[107, 108], which is at odds with the CHAOS study despite similar supplementation 
regimes and a longer follow up (4.5yr vs 1.4yr respectively).   
 
1.6.4 Vitamin E in combination with other antioxidants 
Vitamin E has also been studied in combination with other antioxidants for its effect on 
cardiovascular health in both primary and secondary prevention trials.  The ASAP study 
looked at the effect of vitamin E combined with vitamin C and reported that it 
significantly reduced the intima-to-media progression rates in men [86].  THE ATBC 
study reported no significant benefit on coronary events when vitamin E and β-carotene 
were supplemented in men as a secondary prevention strategy [105].  The large Heart 
Protection Study (HPS) with over 20,000 patients examined the benefit of antioxidant 
combination (vitamin E, C and β-carotene) on secondary prevention.  Although the 
blood antioxidant levels were raised with this treatment regimen, no significant 
reductions in the mortality from, or incidence of, any type of vascular disease, or other 
major outcome was found [109].  Several meta-analyses of these randomised, 
controlled trials have been carried out that support the overall finding that vitamin E 
therapy does not reduce the risk of cardiovascular events [110-113]. 
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Table 1-1 Summary of randomised controlled clinical trials for antioxidant therapy 
 Subjects Treatment 
Study (yr), [ref] No. of 
pts 
Sex Age Characteristics Dose Duration 
(yrs) 
Prevention Study Outcome 
Vitamin E          
ATBC (1994) [99] 29133 M 50-69 Smokers, no 
medical 
history 
50 mg 6.1 Primary Adverse  Increase in 
haemorrhagic stroke 
PPP (2001) [100] 4495 M/F 64 At risk of CVD 300 mg 
(synthetic) 
3.6 Primary Null  No effect on MI/CVD 
death/stroke 
HOPE (2000) [108] 9541 M/F ≥55 High CVD risk 400 IU 
(natural) 
4.5 Primary & 
Secondary 
Null No effect on MI/CVD 
death/stroke 
CHAOS (1996) 
[103] 
2002 M/F 62 Coronary 
disease 
800 vs 400 
IU 
1.4 Secondary Beneficial  Decreased non-fatal 
acute MI 
ATBC (1997) [105] 1862 M 50-69 Smokers who 
had a MI 
50 IU 5.3 Secondary Beneficial  Reduction in non-
fatal MI occurrence 
GISSI (1999) [106] 11324 M/F  Post-MI 300 mg 
(synthetic) 
3.5 Secondary Null  No effect on MI/CVD 
death/stroke 
Micro-HOPE 
(2002) [107] 
3654 M/F 65 Diabetics 400 IU 
(natural) 
4.5 Secondary Null No effect on MI/CVD 
death/stroke 
CHAOS (1996) 
[103] 
2002 M/F 62 Coronary 
disease 
800 vs 400 
IU 
1.4 Secondary Beneficial  Decreased non-fatal 
acute MI 
SPACE (2000) 
[104] 
196 M/F 40-75 Haemodialysis 
patients 
800 IU 2 Secondary Beneficial  Decreases acute MI + 
PVD + UA 
 
β-carotene          
ATBC (1994) [99] 29133 M 50-69 Smokers with 
no medical 
history 
20 mg 6.1 Primary Adverse  Increase in overall 
mortality.  More 
deaths due to: IHD, 
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haemorrhagic & 
ischemic stroke 
ATBC (1998) [84] 27271 M 50-69 Smokers with 
no medical 
history 
20 mg 6.1 Primary Null  No effect on: all 
coronary cases, 
nonfatal MI, fatal 
CHD 
Antioxidant 
cocktails 
         
ATBC (1998) [84] 27271 M 50-69 Smokers with 
no medical 
history 
50 mg vit E 
+ 20 mg β-
carotene 
 
6.1 Primary Null  No effect on: all 
coronary cases, 
nonfatal + fatal MI 
ASAP (2000) [86] 520 M/F 45-69 Elevated 
cholesterol 
levels 
182 mg d-α-
tocopherol 
+ 500 mg vit 
C 
3 Secondary Beneficial Progression of 
intima-media 
thickness reduced 
from placebo in men, 
but not female 
HPS (2002) [109] 20536 M/F 40-80 High CVD risk 600 mg vit 
E, 250 mg 
vit C, 20 mg 
β-carotene 
5 Secondary Null No effect on CVD 
mortality 
Fang et al (2002) 
[114] 
40 M/F ≥18 After cardiac 
transplant 
500 mg vit C 
+ 400 IU vit 
E 
1 Secondary Beneficial No increase in 
intimal index in 
treatment group vs 
placebo group 
Trial names: ATBC – alpha-tocopherol, beta-carotene cancer prevention study; ASAP – antioxidant supplementation in atherosclerosis prevention study; CHAOS – 
Cambridge heart antioxidant study; HOPE – heart outcomes prevention evaluation study; HPS – heart protection study; PPP – collaborative primary prevention 
project; SPACE - Secondary prevention with Antioxidants of Cardiovascular Disease in Endstage renal disease; GISSI – GISSI prevenzione trial. 
Abbreviations: CHD – coronary heart disease; CVD – cardiovascular disease; F - female; IHD- ischaemic heart disease; IU – international units; M – male; MI – 
myocardial  infarction; PVD – peripheral vascular disease; UA – unstable angina; vit – vitamin. 
Table adapted from Katsiki et al. 2009 [115]  with permission from Elsiever.  
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1.6.5 Why have the antioxidant clinical trials failed? 
There are many speculative reasons as to why the results from the clinical trials do not 
support the putative role of antioxidants in the protection against atherosclerosis.  
There is strong experimental evidence to support the conclusion that oxidative stress 
plays a central mechanism by which clinical risk factors lead to vascular damage and 
atherosclerosis.  The concept was that the prevention of oxidative stress induced by CVD 
risk factors would prevent the formation of endothelial dysfunction and the eventual 
manifestation of plaque rupture and thrombosis seen in the acute setting of CAD [58]. 
 
First and foremost, it must be questioned whether the right drug or combination of 
drugs have been used in these trials.  The fact is, the requisite fundamental 
understanding of the relevant oxidants in atherosclerosis is not yet fully appreciated, 
and therefore the appropriate antioxidant treatment has most likely not been tested 
yet.  This is important to consider given that most of the clinical trials have used species 
that are only effective at scavenging a certain type of oxidant [3].  This design flaw may 
potentially mean that only some, but not all, relevant oxidizing species implicated in 
atherosclerosis are metabolised.  Whether the antioxidant agents are selected on the 
basis of their availability is another unknown, and it may be that they are not ideal or 
equivalent to the endogenous antioxidants.  When examining the trials that use vitamin 
E, it is concerning that some report a pro-oxidant effect [116], and that high-dose 
supplementation was associated with an increased mortality [117, 118].  Therefore, 
trials of vitamin E alone could be causing more harm than good.  Even if vitamin E is the 
correct antioxidant agent to use, it is possible that the correct form of vitamin E has not 
been chosen.  Cheap, easily available, synthetic vitamin E is mostly used throughout the 
trials; however natural vitamin E is different from the synthetic form and is composed 
of 8 different isoforms that may render it more potent.  Additionally, vitamin E may 
require a co-antioxidants to prevent oxLDL formation [119].  
 
Another possibility that needs to be evaluated is that although the appropriate drug may 
have been used, were the appropriate doses and/or treatment durations sufficient.  An 
important consideration when determining optimal therapy duration is that animal 
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models tend to show effective treatment with antioxidants in the earliest forms of 
atherosclerotic lesion formation [120].  Even those trials with follow-up lasting years 
may be too short to observe any benefit.  The primary and secondary prevention studies 
used subjects with 40-50 years’ worth of oxidative stress in the endothelium, and it may 
be unrealistic to assume, for example, that vitamin E supplementation can alter this 
within a 1-5 year period.  Dose regimens of particular antioxidant agents also remain 
controversial.  The most effective doses are not known, and doses above 400 UI/day 
have been linked to increases in mortality [118].  Another factor to consider is that 
individual variability in response to vitamin supplements has been proposed to affect 
results [121].  Therefore administering the same dose of vitamin E to everybody will not 
lead to the same effect in all individuals.  
 
This leads to another explanation for the failure of the antioxidant clinical trials in that 
simply the wrong study population were investigated.  First, as highlighted above, it may 
be that intervention in adults is too late in the atherosclerotic process to see a 
difference.  An alternative consideration is that not all patients may require antioxidant 
therapy.  Instead of treating everyone with antioxidant therapy, as has been done to 
date in the clinical trials, it is potentially more beneficial to target the population who 
are proven to be deficient in either antioxidants or have an elevated oxidative stress 
threshold.  This could explain why those trials that have seen benefit of antioxidant 
therapy, did so in a select population, such as subjects with renal failure [103] or having 
had post-cardiac transplantation [114]. 
1.6.6 Antioxidants as a biomarker in coronary artery disease 
The lack of benefit seen in clinical trials and the subsequent ‘antioxidant paradox’ does 
not disprove the central role of oxidative stress in atherosclerosis.  Rather these trials 
prove that better design is required for future antioxidant intervention studies.  Areas 
that need to be addressed are the determination of the best antioxidant species at the 
right doses, and the determination of the correct study population for treatment, as well 
as what the optimal duration of treatment should be.  To address these areas, a strategy 
that has been highlighted in the literature to the attention of trial designers, is to direct 
their focus on enhancing the expression and/or activity of the endogenous antioxidant 
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defence systems and examine whether these systems are affected throughout the 
different stages of CAD.   
 
The principal limitation in this field of research is the lack of understanding of the 
connection between oxidative stress and CVD.  Atherosclerosis is a multifactorial 
disease, and oxidative stress may be the predominant effector of pathology in only a 
subset of patients.    The lack of proven markers for oxidative stress, which could help 
identify a subset of a population that can benefit from antioxidant supplementation, 
and the complexity of the redox reactions, are among some of the factors that are 
responsible for the mixed outcomes in the use of antioxidants for the prevention of CVD.  
Current methods rely on indirect measurements to assess oxidative stress, such as lipid 
and protein oxidation levels [6].  There is limited evidence that these reflect oxidative 
stress in vivo, and the lack of standardisation of many of these methods potentially 
explains different outcomes in the same population group.  An example of this is the 
assessment of oxLDL as a predictor for CVD outcomes.  In the same cohort, Tsimikas et 
al. [122] looked at 5-yr outcomes, Keichl et al. [123] at 10-yr outcomes, and Mayr et al. 
[124] at 5-yr outcomes.  Tsimikas et al. and Keichl et al. found oxLDL predictive of CVD; 
however Mayr et al. did not find any association, despite reporting similar end-points.  
Nevertheless, oxLDL has been the most common oxidative biomarker used to 
investigate CVD progression.  Due to their highly reactive nature ROS molecules usually 
do not lead to the release of stable by-products, and combined with their relatively short 
half-lives, measurement presents a significant challenge to researchers.  It is widely 
accepted that measurement of systemic markers of oxidative stress in the circulation 
offers limited information about the true redox state of the individual in the vasculature 
[56].   Due to the highly contentious argument on which is the most suitable biomarker 
of oxidative stress, the evidence for antioxidants to be used as a potential surrogate 
marker for oxidative stress is emerging.  The implications of using the antioxidant 
defence system as a measure for risk prediction and/or oxidative stress in CAD is an 
important area of research, and one that needs to be closely examined.   
 
A strong piece of evidence supporting the need for this line of research comes from the 
results published by a recent meta-analysis [125].  The 42 case-control and 3 cohort 
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studies analysed suggested that low activity levels of the endogenous antioxidant 
systems, GPx, SOD and CAT were associated with a higher risk of CAD.  Further 
experimental studies have demonstrated that deficiencies in GPx activity promote a pro-
thrombotic state and vascular dysfunction [70], with clinical evidence suggesting that 
GPx activity has potential as a biomarker for predicting future cardiovascular events in 
a CAD population [71].  These findings have prompted renewed interest in the GPx 
antioxidant system in anticipation that it may have clinical relevance in oxidant-
mediated progression of CAD.  The following section will provide an in-depth overview 
of the GPx enzyme and current evidence supporting its role in CAD. 
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1.7 Glutathione peroxidase overview 
Glutathione peroxidases (GPxs) constitute a family of phylogenetically related 
antioxidant enzymes, as evidenced by sequence homology.  GPx was the first 
selenoenzyme discovered in mammals [126, 127], now this family has grown to include 
more than 700 members spread over all living organisms, from prokaryotes to humans 
[128].  In mammals, GPxs constitute a primary defence mechanism against oxidative 
damage.  Along with SOD and CAT, GPxs exert their antioxidant properties in order to 
maintain the redox potential in the body.  Oxidative stress occurs as a consequence of 
an imbalance between the levels of oxidants and antioxidants, tipped in favour of the 
former [7]. An oxidative challenge or a loss of antioxidants alone does not account for 
oxidative stress; it is when there is increased formation of oxidants accompanied by a 
loss of antioxidants and/or accumulation of oxidised forms of the antioxidants, that 
oxidative stress is approached [3].  Disturbances in normal cellular redox homeostasis 
contribute to the susceptibility and/or pathology in many common and complex human 
diseases, such as CAD.   
 
1.7.1 Structural and mechanistic aspects of GPx 
For decades, GPxs have been known to catalyse the reduction of H2O2 and organic 
hydroperoxides to water and the corresponding alcohols, typically using glutathione 
(GSH) as the reductant [129].   
 
In mammals, up to 8 different isoforms of GPx have been described.  GPx1, 2, 3, 4 and 
in humans, GPx6, are selenoproteins, containing a selenocysteine (Sec) at their catalytic 
center [130].  The Sec moiety enables a fast reaction with the hydroperoxide substrates 
and a fast reducibility of GSH as the reductant.  The remaining variants have a redox-
active cysteine residue in place of the Sec moiety, and therefore are functionally 
identified as thioredoxin-dependent peroxidases [131].  As for many other 
selenoproteins, the availability of selenium represents the single most important factor 
for biosynthesis of GPxs, but the individual GPx isoenzymes respond to selenium 
depletion differently. GPx-1 undergoes a particularly rapid decrease of enzymatic 
activity, protein expression and mRNA stability in cultured cells and animals when 
 
 
30 
switched to selenium deficiency [132].  Each isoform is postulated to exhibit tissue-
specific expression and different substrate specificity. They are divided into classes 
based on their primary sequence, substrate specificity and subcellular location.  GPxs 
are predominately located intracellularly, the exception for this being the secreted 
plasma isoform GPx3. Cytosolic GPx1 and phospholipid hydroperoxide GPx4 are 
ubiquitously expressed.  GPx2 is an epithelium-specific gastrointestinal protein, and 
GPx6 is found in the olfactory epithelium and embryonic tissues [133, 134]. Only GPx1, 
3 and 4 have been partially functionally characterized.  Discussion of the individual 
isoforms can be found below. 
 
1.7.2 GPx1 
The first GPx to be identified, GPx1 was discovered by Mills et al. in 1957. It was 
described as a selenoprotein that is able to protect haemoglobin from oxidative 
degradation in red blood cells [135].  GPx1 is the most abundant member of the 
antioxidant family, and is a crucial antioxidant enzyme involved in preventing the 
harmful accumulation of intracellular H2O2.  GPx1 is a ubiquitous enzyme, present in the 
cytosol [127] and mitochondria [136] of mammalian cells – including in the endothelium 
[137] and erythrocytes [138].  It metabolizes H2O2 and some organic hydroperoxides.  
Studies from genetically modified mice where there is a deficiency in GPx1 are 
developmentally normal and show no increased oxidative stress or sensitivity to 
hyperoxia compared with wild-type mice [139].  This indicates that either other proteins 
may compensate for the lack of GPx1, or that GPx1 plays a limited role under physiologic 
conditions.  In contrast, under acute oxidative stress conditions, GPx1 KO mice did not 
survive irrespective of selenium supplementation.  This is in comparison to selenium-
supplemented wild-type mice that survived [140, 141].  These findings show that GPx1 
has a primary antioxidant function and cannot be replaced by another selenoprotein to 
maintain protection from generalised oxidative stress. 
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1.7.3 GPx2 
GPx2 is a homotetramer and another cytoplasmic antioxidant found originally in cells of 
rodent gastro-intestinal (GI) tract.  It was subsequently identified in human cells 
throughout the GI tract.  It is an epithelial-specific enzyme that is highly expressed in the 
intestine of mammals and humans as well as the liver of humans [138, 142].  
Enzymatically, it is postulated that GPx2 is similar to GPx1, and the different gene 
expression patterns are thought to make GPx2 an essential protector against gut 
pathogens and inflammation.  However, since the protein has not been purified so far, 
neither substrate preferences nor kinetic constants have been reported [131]. 
 
1.7.4 GPx3 
Also similar to GPx1, GPx3 is a tetramer and is enzymatically comparable to GPx1 [143].  
However, the physical and kinetic properties are distinct from the other isoforms. GPx3 
is a glycosylated protein secreted from the cell.  It exhibits tissue-specific expression, 
with mRNA expressed in the proximal convoluted tubule of the kidney and released into 
the plasma via the basolateral membrane of the cell [144, 145].  GPx3 mRNA has also 
been found expressed in the heart, liver and breast [146].  In human plasma, GPx3 is the 
most important ROS-detoxifying selenoenzyme, catalysing the reduction of extracellular 
H2O2 and lipid hydroperoxides [147].  It can also accept thioredoxin as well as GSH as a 
reducing co-substrate [148].   GPx3 is widely used as a marker for selenium status [134]. 
Transcriptional regulation of GPx3 has largely remained uncharacterized.  The possibility 
of enhancing GPx3 expression is highly variable between cell types and tissues therefore 
general regulatory mechanisms cannot be postulated [147].  GPx3 can prevent 
hydroperoxide-mediated activation of lipoxygenases (LOX), thereby preventing undue 
inflammatory responses which would otherwise occur by LOX activation [147].  GPx3 
helps to maintain the vascular bioavailability of NO, a major vasorelaxant and inhibitor 
of platelet function [149]. 
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1.7.5 GPx4 
This selenoenzyme is a monomer, that, unlike other GPxs, can reduce phospholipid- and 
cholesterol-hydroperoxides directly, using electrons from GSH as well as from other 
protein thiols in mammalian cells [150].  It is located in cytosolic, mitochondrial and 
sperm nuclear isoforms, and has differential tissue distribution. A systemic knockout of 
the GPx4 gene is lethal in mouse models, with GPx4+/- mice more sensitive to oxidative 
stress [151].  This demonstrates an essential role for GPx4 as an antioxidant in 
mammalian cells, although the particular reason for its unique essentiality remains to 
be determined [147]. 
 
1.7.6 GPx5 
The Cys variants of GPx include the epididymis-specific GPx5 [152, 153].  Its closet 
homologue is GPx; however, the kinetics and substrate specificities remain to be 
investigated.  The putative function of GPx5 in fertility is that it regulates oxidants in the 
epididymis since it has a restricted expression and secretion in this tissue [154]. 
 
1.7.7 GPx6 
GPx6 is a newly discovered GPx, located in olfactory epithelium and embryonic tissue 
[155].  It is a selenoprotein in humans, but a CysGPx in other species.  So far, GPx6 has 
not been purified and kinetic analyses do not exist.  Knowledge about the characteristics 
of this GPx is very limited. 
 
1.7.8 GPx7 and GPx8 
Both the CysGPx, GPx7 and GPx8 have putative roles as antioxidants, although neither 
has been purified to date.  GPx7 was identified in the lumen of the endoplasmic 
reticulum [156], and GPx8 was described as a membrane protein in the endoplasmic 
reticulum (ER) [157].  Because of their location, these enzymes have been hypothesised 
to play a role in protein folding, since disulphide formation is a redox-dependent process 
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that takes place in the ER of eukaryotic cells [157].  More detailed information on GPx7 
and GPx8 is not available. 
 
1.7.9 Experimental implications for GPx in cardiovascular disease 
Experimental studies have highlighted the protective properties of the GPx system 
against oxidative stress in the setting of CVD.  Animal models with GPx1 deficiencies 
show anomalies in the structure and function of the vessels and heart [69] and increases 
in the level of lipid oxidation [78].  Overexpression of GPx1 improves ventricular 
remodelling after an MI [158].  Mice deficient in GPx3 enter a pro-thrombotic state with 
vascular dysfunction that promotes platelet-dependent arterial thrombosis [70].  Long-
term selenium deficiency results in markedly decreased GPx activity in the arterial wall 
and in the heart of rats, accompanied by enhanced levels of lipid peroxides, and clear 
oxidative damage in the tissues.  Sodium selenite supplementation restores GPx activity 
and decreases the formation of lipid hydroperoxides [159].  Ischemic animal models fed 
a hyperlipidemic diet show increases in selenium- dependent GPx activity [160].  GPx2 
knock-out mouse models do not develop any obvious phenotype under unstressed 
conditions; however, studies indicate that it has important anti-inflammatory properties 
since deficiencies in GPx2 expression are linked to inflammatory bowel disease [147].  
Together these experimental studies illustrate the importance of this key antioxidant 
enzyme in the functional and structural responses of the mammalian cardiovascular 
system.  
 
1.7.10 Clinical relevance of the GPx enzymes 
With experimental studies suggesting a protective role of GPx in CVD, translational 
studies have been carried out to determine whether GPx is a factor in contributing CVD 
risk in humans.  Supportive evidence includes the finding that GPx1 activity is decreased 
or absent in carotid atherosclerotic plaques, and that the lack of GPx1 activity in 
atherosclerotic lesions appears to be associated with the development of more severe 
lesions in humans [161].  Decreased GPx3 activity is found in patients with a history of 
arterial thrombosis and stroke syndromes [72].  It has been postulated that GPx3 
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potentiates the inhibition of platelet function by NO by maintaining low levels of ROS.  
Selenium is an essential cofactor for the activity of the seleno-GPxs, but the role of 
selenium in CVD is controversial.  Low serum selenium levels may be a risk factor for 
CVD; however epidemiologic studies have been inconclusive, and prospective, 
controlled trials of selenium supplementation report inconsistent results [162].  
Keshan’s disease is a cardiomyopathy primarily due to dietary deficiency in selenium.  A 
link has been suggested between a polymorphic gene variation of GPx1 that results in 
decreased activity and the development of Keshans disease in a regional selenium-
deficient area of China [163]. 
 
The association of GPx activity and risk of CAD is not completely understood to date.  It 
is postulated that low levels of GPx activity are associated with an increased risk of CAD 
events, but the literature on this topic is divergent.  A recent meta-analysis examined 32 
case-control studies and 2 prospective studies and concluded that GPx activity levels are 
protective against CAD outcomes [125].  However the results are not as clear-cut as they 
appear.  Most of the studies examined were small case-control studies and lacked 
adjustment for factors such as smoking, age, diet and other conditions known to be 
affected by oxidative stress.  More rigorous adjustments for cardiovascular risk factors 
are needed to ensure that the association between antioxidant activity and CAD is 
robust.  Additionally the majority of the studies examined were carried out in patients 
who had a chronic CAD.  This includes The Atherogene Study, the largest study to 
examine the association between GPx1 activity and CAD outcomes.  In 636 stable 
coronary patients, an inverse association was shown between levels of GPx1 activity and 
risk of CAD events [71].   
 
Consequently, due to the divergent reports from the current literature, the effects of 
GPx activity on CAD outcomes in the acute setting have been poorly evaluated.  On study 
has reported contrasting results to the above studies, where high levels of plasma-borne 
GPx activity was associated with worse clinical outcomes in 137 ACS patients [70].   
During an acute event there is an increase in ROS production and antioxidants have 
ability to change rapidly.  The magnitude and the time course of these changes can be 
affected by the severity of the acute event, by therapeutic interventions, and by the 
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development of complications.  Even in the studies that measured GPx activity in stable 
CAD, activity may be affected by the use of some medications (e.g. statin use) or lifestyle 
(e.g. smoking).  High-quality prospective studies evaluating the association between GPx 
activity and CAD endpoints in an acute population are warranted. 
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1.8 Overall aims  
 
This thesis explores the variability of the plasma levels of GPx activity and its prognostic 
value in determining clinical risk in an ACS population.  Investigation of the relationship 
between GPx activity and levels of platelet reactivity and ROS, both factors implicated 
in ACS, are studied in an ACS population.  How levels of the GPx system are affected in 
different stages of CAD are examined by comparison of ACS patients to stable coronary 
disease patients and healthy subjects.  Corresponding changes in oxidative stress levels 
are also examined.  Finally, the temporal changes of GPx activity are studied during the 
acute phase of a STEMI, along with corresponding changes in oxidative stress levels.  This 
allows for the determination of the dynamic nature of GPx activity present during an 
ACS event.  The results from this thesis will help determine the suitability of GPx as a 
potential biomarker in an ACS population. 
 
Therefore the aims of the thesis are: 
 To examine the variance that exists in GPx activity in an ACS population  
 To determine whether GPx activity is predictive of major adverse 
cardiovascular outcomes in an ACS population 
 To examine the relationship between GPx activity and levels of platelet 
reactivity and ROS in an ACS population 
 To determine how levels of GPx activity, protein concentration and mRNA 
expression changes in ACS patients compared to stable coronary disease 
patients and healthy subjects 
 To determine how levels of oxLDL change in ACS patients compared to stable 
coronary disease patients and healthy subjects  
 To explore the temporal changes in GPx activity and oxLDL over the acute 
phase of a STEMI 
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2.1 Introduction 
 
ROS are maintained at physiological levels by antioxidant enzymes such as GPx and SOD, 
to keep a balanced redox state.  Experimental studies have demonstrated that 
deficiencies in plasma-borne GPx activity have resulted in abnormal vascular and cardiac 
structure and function [69], promoting a pro-thrombotic state in mice [70].  Additionally 
overexpression of extracellular SOD has been shown to improve endothelial dysfunction 
in mice [164] and reduce myocardial infarct size in rabbits [165].   
 
Although previous studies have attempted to determine the relationship between levels 
of antioxidant activity and clinical cardiovascular complications, no consensus has yet 
been reached.  This is due to studies publishing contradictory results, and the fact that 
divergent reports exist depending on whether chronic [71] or acute coronary 
populations [166] are examined.  This makes it difficult to compare findings, and 
therefore it has not been determined whether GPx and SOD activity can act as a 
biomarker to predict clinical risk in CAD. 
 
The pro-thrombotic and pro-inflammatory state of ACS patients causes them to be at an 
increased risk of major adverse cardiovascular events (MACE).  One study has suggested 
that GPx activity is a surrogate marker for the level of oxidative stress in ACS patients, 
with higher levels associated with a higher rate of MACE [166].  However, this finding is 
at odds with a recent meta-analysis demonstrating that the majority of clinical studies 
find an inverse relationship between antioxidant activity and CAD outcomes [125].  To 
address this discrepancy in the literature this study aimed to examine the variance in 
GPx and SOD activity in a large ACS population.  Combined with the experimental studies 
that suggest GPx and SOD activity are protective against oxidant-mediated damage, and 
the meta-analysis results showing an inverse association with CAD outcomes, we 
hypothesise that low levels of GPx and SOD activity will be associated with higher rate 
of MACE in an ACS population, therefore identifying a subset of patients at increased 
risk of adverse clinical events occurring. 
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Thus the aims of this study were: 
 To examine the variance in GPx and SOD activity in an ACS population 
 To determine whether this variance in activity levels is associated with the rate 
of MACE in an ACS population. 
  
 
 
40 
2.2 Methods 
 
2.2.1 Study population 
A group of 262 patients presenting to Wellington Regional Hospital between January 
2012 and October 2012 diagnosed with an ACS and undergoing an invasive treatment 
(coronary angiography ± PCI) were eligible for inclusion in the study.  ACS was defined 
by a cardiologist where symptoms suggestive of myocardial ischemia lasting longer than 
10 min with either troponin elevation or ≥1 mm of new ST-segment deviation or T wave 
inversion on an ECG in at least 2 contiguous leads was observed, consistent with the 
current universal definition of ACS [24].  Patients were adequately pre-treated with dual 
anti-platelet therapy defined as chronic therapy with aspirin (≥75 mg/day) and 
clopidogrel (≥75 mg/day) and/or loading with aspirin ≥300 mg and clopidogrel ≥300 mg 
at least 6 hrs prior to enrolment.  Exclusion criteria included a platelet count of less than 
100 x 109/L, a known platelet function disorder, administration of a thrombolytic agent 
within 24 hr of enrolment or administration of a glycoprotein IIb/IIIa receptor antagonist 
within a week prior to enrolment.  This study was reviewed and approved by the Lower 
South Ethics Committee (LRS/11/09/035) (Appendix 1).  Participation was voluntary, and 
each patient gave informed written consent at the time of recruitment. 
2.2.2 Data collection  
Patient demographics, clinical characteristics, medications and clinical management 
were collected prospectively from review of the medical records and cardiac 
catheterisation database.  Cardiology registrars collected procedural variables and in-
hospital outcomes.  Cardiology research nurses collected follow-up data with telephone 
calls at 30 days and 1 year.  Where necessary, a cardiologist performed a review of case 
notes and the appropriate general practitioner contacted to further classify clinical 
outcomes. 
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2.2.3 End points and definitions 
The primary endpoint was a composite of major adverse cardiovascular events (MACE) 
including death, nonfatal MI, nonfatal ischaemic stroke, stent thrombosis and new heart 
failure presentation. 
2.2.3.1 Major adverse cardiac event (MACE) 
Death encompassed all-cause mortality including cardiovascular death.  Acute MI was 
defined using the third universal definition of myocardial infarction [24].  This included 
the detection of a significant high sensitivity troponin (hs-TnT) rise and the presence of 
symptoms suggestive of myocardial ischaemia, new or presumed new ST-segment-T 
wave changes or new left bundle branch block, development of new pathological Q 
waves, or imaging showing new loss of myocardial tissue.  Evaluation of definite stent 
thrombosis was performed according to the Academic Research Consortium criteria 
[167].  Acute ischaemic cerebrovascular accident (CVA) was defined as signs of CVA 
confirmed with imaging studies. 
2.2.3.2 GRACE score 
The Global Registry of Acute Coronary Events (GRACE) is a prospectively studied scoring 
system to risk stratify patients with diagnosed ACS to estimate their in-hospital and 6-
month to 3-year mortality [168].  The score is calculated using the following clinical 
factors; age, heart rate, systolic blood pressure, creatinine, heart failure class, ST-
segment deviation, troponin level and cardiac arrest at index presentation to determine 
the mortality risk post-ACS discharge.  All patients had a 6-month GRACE score 
calculated using Microsoft Excel software (Microsoft Corporation; Washington, USA).  
2.2.4 Blood collection  
Blood samples were collected from ACS patients within a mean time of 2-4 days post-
presentation to hospital.  Whole blood samples were collected into tubes anti-
coagulated with sodium citrate (0.109M, BD Vacutainer; New Jersey, USA) from a 
peripheral vein using a 21-gauge needle performed myself before angiography or by the 
interventional cardiologist in the cardiac catheterisation laboratory from the arterial 
sheath immediately after insertion and prior to heparin administration.  Citrated whole 
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blood was centrifuged (1500 g, 12 min, 4°C), to separate the plasma from the cellular 
components.  Aliquots of plasma were stored at -80°C for subsequent analysis of 
antioxidant activity measurements. 
2.2.5 Antioxidant activity measurement 
2.2.5.1 Glutathione peroxidase activity assay 
GPx activity kits (Enzo Lifesciences; New York, USA) were used as per manufacturer’s 
instructions using a colourimetric-based assay.  The experimental protocol was based 
on a coupled reaction of the GPx reaction with the reduction of oxidised glutathione by 
glutathione reductase using NADPH.  The oxidation of NADPH to NADP+ accompanies a 
decrease in absorbance at 340 nm that is proportional to total GPx activity found in the 
plasma sample. 
 
 
 
 
 
 
Briefly, plasma samples were aliquoted in triplicate into 96-well microtitre plates 
containing 1x Assay Buffer.  GPx supplied in the kit served as a positive control and a set 
of wells containing 1x Assay Buffer in place of GPx or sample served as a negative 
background control. These wells were assayed in triplicate alongside the plasma 
samples.  A 10x Reaction Mix containing glutathione reductase and GSH + NADPH was 
added to each well, followed by addition of Cumene Hydroperoxide to initiate the 
reaction.  The rate of transformation of NADPH to NADP+ was measured by absorbance 
readings at 340 nm every minute for 10 mins in a microplate reader (VersaMax™, 
Molecular Devices; California, USA). GPx activity was defined as nanomoles of NADPH 
consumed per minute and expressed as units per mL of plasma. The intra-assay 
coefficient of variance was 7.3%, and the inter-assay coefficient of variance was 9.9%.   
 
GPx 
GR 
2GSH + 2H2O2 GSSG + H2O 
GSSG+ NADPH + H+ 2GSH + NADP+ 
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2.2.5.2 Superoxide dismutase activity assay 
SOD activity was measured in a similar manner to GPx activity using a coupled reaction 
with xanthine oxidase, which generates the superoxide anion from oxygen.  A 
superoxide radical reduces the dye, WST-1, to a coloured product that absorbs light at 
450 nm.  SOD scavenges superoxide anions, thereby reducing the rate of formation of 
the coloured dye product, WST-1-formazan.  Reduction in the appearance of WST-1-
formazan is proportional to the SOD activity present in the sample.  
 
 
 
 
 
 
 
Briefly, plasma extracted from whole blood samples was aliquoted in triplicate into 96-
well microtitre plates containing 1X SOD Buffer.  A concentration range of SOD standards 
was prepared spanning from 10 U to 0.1 U per well, and these standards were run in 
triplicate alongside the plasma samples.  A Master Mix containing WST and xanthine 
oxidase was added to each well, followed by the addition of Xanthine Solution to initiate 
the reaction.  Absorbance was measured at 450 nm using a microtitre plate reader 
(VersaMax™), and subsequent data analysis reported units of SOD activity expressed as 
per mL of plasma.  Intra-assay coefficient of variance was 8.6%, and inter-assay 
coefficient of variance was 10.2%. 
 
 
WST-1 
WST-1 Formazan Xanthine 2O2 
O2 + H2O2 
2O2- 
SOD 
H2O2 + uric acid 
XOD 
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2.2.6 Statistical Analysis 
Continuous variables were reported as the mean ± standard deviation (SD), and 
categorical variables were reported as frequencies and percentages.  Statistical tests to 
compare continuous variables with the rate of MACE were carried out using a Student’s 
unpaired t-test and categorical variables were analysed using chi-square tests.  
Relationships between continuous parameters were determined by the Pearson’s 
correlation coefficient.  A receiver operator curve was used to examine the relationship 
between enzyme activity levels and MACE.  GPx activity was divided into quartiles in 
order to examine the rate of MACE using a linear-by-linear association test.  Differences 
in values corresponding to p<0.05 were taken as statistically significant. All statistical 
analyses were carried out in either GraphPad Prism Software v.06 (GraphPad Software 
Inc; California, USA) or SPSS v.22 (IBM; Armonk, NY).  
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2.3 Results 
 
2.3.1 Baseline characteristics 
The demographic data and clinical characteristics of the 262 ACS patients are 
summarised in Table 2-1.  The study population was 69% male, had a mean age of 63 
years and a mean BMI of 29.5.  The clinical presentation was STEMI in 23%, NSTEMI in 
71% and UA in 7%.  The mean Grace Score on admission was 100.  The clinical 
management of the study group was as follows: PCI in 50%, coronary artery bypass 
grafting (CABG) in 14% with the remaining 34% being medically managed.   
2.3.2 Patient outcome 
At 1 year follow up, 34 (13%) patients experienced MACE.  This included 10 deaths 
(3.8%) all from cardiovascular causes (1 CVA, 9 from cardiac causes). Nonfatal MI 
occurred in 11 patients (4.2%), and ischemic CVA in 4 patients (1.5%).  The rate of stent 
thrombosis was relatively low, occurring in 2 patients (0.8%) during the follow-up 
period.  A further 7 patients (2.7%) were admitted with acute heart failure 
presentations. 
Comparing the patients with MACE to the patients without MACE (Table 2-1), MACE 
patients were older, more likely to have a history of hypertension, dyslipidaemia, 
diabetes and renal dysfunction, and have higher GRACE Scores. 
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Table 2-1  Baseline characteristics of the ACS study population. 
Characteristic ACS patients 
(n=262) 
MACE Group  
(n=34) 
No MACE Group 
(n=228) 
p value 
Male 180 (69) 26 (76) 154 (68) 0.29a 
Age (years) 63 ± 10 66 ± 11 62 ± 10 0.02b 
Body Mass Index  29.5 ± 5.8 29.9 ± 7.2 29.5 ± 5.5 0.64b 
Risk Factors     
Hypertension 175 (67) 31 (91) 144 (63) 0.001a 
Dyslipidaemia 182 (70) 31 (94) 151 (66) 0.003a 
Diabetes 66 (25) 18 (52) 48 (21) 0.001a 
Current Smoker 54 (21) 8 (25) 46 (20) 0.65a 
Renal Dysfunction 17 (7) 6 (17) 11 (5) 0.005a 
Clinical Presentation     
STEMI 59 (23) 4 (12) 55 (24) 
0.24a NSTEMI 185 (71) 28 (82) 157 (69) 
Unstable Angina 18 (7) 2 (6) 16 (7) 
Grace Score 100 (24) 111 (27) 99 (24) 0.006b 
Clinical Management     
Medical Management 95 (36) 15 (44) 83 (36) 
0.12a PCI 131 (50) 12 (35) 119 (52) 
CABG 35 (14) 7 (21) 26 (11) 
a chi-square test b Student’s unpaired t-test,.  Continuous variables are expressed as 
mean ± SD, categorical variables are expressed as frequencies and (percentages). 
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2.3.3 Antioxidant activity 
GPx activity in the ACS population ranged from 30.4 to 180 U/mL, with a mean ± SD of 
123 ± 32 U/mL.  MACE patients were found to have significantly lower GPx activity 
compared to patients who did not experience MACE (p<0.05) (Table 2-2).   GPx activity 
was found to be significantly lower in diabetic patients (115 ± 32 U/mL) compared to 
non-diabetic patients (126 ± 32 U/mL) (p<0.05), and significantly lower in males (120 ± 
33.5 U/mL) compared to females (129 ± 29 U/mL) (p<0.05).  Remaining cardiovascular 
risk factors did not appear to influence levels of GPx activity. 
SOD activity in the ACS population ranged from 8.2 to 725 U/mL, with a mean ± SD of 
67.3 ± 82.5 U/mL.  There were no significant differences detected between patients who 
experienced MACE, compared to those who did not (Table 2-2).  No correlation between 
GPx and SOD activity was detected. 
 
Table 2-2  GPx and SOD activity in ACS patients.  
Student’s unpaired t-test was used to detect differences in GPx and SOD activity in 
patients who had MACE, compared to those that did not. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antioxidant 
Enzymes 
ACS patients 
(n=262) 
MACE 
Group 
(n=34) 
No MACE Group 
(n=228) 
p value 
GPx (mean ± SD) 123 ± 32.4 112 ± 33.5 125 ± 32.0 0.03 
SOD (mean ± SD) 67.3 ± 82.5 72.1 ± 80.6 67.0 ± 83.0 0.80 
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2.3.4 Predictive value of GPx activity for MACE 
To assess the predictive value of GPx activity at identifying patients at increased risk of 
MACE, a receiver operator curve (ROC) analysis was conducted.  GPx activity was found 
to be a moderate predictor of MACE with an area under the curve of 0.62 (0.57-0.67, 
SEM) that was significantly different from 0.5 (p=0.02) (Figure 2-1).  However, the ROC 
curve demonstrated the lack of a single cut-point that would indicate an optimal level 
of GPx activity that was predictive of MACE risk. 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 2-1 ROC curve analysis of GPx activity and MACE.   
The ROC curve is a graph of sensitivity (y-axis) vs. 1-specficity (x-axis).  Although the area 
under the curve was significantly different (0.62, p<0.05), a single cut-off value 
corresponding to maximum sensitivity with a high sensitivity could not be determined 
for GPx activity and prediction of MACE. 
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When the MACE rate was examined by quartiles of GPx activity, a significant decrease 
of MACE was demonstrated across the four quartiles (p<0.05).  Event rate for patients 
in the lowest quartile of GPx activity (19.6%) was approximately 2.5 times higher than 
that for the patients in the upper quartile of GPx activity (7.9%) (Figure 2-2).   
 
Figure 2-2  MACE rate by GPx quartile.   
The fraction of MACE rate as observed by GPx activity quartile.  MACE rate significantly 
decreased across the GPx quartiles, with the highest fraction of MACE occurring in the 
lowest quartile of GPx activity.  The lowest MACE fraction occurred in the upper quartile 
of GPx activity. Data plotted from all 262 ACS patients, p<0.05 Linear-by Linear 
association. 
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2.4 Discussion 
 
To date, this is the largest prospective cohort study we are aware of that examines the 
relationship between GPx and SOD activity levels and the occurrence of MACE in 
patients with ACS.  We found significantly lower levels of GPx activity in patients who 
experienced MACE compared to those who did not.  Our ROC curve analysis 
demonstrated a modest, but significant relationship between GPx activity and MACE, 
although a clear cut-point in which GPx activity predicts risk could not be defined.  The 
MACE rate in patients found in the lower quartile of GPx activity was 19.6% compared 
to 7.9% found in patients in the upper quartile. We did observe significantly lower levels 
of GPx activity in both diabetic patients and in male patients.  It is possible that these 
factors may contribute to the inverse relationship observed between GPx activity and 
MACE, however this study was underpowered to examine these factors in a multivariate 
model. No significant relationship was observed between SOD activity and MACE rate in 
this ACS population. 
The GPx enzyme is well established as an antioxidant defence mechanism against 
oxidative stress.  Its importance as a potential anti-atherogenic enzyme has been 
highlighted in the growing body of literature, with both experimental and translational 
studies demonstrating supportive evidence for its ability to protect against oxidative 
stress damage in a cardiovascular setting.  In animal models, reduced GPx expression 
has been shown to increase cell-mediated oxidation of LDL [78], with heterozygous 
mutations of the GPx1 gene promoting endothelial dysfunction and structural and 
functional anomalies of the heart [69], effects presumed to be caused by increased 
oxidative stress. Supportive evidence from translational studies includes the finding that 
GPx activity is decreased or absent in carotid artery lesions, with the lack of GPx activity 
associated with more severe lesion progression [161].  Further examples of glutathione 
pathways being important in preventing vascular injury include a study by Voetsch et al 
[149] who reports polymorphisms that are present within the promoter region of 
plasma-borne GPx resulting in decreased activity, and that impaired GPx defence is 
associated with increased risk of premature ischemic strokes [72].     
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From a clinical perspective, it is therefore postulated that a defence system such as GPx 
will play a protective role in CAD, potentially lending itself as a prognostic marker for 
risk prediction in CAD patients.  However, as highlighted by a recent meta-analysis [125], 
the relationship between GPx activity and CAD is not well-understood, with divergent 
study results demonstrating this relationship is not to be as straightforward as initially 
hypothesised.  Overall, the meta-analysis carried out by Flores-Mateo et al. concluded 
that lower activity levels of antioxidant enzymes such as GPx and SOD were associated 
with increased CAD risk.  However the limitations arising from the study highlight the 
fact that this message is not consistent throughout the individual studies and that the 
association is difficult to interpret in mechanistic or etiologic terms.  The majority of 
studies examined were small case-control populations consisting of both chronic and 
acute coronary disease patients. 
Although our observation that lower levels of GPx activity are associated with a higher 
rate of MACE is consistent with reports from chronic coronary population studies, it is 
in direct contrast to the study by Garcia-Pinilla et al. [166]. In this study carried out in 
137 ACS patients, Garcia-Pinilla et al. reported that the 2-year MACE rate was 
significantly higher in patients whose GPx activity was above the 50th percentile, 
compared with those below. There are a number of potentially important differences 
between our two studies that merit discussion.  Our study collected blood samples prior 
to angiography, whereas Garcia-Pinilla et al. collected blood following angiography.  It 
is likely that GPx activity levels are highly dynamic during an ACS presentation, but the 
nature of that change and whether factors arising from the angiography procedure e.g. 
revascularisation, affect activity levels are not well-understood.  Our study population 
was similar in age and gender ratio to Garcia-Pinilla et al., but we report a substantially 
lower rate of diabetes (25% vs 37%) and proportion of smokers (21% vs 64%).  While 
diabetes was related to the occurrence of MACE in our study, and smoking was related 
to MACE in the Garcia-Pinilla et al. study, the literature reports divergent results on how 
either is related to GPx activity [169, 170].  Although diabetes was associated with GPx 
activity and with the occurrence of MACE in our study, we were not powered to examine 
this relationship in a multivariate model.  Therefore it is possible that the presence of 
diabetes contributes to the inverse relationship between GPx activity and MACE.  
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Although our cohort is substantially larger, our follow-up period is 1 year rather than 2, 
therefore our event rate is significantly lower.   
A common limitation that both studies have is the fact that no measurement was made 
that could be directly related to a baseline oxidative stress value.  Because of this, it is 
difficult to exactly determine if high levels of GPx activity is a response to a greater 
oxidative stress load experienced by patients, and therefore an indirect measure of an 
adverse risk profile as suggested by Garcia-Pinilla et al.  Or, the alternative is that high 
levels of GPx activity reflect a greater ability to defend against oxidative stress, and 
therefore is a protective marker associated with better clinical outcomes, as suggested 
by our study.  
As an antioxidant enzyme, the assumption is that it is a protective molecule which can 
prevent or alleviate oxidant-induced damage, therefore could have prognostic value.  It 
is plausible to suggest that patients with lower levels of GPx activity have a reduced 
defence against ROS, making them susceptible to oxidative-stress mediated damage in 
the vasculature after an ACS event.  To explore this hypothesis further it is first central 
to understand how both the oxidative and antioxidant systems interact with each other, 
and how they change over the different stages of CAD.  If GPx activity was to be utilised 
as a risk marker it is essential to understand how dynamic the activity is over the course 
of an ACS event. It is not ideal to have a biomarker that is highly dependent on sampling 
time.  Our results are assessed from blood collection taken at a mean time of 2-4 days 
post-presentation to hospital.  The variability in the timing of assessment of GPx activity 
in respect to the onset of an ACS has added an unknown quantity of within-study 
variability to our results. The magnitude and the time course of antioxidant enzyme 
changes can be affected by the severity of the acute event [171] and subsequent 
therapeutic intervention such as reperfusion [172].  Closer examination of the dynamic 
change in GPx activity during an ACS event will be crucial to understand how it is affected 
by sampling time and interventional strategies such as revascularisation. 
Vitamin supplements of dietary antioxidants have been largely ineffective in preventing 
the complications of atherosclerotic disease [121].  There are various speculative 
explanations for these findings, but the most crucial is that we still do not fully 
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understand what drives the variance in the antioxidant system and how this translate to 
clinical practice.  The present study demonstrates that there is a large variance in GPx 
activity following an ACS event.  Whether this variance exists throughout the 
progression of CAD, or whether it is induced by an ACS event is largely unknown.  
Understanding what drives this variance, and how it relates to measures of oxidative 
stress will be crucial to understanding how therapeutic strategies can be designed.  
Currently we demonstrate that ACS patients with low levels of GPx activity are at an 
increased risk of MACE.  The transfer of this knowledge to a clinical setting potentially 
means that GPx activity could identify a population that would benefit from targeted 
antioxidant therapy.  It is possible that the large clinical trials with antioxidant therapies 
have been too broad in terms of population heterogeneity.  In an acute population at 
least, subjects with high GPx activity might profit less from antioxidant supplementation 
than patients with lower concentrations of this enzyme.  What the antioxidant 
supplemental strategy should be in this population remains to be determined. 
SOD activity is another antioxidant defence system thought to have a protective effect 
in a cardiovascular setting.  The meta-analysis published by Flores-Mateo et al. [125] 
reported that the majority of studies found an inverse association between SOD activity 
and CAD risk, however not all studies were statistically significant [71].  Our study did 
not observe a significant relationship between SOD activity and rate of MACE.  However 
we did observe a considerable variation in levels of SOD activity between the ACS 
patients, and it is possible that our study was underpowered to detect differences in this 
population due to this large variance.  Additionally SOD has been shown to be most 
active in the vessel wall and sampling the circulating SOD may not be the best 
representative of its antioxidant abilities [71, 173]. It is feasible that the protective effect 
of GPx activity on lipid peroxidation arises from the detoxification of H2O2 produced by 
SOD enzyme as well as converting lipid hydroperoxides to non-toxic alcohols, therefore 
making it the primary plasma enzyme in protecting against increased free radical 
production in ACS.  
A common limitation in both SOD and GPx activity assays is that they are not designed 
to differentiate between the isoforms for each enzyme found in the plasma.  Although 
GPx3 and SOD3 are reported to be the predominant isoforms in the plasma, there is an 
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inability to determine if other isoforms have been secreted from cellular locations and 
are contributing to total activity.  This study was designed to capture the global activity 
present in the circulating plasma, however we cannot determine what proportion each 
isoform is contributing to the total activity measured in our plasma samples.  
2.5 Conclusion 
This study demonstrates a significant inverse relationship between GPx activity and rate 
of MACE in ACS patients.  These findings suggest that patients with lower levels of GPx 
activity are at increased risk of developing adverse clinical events within 1-yr following 
an ACS event, possibly due to a decreased defence against oxidant-mediated damage.  
What factors may influence this variability in GPx activity in an ACS population will be 
further examined in this thesis. 
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Chapter 3 - Relationship between glutathione 
peroxidase and platelet reactivity in acute coronary 
syndromes 
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3.1 Introduction 
 
In the previous study we observed that low levels of plasma GPx activity was associated with 
increased rate of MACE.  There is mechanistic evidence that indicates deficiencies in GPx 
activity is related to enhanced platelet function and an enhanced ROS flux [70].  Excessive 
platelet reactivity is correlated with worse clinical outcomes in an ACS population [174], and 
high levels of ROS are produced during myocardial ischaemia [41].  ROS are known to rapidly 
consume nitric oxide (NO), a vasodilator released from the endothelium and an important 
inhibitor of platelet activation [175].  Therefore we hypothesise that low levels of GPx activity 
will be associated with high platelet reactivity, and a high level of ROS in an ACS population.  
We suggest that high platelet reactivity and ROS levels due to low GPx activity may account 
for the increased MACE we see in the previous chapter. 
 
Experimental studies have demonstrated GPx activity potentiates the inhibition of platelet 
activation by NO in healthy volunteers [176].  A case study examining familial arterial 
thrombosis found decreased levels of plasma GPx activity, an increased level of H2O2, and an 
attenuation of platelet inhibitory response to NO [72].  The authors deduce that it is the 
interaction with ROS that reduces the bioavailability of NO leading to a thrombotic state. 
Addition of exogenous GPx led to a restoration of platelet inhibition by NO.  Further 
experimental studies have demonstrated an association between deficiencies in plasma GPx 
activity (GPx3) and enhanced platelet reactivity [70].  Impaired endothelial function, an 
enhanced ROS flux and larger stroke size greater stroke infarct volumes in the GPx3 knock-
out mice were also observed.  The authors concluded that a GPx deficiency promotes platelet-
dependent thrombosis due to an impaired ROS metabolism and an impaired platelet 
inhibition mechanism. 
 
In order to test our hypothesis we utilised the Multiplate system, a measure of platelet 
function, to quantify platelet reactivity.  To examine whether GPx activity is associated with 
high levels of ROS we adapted the methodology described from Freedman et al. [72, 176].  
This allowed us to develop a test that measured both platelet reactivity and gave an indirect 
measure of ROS in a single test. 
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The principle of this method is based on the consumption of NO by ROS.  By measuring 
platelet function in whole blood samples with and without the addition of exogenous NO, it 
was possible to quantify the level of NO-mediated platelet inhibition.  Based on the principle 
that ROS rapidly inactivates NO, high levels of ROS would be associated with a rapid 
consumption of NO, and a lower level of NO-mediated platelet inhibition.  In contrast, where 
levels of ROS are low, NO would be able to have a greater effect on inhibiting platelet 
function.  In this way, the percentage (%) of inhibition of platelet aggregation by NO acts as 
an inverse marker for ROS. 
 
Therefore this study aimed to: 
 To examine the relationship of GPx activity and platelet reactivity in ACS patients 
 To develop a methodology that allows an indirect measure of ROS based on NO-
mediated platelet inhibition 
 To examine the relationship between ROS levels, GPx activity and platelet reactivity 
in ACS patients   
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3.2 Methods 
 
3.2.1 Study population 
From the recruited cohort described in Section 2.2.1, a subset of 51 consecutive ACS patients 
was further examined for GPx activity, platelet reactivity and ROS measurements.  This study 
was conducted under the same ethical approval as Chapter 2 (LRS/11/05/035) (Appendix 1). 
3.2.2 Data collection 
Patient demographics, clinical characteristics and clinical management were previously 
collected as described in Section 2.2.2. 
3.2.3 Blood collection 
Whole blood samples were collected into tubes anticoagulated with hirudin (25 µg/ml, 
Dynabyte; Munich, Germany) or sodium citrate (0.109 M, BD Vacutainer) from a peripheral 
vein using a 21 gauge needle performed myself before angiography, or by an interventional 
cardiologist in the cardiac catheterisation laboratory from the arterial sheath immediately 
after catheter insertion and prior to administration of heparin.  Plasma was extracted from 
citrated whole blood by centrifugation at 1500 g for 12 min at 4˚C, and stored at -80˚C for 
GPx activity measurements. 
3.2.4 Preparation of S-nitrosothiol 
The endothelium-derived relaxing factor (EDRF) congener, a naturally occurring thiol adduct 
of NO, S-nitrosoglutathione (SNO-Glu) was prepared by reacting equimolar concentrations of 
freshly prepared solutions of glutathione with sodium nitrite (NaNO2) at an acidic pH, as 
previously described [177].  Due to the unstable nature of the S-nitrosothiol, SNO-Glu was 
prepared within 10 min of use, kept at 4˚C and diluted as necessary into aqueous buffer 
immediately before addition to the Multiplate analyser assay system. 
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3.2.5 Platelet function testing 
Platelet reactivity was assessed using whole blood multiple electrode impedance platelet 
aggregometry with the Multiplate analyser (Dynabyte; Munich, Germany) as previously 
described by our laboratory [178].  An illustration of the Multiplate is depicted in Figure 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1   Multiplate analyser system. 
Image recreated from Multiplate educational material  
http://www.cobas.com/home/product/hemostasis-testing/multiplate-analyzer.html 
 
 
Briefly, blood samples were tested within 30 min of collection.  Hirudin anticoagulated whole 
blood was diluted 1:1 with 0.9% NaCl solution to give a final volume of 600 µL.  Each test 
cuvette possessed a Teflon-coated magnetic stirring bar (Figure 3-2A) and samples were 
stirred for 3 min at 37˚C, after which 20 µL of 0.2 mM ADP (adenosine diphosphate, Dynabyte) 
was added to give a final concentration of 6.5 µM.  Addition of ADP stimulates platelets to 
aggregate to the paired electrodes, impeding the current between them (Figure 3-2B&C). 
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Figure 3-2  Multiplate electrode impedance platelet aggregometry 
Saline and whole blood were added to a test cuvette using an automated pipette (A).  Paired 
electrodes are present in each test cuvette and with addition of ADP, a platelet agonist, 
platelets are activated and aggregates are formed on electrodes, which impedes the current 
(B).  A scanning electron microscopy image of platelet aggregates on the electrode surface 
(C).  The images are recreated from the Multiplate educational material, sourced from 
http://www.multiplate.net/en/detection.php. 
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Platelet aggregation was then continually recorded for 6 min.  The increase of impedance due 
to the attachment of platelets to the paired electrodes was detected for each sensor unit 
separately and transformed to arbitrary units (AU) that are plotted against time.  Aggregation 
values are quantified as area under the aggregation curve expressed as aggregation units x 
minutes (AU.min).   
 
For the experiments to assess the effect of SNO-Glu on platelet aggregation and give a ROS 
measurement, two test cuvettes were run simultaneously on the Multiplate analyser.  One 
test cuvette contained the diluted whole blood and was incubated with just ADP (6.5 µM) to 
give a platelet reactivity measure.  The second cuvette was incubated with the SNO-Glu 
compound (6.5 µM) for 1 min before platelet aggregation was stimulated with ADP (6.5 µM).  
A representative example from an individual patient showing platelet impedance 
aggregometry with and without the addition of SNO-Glu is shown in Figure 3-3.  The 
difference in the areas under the curve from the two tests is expressed as % inhibition of 
platelet aggregation, and is the inverse representation of the amount of ROS in the blood 
sample. 
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Figure 3-3 Platelet impedance aggregometry with and without SNO-Glu. 
An individual representation of platelet impedance aggregometry in two test cuvettes 
containing paired electrodes from an ACS patient.  Whole blood from a patient was measured 
for platelet reactivity (AU) after ADP stimulation (6.5 µM) using the Multiplate analyser. The 
red line represents platelet reactivity from one cuvette after ADP alone, and the blue line 
represents platelet reactivity in the second cuvette after incubation with SNO-Glu (6.5 µM) 
for 1 min followed by ADP stimulation.  The difference between the areas under the curve for 
the two cuvettes (without SNO-Glu - with SNO-Glu) was calculated and expressed as % 
inhibition of platelet aggregation.  
 
3.2.6 Pilot study – Platelet aggregation: Effects of SNO-Glu & GPx activity 
To ensure the % change in platelet inhibition we observe by SNO-Glu is through the action of 
NO, and therefore can be a representative of ROS levels, we replicated a further methodology 
proposed by Freedman et al.  GPx activity has been shown to potentiate the SNO-Glu 
mediated platelet inhibition of platelet aggregation [176].  The concept is that addition of GPx 
will help scavenge ROS, preventing it from activating the platelet or from destroying NO.  
Either way, it will preserve the bioavailability of SNO-Glu therefore we will observe a greater 
inhibition of platelet aggregation. Freedman et al. have demonstrated this concept; therefore 
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we sought to carry out a pilot study to measure platelet reactivity in 6 healthy individuals 
where whole blood was incubated with ADP and SNO-Glu in addition to the GPx enzyme. 
As described above, whole blood was incubated with and without SNO-Glu, followed by ADP 
stimulation in two separate test cuvettes, with subsequent platelet aggregation recorded for 
6 min.  In a third cuvette GPx (1 U/mL, Enzo Lifesciences) was incubated with stirred whole 
blood for 30 s before stimulation with ADP and subsequent recording of platelet aggregation.  
In a fourth cuvette, GPx and SNO-Glu was sequentially added, followed by ADP stimulation 
and subsequent recording of platelet aggregation.  A control test cuvette was run in parallel 
where only phosphate buffered saline (1x PBS) was added, followed by ADP-stimulated 
platelet aggregation.  This was to ensure the differences in platelet aggregation were due to 
the different treatments, and not confounding factors.  Results were expressed as platelet 
reactivity aggregation units (AU).  
3.2.7 Glutathione peroxidase activity assay 
Plasma extracted from sodium citrated whole blood was assayed for GPx activity as previously 
described in Section 2.2.5.1. GPx activity was defined as nanomoles of NADPH consumed per 
minute and expressed as units per mL of plasma.  Intra-assay coefficient of variance was 7.3% 
and inter-assay coefficient of variance was 9.9%. 
3.2.8 Statistical analysis 
Continuous variables were reported as the mean ± SD and categorical variables as frequencies 
and percentages.  Relationships between continuous parameters were analysed using the 
Pearson’s correlation coefficient test.  Statistical tests to compare means between continuous 
variables were carried out using a one-way ANOVA with Tukey’s multiple comparison test.  
Differences corresponding to values of p<0.05 were taken as statistically significant.  All 
statistical analyses were carried out in either GraphPad Prism Software v.06 or SPSS v.22. 
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3.3 Results 
 
3.3.1 Pilot study - Platelet aggregation: effects of SNO-Glu and GPx activity 
Addition of SNO-Glu significantly inhibited platelet aggregation compared to ADP treatment 
alone (p<0.05).  The addition of GPx potentiates the level of inhibition of platelet aggregation 
mediated by SNO-Glu compared to ADP alone (p<0.0001) and ADP + SNO-Glu (p<0.05) (Figure 
3-4A).  Addition of GPx alone was not found to be significantly different from ADP treatment 
alone (p=0.48), the small study population and level of variance may account for why 
differences in this treatment was not statistically significant.  Figure 3-5B shows a 
representative example of platelet reactivity in response to each of the treatments from one 
study participant. 
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Figure 3-4  Effect of GPx activity on platelet aggregation. 
(A) Addition of GPx (1U/mL) to stirred whole blood for 30 s, followed by addition of SNO-Glu 
(6.5 µM) for 1 min was carried out before platelet aggregation was induced by addition of 
ADP (6.5 uM).  Platelet reactivity was measured for 6 min and plotted as AU.  SNO-Glu and 
GPx were carried out as single treatments in separate cuvettes followed by ADP stimulation 
for comparison.  Controls included 20 µL of 1x PBS followed by ADP stimulation and ADP 
stimulation alone in separate cuvettes. Data plotted is platelet reactivity (AU) from 6 healthy 
individuals as mean ± SD.  *p<0.05, **p<0.01, ****p<0.0001, one-way ANOVA with Tukey’s 
multiple comparisons test was used to detect differences. (B) A representative example of a 
healthy individual showing the difference in impedance platelet aggregometry (AU) when GPx 
was added to SNO-Glu + ADP (green) compared to SNO-Glu + ADP (blue), GPx + ADP (purple), 
PBS + ADP (black) and ADP alone (red). 
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3.3.2 ACS population – Platelet reactivity, GPx activity & ROS 
3.3.2.1 Baseline characteristics 
Baseline demographics and clinical characteristics of the study population are presented in 
Table 3-1.  The study population was 68.6% male, had a mean age of 60.7 years and a mean 
BMI of 31.7.  Of the 51 ACS patients, 25.5% presented with STEMI and 74.5% with NSTEMI.  
No patients presented with UA in this study population. 
 
3.3.2.2 Glutathione peroxidase, platelet reactivity and ROS levels 
GPx activity from the study population is shown in Figure 3-5A.  The mean GPx activity was 
108 ± 32 U/mL.  Platelet reactivity from the study population is shown in Figure 3-5B.  The 
mean platelet reactivity was 45 ± 21 AU.  The % inhibition of platelet aggregation in response 
to SNO-Glu was calculated for each patient, and is shown in Figure 3-5C.  The mean % 
inhibition was 39%.  The inverse of these values corresponds to the arbitrary ROS levels, as a 
larger shift in % inhibition represents greater NO-mediated platelet inhibition, suggesting a 
lower level of ROS is present.  ROS levels are shown in Figure 3-5D.  The mean ROS level was 
61 AU.  
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Table 3-1  Baseline characteristics of the ACS study population 
Characteristic ACS patients (n=51) 
Male 35 (68.6) 
Age (years) 60.7 ± 9.8 
Body mass index 31.7 ± 6.0 
Risk Factors  
Hypertension 30 (58.8) 
Dyslipidaemia 36 (70.6) 
Diabetes 11 (21.6) 
Current Smoker 11 (21.6) 
Clinical Presentation  
STEMI 13 (25.5) 
NSTEMI 38 (74.5) 
Continuous variables are expressed as mean ± SD , categorical variables as frequencies (percentages) 
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Figure 3-5  GPx activity, platelet reactivity, SNO-Glu and ROS levels.  
In 51 ACS patients the following measures are displayed A) GPx activity had a mean of 108 ± 
32 U/mL, range of 32-180 U/mL, B) platelet reactivity had a mean of 44 ± 21 AU, range of 11-
108 AU C) % inhibition of platelet aggregation mediated by SNO-Glu had a mean of 39 ± 16 %, 
range of 0-70 %, with inverse of these values corresponding to D) ROS levels that had a mean 
of 61 ± 16 AU, range of 29-100 AU.  
 
 
 
0
2
4
6
8
10
12
14
16
18
20
N
u
m
b
e
r 
o
f 
P
a
ti
e
n
ts
GPx Activity U/ml
0
5
10
15
20
25
N
u
m
b
e
r 
o
f 
P
a
ti
e
tn
s
Platelet reactivity (AU)
0
2
4
6
8
10
12
14
N
u
m
b
e
r 
o
f 
P
a
ti
e
n
ts
ROS levels (AU)
0
2
4
6
8
10
12
14
N
u
m
b
e
r 
o
f 
P
a
ti
e
n
ts
% Inhibition of Platelet Aggregation in 
response to SNO-Glu
A B 
C D 
 69 
No significant correlation was observed between GPx activity and absolute levels of platelet 
reactivity (Figure 3-6A).  Again, a non-significant relationship was observed between % 
inhibition of platelet aggregation in response to SNO-Glu, and the absolute level of platelet 
reactivity (Figure 3-6B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6  Correlation between platelet reactivity, GPx activity and SNO-Glu. 
A) Platelet reactivity (AU) was not significantly correlated with GPx activity (U/mL), r2=0.002, 
p=0.8, nor was B) platelet reactivity significantly correlated with % inhibition of platelet 
aggregation mediated by SNO-Glu, r2=0.007,p=0.6, Data plotted for all 51 ACS patients with 
Pearson’s correlation coefficient test. 
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A significant correlation was observed between GPx activity and the % inhibition of platelet 
aggregation in response to SNO-Glu (Figure 3-7A) (p<0.05).  This suggests that high levels of 
GPx activity are associated with a larger shift in inhibition of platelet aggregation mediated 
by SNO-Glu, which is indicative of lower levels of ROS.  Therefore high levels of GPx activity 
are correlated with low levels of ROS (Figure 3-7B) (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7  Correlation between GPx activity and ROS levels. 
A) GPx activity (U/mL) was significantly correlated with the level of % inhibition of platelet 
aggregation mediated by SNO-Glu, r2=0.1, *p<0.05.  % Inhibition is the inverse marker of ROS, 
therefore B) GPx activity was significantly inversely correlated with ROS levels (AU) r2=0.1, 
*p<0.05, Pearson’s correlation coefficient test. 
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3.4 Discussion 
 
This study aimed to examine the relationship between levels of GPx activity, platelet reactivity 
and ROS levels in an ACS population.  ROS levels were interpreted as the inverse values 
corresponding to SNO-Glu-mediated inhibition of platelet aggregation.  High levels of 
inhibition were suggested to reflect low levels of ROS in the blood, whilst lower levels of 
inhibition were suggested to reflect high levels of ROS in the blood.  Absolute levels of platelet 
reactivity were not found to correlate with GPx activity, nor with levels of ROS.  This suggests 
that neither GPx activity nor ROS levels are significant determinants of platelet reactivity in 
an ACS population.  GPx activity was found to significantly correlate with ROS levels, with high 
levels of GPx activity associated with low levels of ROS.  This is consistent with the theory 
from the previous chapter that high levels of GPx activity may play an important protective 
role in an ACS population by reducing ROS-mediated damage. 
 
Previous research has demonstrated that deficiencies in GPx activity is associated with a pro-
thrombotic state [70], and is implicated in platelet-dependent arterial thrombosis [72].  GPx 
activity has also been shown to preserve the bioavailability of NO [72], therefore sustaining 
platelet inhibitory mechanisms.  Additionally aberrant NO signalling has been associated with 
an increased risk of an MI [179].  Therefore we suggested that low levels of GPx activity may 
be associated with a higher level of platelet reactivity in an ACS population. This may have 
contributed to the increased MACE we observed in the ACS population from the previous 
chapter.  However we did not observe a significant association between GPx activity and 
platelet reactivity in this ACS cohort, suggesting that these two parameters are independent 
of each other.  
 
A possible explanation for the lack of relationship between GPx activity and platelet reactivity 
that we observed is the use of antiplatelet therapy in these patients.  All patients were on 
dual antiplatelet therapy consisting of clopidogrel and aspirin as part of their routine clinical 
management.  The residual platelet reactivity on treatment with these agents will be 
determined by a range of factors including patient co-morbidities and genetic variants [180, 
181].  It is probable that these factors may be more significant than the influence GPx may 
have on NO-mediated platelet inhibition for determining platelet reactivity levels. 
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It is well known that NO has the ability to critically affect platelet activation, but that NO is 
also inactivated upon interaction with ROS in the vasculature, leading to an impairment in its 
vascular dilatory and platelet inhibitory function [182].  We utilised the inhibitory nature of 
NO by adding the exogenous NO donor, S-nitrosoglutathione (SNO-Glu), a stable conjugate of 
endothelium derived NO.  S-nitrothiols, such as SNO-Glu, are naturally occurring thiol adducts 
of NO, and exhibit properties of NO, such as inhibiting platelet function and elevating 
intracellular cyclic guanosine monophosphate (cGMP) [72, 183].  By measuring platelet 
reactivity in our ACS study population, we were able to examine the level of inhibition by 
SNO-Glu on the level of platelet aggregation induced by ADP.  The difference was expressed 
as % inhibition of platelet aggregation.  Because SNO-Glu will be inactivated by high levels of 
ROS as demonstrated by Freedman et al. [72], we suggest that high levels of inhibition of will 
be due to low levels of ROS.   
 
We observed a considerable variability in ROS levels calculated by this method, and due to 
the knowledge that ROS levels have the ability to activate platelets [184], we hypothesised 
that ROS levels would be correlated with levels of platelet reactivity in the ACS patients.  
However, similar to the correlation between platelet reactivity and GPx activity, we did not 
observe a significant relationship between platelet reactivity and ROS levels in this ACS 
cohort.  A possible explanation for this relationship is again, that any effects of ROS on platelet 
reactivity are relatively small compared to the other factors driving variability in response to 
clopidogrel and aspirin. 
 
Our results did demonstrate a significant inverse correlation between levels of GPx activity 
and ROS.  This suggests that high levels of GPx are associated with lower levels of ROS in an 
ACS population.  This is consistent with the view from our previous chapter where GPx may 
have a protective role in an ACS population by mediating oxidant damage, and may contribute 
to the relationship seen between low levels of GPx activity and a higher rate of MACE.  
However we have not established whether this is a causative relationship.  On the basis that 
ACS patients demonstrate considerable variability in GPx activity levels from the previous 
chapter, we suggest that patients have a differential capacity to respond to levels of oxidative 
 73 
stress during an ACS event that may contribute to clinical risk.  However where this variability 
originates from and what is driving it remains undetermined. 
 
We observed an increased level of platelet inhibition after addition of GPx to SNO-Glu + ADP-
stimulated platelets, and we suggest that this is due to a decrease in ROS levels caused by 
GPx activity.  Therefore this allows SNO-Glu to inhibit platelet aggregation to a greater extent, 
than SNO-Glu treatment alone.  We suggest this demonstrates using SNO-Glu as a marker for 
ROS is an effective method in this study.  These assay conditions have been described 
previously by Freedman et al [176], where it was suggested that GPx activity preserves the 
function of SNO-Glu by scavenging ROS and lipid hydroperoixdes thereby preventing the 
inactivation of NO.  A further study confirms this concept in human studies where the addition 
of exogenous GPx normalised the platelets attenuated response to SNO-Glu [72].  
3.4.1 Limitations 
ACS represents a dynamic, rapidly evolving clinical condition.  This study was designed to 
examine the relationship between GPx activity, platelet reactivity and ROS levels.  It is likely 
that all three of these parameters will change rapidly during the time course of an ACS event, 
and may all be influenced by therapeutic interventions.  Our study has looked at these using 
a snapshot approach, taking samples at a single, non-standardised time point from each 
individual.  While this does allow us to examine the correlations that exist between these 
measures, this approach does not allow us to explore the dynamics of the system, and how 
this may influence the associations. 
 
While we have examined the relationships between GPx activity, platelet reactivity and ROS 
levels, this has been carried out in patients receiving antiplatelet therapy.  The influence that 
clopidogrel and aspirin have on platelet function may obscure relationships between these 
factors that may be different under other circumstances.  Furthermore, due to the SNO-Glu 
method being dependent on platelet function it is only suitable for comparing ROS levels 
within an ACS population.  It would have limited use for comparing across other coronary 
populations who have different antiplatelet medication profiles. 
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While we can provide robust, verified measures of GPx activity and platelet function through 
commercially available products that are widely used, there are significant limitations when 
choosing a marker for ROS in a clinical setting.  There are numerous species of ROS, most of 
which are volatile and have short half-lives.  This makes accurate and reproducible measures 
of ROS a challenge.  Because of this, there is a lack of widely used gold standard marker to 
quantify total ROS in a clinical setting.  We utilised a platelet function methodology based on 
the principal of NO consumption by ROS to determine ROS levels in whole blood. Although 
further validation studies are warranted to ensure this is an accurate representation of ROS 
in the blood, this measure has promising clinical application due to its simple, time-effective 
method.  Variation in sample timing and preparation may introduce unknown variability in 
ROS measures, therefore blood sampling was standardized and strict time protocols were 
adhered to in order to minimise these limitations. 
3.5 Conclusion 
In conclusion we demonstrate that GPx activity and ROS levels are not correlated with levels 
of platelet reactivity in ACS patients.  However low levels of GPx activity were found to be 
significantly associated with high levels of ROS.  This suggests that ACS patients may have a 
differential capacity in response to ROS levels, and that high levels may protect against ROS-
mediated damage.  However where this variability originates from and what is causing it, 
remains to be determined. 
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Chapter 4 - Comparison of the glutathione 
peroxidase system in healthy subjects, stable 
coronary artery disease and acute coronary 
syndromes 
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4.1 Introduction 
 
In Chapter 2, we reported a considerable variation in levels of GPx activity in ACS patients, 
with lower levels associated with an increased rate of MACE at 1 year.  We do not know 
whether GPx activity changes in response to an ACS event, and whether the variability we 
have observed is the product of a differential capacity to respond to an acute injury.  The 
alternative is that GPx activity may not differ with coronary disease progression, and the 
variability may occur regardless of disease state.  Previous literature on how GPx changes in 
an ACS population relative to healthy controls and patients with stable CAD has given 
conflicting results, with reports of increases [185], decreases [186] and no change [187] all 
featuring.  Resolving these contradictory reports regarding how the GPx enzyme differs in 
coronary disease progression is important for understanding its clinical significance.   
 
Understanding if there is variability between coronary disease states is not well defined; a 
common limitation among the studies is the lack of control for CVD risk factors that may 
influence the level of GPx activity.  Diabetes and gender may affect GPx activity levels, as seen 
in Chapter 2, and reported in previous studies [188, 189].  In addition, smoking, heart failure 
and arrhythmias such as atrial fibrillation may also affect GPx levels [170, 190, 191].  In order 
to clarify the differences in GPx levels in disease progression, it is necessary to control for 
these factors.  In addition, previous work has been mainly focused on examining GPx activity, 
with little or no information on corresponding changes in protein and mRNA expression 
levels.  By examining activity, protein and mRNA levels, a thorough understanding of the 
production, activity and variation of this antioxidant enzyme is possible. 
 
Since we previously assayed GPx activity from the plasma, and GPx3 is the predominant 
isoform reported to be present in the plasma [145] and implicated in thrombosis [70, 72], 
levels of the GPx3 protein were the main focus in this study.  Whole blood was used to 
determine levels of GPx mRNA expression, as levels have been shown to be comparable to 
those isolated from the major tissues [192]  e.g. heart, liver and kidney.  As well as GPx3, GPx1 
and GPx4 were measured for comparison, as all three isoforms have been implicated in CAD 
[70, 71, 193].  Since GPx2 is restricted to the gastrointestinal tract, and GPx5-GPx8 have only 
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putative roles or have not yet been characterised (Section 1.7.6-8), they were excluded from 
analysis. 
 
Thus, the aims of this study were to investigate the following parameters in healthy subjects, 
stable CAD patients and ACS patients:   
 
 To examine the levels of GPx activity and GPx3 protein concentration. 
 To examine GPx1, 3 and 4 mRNA expression levels. 
 To examine the levels of oxLDL in order to relate the GPx measures to an oxidative 
stress marker. 
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4.2 Methods 
 
4.2.1 Study population 
Three patient groups were included to investigate the GPx system and oxidative stress status.  
All patients in the healthy and stable CAD groups provided informed written consent, and the 
study was reviewed and approved by the Central Health and Disability Ethics Committee 
(13/CEN/29) (Appendix 1).  Similarly, a subset of ACS patients from a larger ongoing study 
from our laboratory group provided informed written consent that received ethics approval 
from the Lower South Ethics Committee (LRS/11/09/035) (Appendix 1). 
4.2.1.1 Healthy volunteers 
Healthy volunteers were recruited using poster advertisements and word of mouth.  Twenty 
volunteers were age-matched and gender-matched to the cohort of 20 ACS patients.  Criteria 
of the study dictated that volunteers had no known cardiovascular disease, or other acute 
illness in the preceding six weeks.  Other exclusion criteria included diabetes, smoking, 
pregnancy, and those who were on regular cardiovascular or immune-modulating medication 
or had been treated with antiplatelet therapies or non-steroidal anti-inflammatory drugs 
(NSAID) within the last 7 days. 
4.2.1.2 Stable coronary disease patients 
Stable coronary patients were recruited through Wellington Hospital cardiology outpatient 
clinics.  Twenty stable CAD patients were age-matched and gender-matched to the cohort of 
20 ACS patients.  Criteria of the study dictated that patients have confirmed coronary disease 
by either angiographic evidence of a greater than 70% stenosis in a significant coronary artery 
and be receiving chronic aspirin therapy (100 mg/day).  Exclusion criteria included diabetes, 
pregnancy, smoking, and acute illness in the preceding six weeks. 
4.2.1.3 Acute coronary syndrome patients 
Patients presenting to Wellington Regional Hospital with ACS and undergoing an invasive 
approach (coronary angiography ± PCI) adequately pre-treated with dual antiplatelet 
medications were eligible for inclusion.  ACS was defined as having symptoms suggestive of 
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ischaemia lasting > 10 min in duration coupled with either a troponin elevation or new 1 mm 
ST-segment deviation or T wave inversion in at least 2 contiguous leads [24].  Adequate pre-
treatment with antiplatelet medications was defined as chronic therapy with aspirin (≥75 mg) 
and clopidogrel (≥75 mg) or loading with aspirin ≥300 mg at least 2 hours before or clopidogrel 
≥300 mg at least 6 hours before enrolment.  Exclusion criteria included a platelet count less 
than 100 x 109/L, known platelet function disorder, administration of a fibrinolytic agent 
within 24 hr of enrolment and administration of a glycoprotein IIb/IIIa receptor antagonist 
within a week prior to enrolment.  Additional exclusion criteria included smoking, diabetes, 
pregnancy, or an age outside the range of 45-65 years old.  
4.2.2 Data collection and blood sampling 
Patient demographics, clinical characteristics, medications including antiplatelet therapy and 
clinical management were collected prospectively from review of the medical records and 
cardiac catheterisation database. Blood samples were collected from ACS patients within a 
mean time of 2-4 days post-presentation to hospital.  Samples were collected into tubes 
anticoagulated with sodium citrate (0.109M, BD Vacutainer) from a peripheral vein using a 
21-gauge needle before angiography or alternatively in the cardiac catheterisation laboratory 
from the arterial sheath immediately after catheter insertion and prior to administration of 
heparin.  Blood samples from stable CAD patients and healthy subjects were collected from 
the Clinical Measurement Unit at Wellington Hospital.  Citrated whole blood was centrifuged 
at 1500 g for 12 min at 4°C to extract plasma for antioxidant activity measurement.  Aliquots 
were stored at -80˚C until required for analysis.  
4.2.3 Glutathione peroxidase system 
4.2.3.1 GPx activity assay 
Glutathione peroxidase activity assay kits (Enzo Lifesciences) were carried out as described in 
Section 2.2.5.1.  GPx activity was defined as nanomoles of NADPH consumed per minute, and 
expressed as units per mL of plasma.  Intra-assay coefficient of variance was 9.9%, and inter-
assay coefficient of variance was 8.1%. 
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4.2.3.2 GPx3 protein ELISA kit 
GPx3 has been the predominant isoform reported to be present in human plasma, therefore 
a sandwich GPx3 (human) ELISA KitTM (Adipogen International, CA, USA) was used to detect 
GPx3 protein levels in the plasma as per manufacturer’s instructions.  Plasma samples were 
diluted 1:1000 with 1x ELISA buffer and measured in duplicate.  Human GPx3 standard 
supplied by the manufacturer was used to construct a protein standard curve.  The standard 
protein concentrate (64 ng/mL) was reconstituted with 1 mL deionised water and 2-fold serial 
dilutions made with 1x ELISA buffer to generate a seven-point standard curve (0-32 ng/mL).  
100 µL of standards and samples were added to 96-well plates pre-coated with a specific 
polyclonal antibody to GPx3, and incubated for 1 hr at 37˚C.  The standards and samples were 
discarded and the plate washed three times with 1x Wash Buffer.  A 100 µL volume of the 
Detection Antibody, a biotinylated polyclonal antibody specific to GPx3, was added to each 
well and incubated for 1 hr at 37˚C.  After the antibody solution was removed and the plates 
washed three times with 1x Wash Buffer, 100 µL of horse radish peroxidase labelled 
streptavidin (STREP-HRP, 1:200) was added and incubated for 1 hr at 37˚C.  The STREP-HRP 
solution was discarded and plates washed five times with 1x Wash Buffer.  After the final 
wash, 100 µL of TMB Substrate Solution was added to the wells, and the colour allowed to 
develop for 20 min at room temperature.  The colour reaction was stopped by addition of 100 
µL of the acidic Stop Solution to each well.  The optical density of the plate was measured at 
450 nm on microplate reader (VersaMax™) and a standard curve was generated on Microsoft 
Excel software to determine the sample concentrations of GPx3 protein.  Intra-assay 
coefficient of variance was 2.5% and inter-assay coefficient of variance was 7.2%. 
4.2.3.3 Quantitative real-time PCR (qPCR): GPx mRNA expression 
4.2.3.3.1 RNA extraction and cDNA synthesis 
Total RNA from whole blood was extracted using the QIAamp® RNA blood mini kit (Qiagen; 
Hilden, Germany) following the manufacturer’s instructions.  In detail, 1 mL of citrated whole 
blood was incubated with 5 mL of Buffer EL for 15 min on ice to ensure erythrocyte lysis.  
Leukocytes were pelleted by centrifugation at 400 x g at 4˚C for 10 min, and resuspended 
with a further 2 mL of Buffer EL.  The pellet was recovered by another centrifugation spin at 
400 x g at 4˚C for 10 min.  A volume of 600 µL of Buffer RLT was used to resuspend the pellet 
 81 
by thorough vortexing for 1 min.  The lysate was transferred to a QIAshredder spin column 
and centrifuged at maximum speed (16,000 x g) for 2 min at room temperature to 
homogenize the lysate pellet.   Precipitation of the homogenized lysate was carried out by 
mixing with 600 µL of 70% ethanol to adjust binding conditions.  The sample was transferred 
to a QIAamp spin column and centrifuged at 10,000 x g at room temperature for 15 s to allow 
selective binding of RNA to the silica-based membrane in the spin column.  After washing 
away contaminants by centrifuging 350 µL Buffer RW1 through the spin column at 10,000 x g 
at RT for 15 s, 80 µL of DNase Buffer containing 10 µL of Dnase I stock solution was added to 
the column and incubated at room temeprature for 15 min.  A further wash step with Buffer 
RW1 was carried out.  Buffer RPE (500 µL) containing 99% ethanol was used to wash the spin 
column by centrifugation at maximum speed for 3 min.  Traces of ethanol were removed by 
a second centrifugation of the empty spin column at maximum speed for 1 min.  The QIAamp 
spin column was transferred to a 1.5 mL microcentrifuge tube and 30 µL of RNase-free water 
was used to elute the RNA bound to the column by centrifugation at 12,000 x g for 1 min.  
This step was repeated to ensure all RNA was eluted.  RNA was quantified using a Bioanalyzer 
2100 (Agilent Technologies Inc; Santa Clara, USA).  Aliquots of RNA were stored at -80˚C until 
required for complementary DNA (cDNA) synthesis as described below. 
 
The synthesis of cDNA from total RNA was performed using the SuperScript® ViLo™ cDNA 
Synthesis Kit (Invitrogen; Auckland, NZ) following the manufacturer’s instructions.  In detail, 
10 ng of the RNA sample made up to a final volume of 10 µL was added to 4 µL of 5x VILO 
reaction mix, 2 µL of 10x SuperScript® ViLo™ enzyme and made up to a total volume of 20 µL 
with 4 µL of RNAse-free distilled water.  The reaction was mixed by thorough vortexing, and 
the samples were incubated in the Corbett Rotor-Gene 6000 machine (model no. 11754-050; 
Corbett Life Science; Sydney, Australia) under the following conditions: 25˚C for 10 min, 42˚C 
for 120 min, 85˚C for 5 min.  The samples were removed immediately following cDNA 
synthesis and stored at -20˚C until required for qPCR experiments (described below). 
4.2.3.3.2 Real-time qPCR with SYBR Green chemistry 
Gene expression was quantified on the Corbett Rotor-Gene 6000 machine using Brilliant II 
SYBR® Green QPCR Master Mix (Agilent Technologies).  SYBR® Green dye detects PCR 
products by binding to double-stranded DNA formed during DNA polymerase amplification of 
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the target sequence.  The result is an increase in fluorescence intensity proportional to the 
amount of PCR product produced.  Each reaction contained a set of optimised concentrations 
of the appropriate forward and reverse primers (Invitrogen; Auckland, NZ), SYBR® Green 
master mix (Agilent Technologies), and cDNA template, and was made up to a total volume 
of 52 µL with UltraPure dH2O (Invitrogen).  This reaction was mixed by vortex before being 
pipetted in duplicate 25 µL aliquots into 0.1 mL strip eppendorfs.  Each qPCR experiment 
contained a calibrator control, a no template control and an RNA control.  The calibrator 
control contained RNA extracted from a healthy subject used for all qPCR optimization 
experiments, and was included in every experiment to enable normalisation against 
differences in the qPCR reactions.  The thermal cycle conditions were as follows: 10 min at 
95˚C, then 40 repeats of 15 s at 95˚C and 60 s at 60˚C.  To check primer specificity, a final melt 
step was added that involved heating the samples from 60˚C to 95˚C, with 5 s incubations for 
each 0.5˚C rise in temperature.  As the temperature rises, double-stranded DNA will denature 
at a specific temperature depending on the sequence, which results in the release of the 
intercalated SYBR green and therefore a reduction in the fluorescent signal.  The Corbett 
Rotor-Gene Q Series Software v2.3.1 then plots the negative first derivative of the change in 
fluorescence as a function of temperature, and specific PCR products will produce distinct 
peaks in the graph.  Single peaks indicate a single product, whereas a diffuse peak in the lower 
temperature range indicates other products such as primer dimers, or genomic DNA 
contamination.  Melt curve analysis was also carried out on negative controls to ensure there 
was no contamination. 
4.2.3.3.3 Primer optimisation and efficiency testing 
To determine gene expression levels of GPx1, GPx3 and GPx4, specific primer sequences were 
chosen from the literature and ordered through Invitrogen, along with reference genes 
glyceraldehye-3-phosphate dehydrogenase (GAPDH) and 18S ribosomal RNA (18S) which 
were designed using the Beacon Designer™ software v8.0 (Premier Biosoft International; 
California, USA).  The sequences of each forward and reverse oligonucleotide primer set are 
listed in Table 4-1.   
 
The optimal concentration of the forward and reverse primers for each gene was determined 
individually by titration of the primer concentrations between 50 nM and 300 nM.  The 
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combination of primer concentrations that gave the lowest cycle threshold (Ct) value without 
compromising on endpoint fluorescence was chosen.  The optimal primer concentrations for 
each gene are shown in Table 4-2. 
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Table 4-1 Oligonucleotide sequences.   
Oligonucleotide sequences for forward and reverse primers used in SYBR Green qPCR 
reactions, including reference source and NCBI accession numbers, for each gene 
investigated. 
 
 
Table 4-2  Optimal final concentrations (nM) of forward and reverse primers. 
Gene Forward Primer Reverse Primer 
GPx1 100 100 
GPx3 100 200 
GPx4 200 200 
GAPDH 300 200 
18S 200 300 
 
 
 
 
 
 
Primer Target/Ref NCBI Accession 
No. 
Forward (F)/ 
Reverse R) 
Primer Sequence 5’-3’ 
GPx1 [194] NM_000581 F GCAACCAGTTTGGGCATCAG 
  R CGTTCACCTCGCACTTCTCG 
GPx3 [195] NM-002084 F CATCCCCTTCAAGCAGTATGC 
  R GCCCGTCAGGCCCTCAGTAG 
GPx4 [194] NM_001039848 F TGGGAAATGCCATCAAGTGG 
  R GGTCCTTCTCTATCACCAGGGG 
GAPDH NM_001289745 F CGGATTTGGTCGTATTGG 
Beacon Designer™  R GGTGGAATCATATTGGAACAT 
18S M10098 F GACAGGATTGACAGATTGATAG 
Beacon Designer™  R AATCGCTCCACCAACTAA 
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Primer efficiencies were calculated for each primer set.  Determining the reaction efficiency 
is critical for data interpretation, as primer sets with poor efficiency will have poor sensitivity.  
A cDNA dilution series was prepared, with each successive dilution containing half the 
concentration of cDNA.  Mean Ct values were plotted against the log of the concentration of 
the template, and the reaction efficiency calculated by the Rotor-Gene Q Series Software.  R2 
values show the fit of the trendline to the data, and the efficiency is related to the slope (m):  
E=(10-1/m)-1 
E=1=100% 
If the reaction had 100% efficiency, the Ct value for each successive dilution would differ by 
1.0, as Ct values are on a logarithmic scale.  Ideally primer efficiencies should be 
approximately 100%, as less indicates the presence of primer dimers, and greater than 100% 
indicates the presence of non-specific products.  The primer efficiencies for each of the genes 
are presented in Figure 4-1.  Primer efficiencies were calculated from the slope of the line and 
are: GPx1 100%, GPx3 98%, GPx4 103%, GAPDH 100%, 18S 95%.   
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Figure 4-1  Primer Efficiencies. 
cDNA template dilutions were amplified in duplicate and the average Ct value was plotted 
against the log of the concentration for each primer set. R2 values show the line of best fit, 
and the slope was used to calculate the efficiencies (E) for each primer set.  
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4.2.3.3.4 qPCR Analysis 
Two technical replicates were performed on all samples, with each replicate measuring all 
samples in duplicate.  The mean Ct value of each duplicate was used for analysis.  Any 
duplicates with Ct values differing by more than 0.5 were not used in the final data.  Validation 
of the two reference genes, GAPDH and 18S, was carried out by plotting the mean Ct values 
in GraphPad Prism 6 Software and demonstrate a significant correlation (p<0.0001) (Figure 4-
2).  The gene abundance of GAPDH was a closer match to the target genes, therefore GAPDH 
was used as the reference gene for further analysis of target gene expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2 Linear regression of mean Ct values for GAPDH vs 18S.   
Pearson’s correlation test showed a significant relationship, r2 value = 0.7, ****p<0.0001. 
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Relative gene expression was calculated using the 2(-ΔΔCt) as described previously by Livak et 
al. [196].  Each sample had its gene expression normalised to the reference gene (GAPDH), 
then further corrected for the internal calibrator control, and the result obtained is the 
relative fold increase (or decrease) of the target gene.  Normalising the expression of the 
target gene to that of the reference gene compensates for any difference in the amount of 
RNA added to the reverse transcription reactions, and using an internal calibrator control 
corrects for inter-assay differences. 
 
For each sample and calibrator control, the Ct value for GAPDH was subtracted from the Ct 
value of the gene (Gpx1 or GPx3 or GPx4) to give the ΔCt value.  For each gene, the average 
ΔCt of the calibrator control was calculated and subtracted from the ΔCt values for each 
sample to give the ΔΔCt.  The ΔΔCt values were converted to linear values by applying the 
formula 2(-ΔΔCt).  This formula gives a positive change in linear values as mRNA levels increase.  
The average 2(-ΔΔCt) was calculated for the two technical replicates carried out to give the 
mean relative change in gene expression corrected to the calibrator control and normalised 
to GAPDH.  Statistical analysis was performed using the GraphPad Prism 6 software program 
with a one-way ANOVA with Tukey’s multiple comparisons test to detect mRNA expression 
differences between the patient cohorts.  Intra- and inter-assay coefficient of variance values 
were calculated based on mean Ct values for each gene using a two-way ANOVA.  Intra- and 
inter-assay coefficient of variances are as follows, respectively: GPx1 (1.7% & 0.9%), GPx3 
(0.3% & 0.9%), GPx4 (0.4% & 0.9%) and GAPDH (0.4% & 0.3%). 
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4.2.4 Oxidised LDL ELISA 
The amount of oxLDL present in plasma samples was measured using a sandwich ELISA in 
accordance with the manufacturer’s guidelines (Oxidized LDL ELISA, Mercodia; Uppsala, 
Sweden).   The solid phase two-site enzyme immunoassay is based on the direct sandwich 
technique in which two monoclonal antibodies are directed against separate antigenic 
determinants on the oxidized apolipoprotein B molecule.  Briefly, all reagents were brought 
to room temperature and the lyophilized human oxLDL calibrators were reconstituted in 
redistilled water and used to construct a calibrator curve for each assay. Concentrations 
ranged from 1.24 – 20.1 mU/L.  A 25 µL sample, calibrator or control was added to a 96-well 
plate that was pre-coated with the specific murine monoclonal antibody, mAb-4E6 that 
targets oxLDL.  Plasma samples were diluted 1/6561 using Sample Buffer 1X solution and all 
samples were tested in duplicate.  The plate was sealed and incubated at room temperature 
for 2 hr while shaking at 800 rpm.  The plate was washed and incubated for 1 hr at room 
temperature while shaking with the detector antibody, peroxidase-conjugated anti-human 
apolipoprotein B antibody that recognises the oxLDL bound to the solid phase.  The bound 
conjugate was detected after washing of the plate by addition of Substrate TMB (3,3’, 5,5’-
tetramethylbenzidine) and incubation for 15 min in the dark at room temperature.  The 
reaction was stopped by addition of acid (Stop Solution) to give a colourimetric endpoint that 
was read spectrophotometrically at 450 nm (VersaMax™).  The concentration of oxLDL in the 
samples was determined by computerised data reduction of the absorbance for the 
calibrators’ vs the concentration using a cubic spline regression in GraphPad Prism 6 software.  
Intra-assay coefficient of variance was 3.9% and inter-assay coefficient of variance was 9.9%. 
4.2.5 Statistical analysis 
Based on the observed level of GPx activity in Chapter 2 (mean ± SD, 123 ± 32.4 U/mL) we 
determined that to have an 80% chance of detecting a change of ± 30% across the three 
groups at p≤0.05 required 19 subjects per group.  We therefore designed the study to have 
20 patients per group.  Continuous variables were reported as mean ± SD, and categorical 
variables were reported as frequencies and percentages.  Statistical tests for continuous 
variables were performed using Student’s t-test and one-way ANOVA with Tukey’s multiple 
comparisons test, and chi-square or Fisher Exact tests for the categorical variables.  
Relationships between parameters were determined by Pearson’s correlation coefficient 
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tests.  Differences in values corresponding to p<0.05 were taken as statistically significant. All 
statistical analyses were carried out in either GraphPad Prism Software v.06 or SPSS v.22.  
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4.3 Results 
4.3.1 Baseline characteristics 
All three cohorts were age- and gender-matched. Baseline characteristics are presented in 
Table 4-3 and displays differences found between the cohorts.  The ACS patients had a 
significantly higher BMI than the stable CAD and healthy populations (p<0.001).  In the stable 
CAD cohort, 13 patients (65%) had hypertension and 16 patients (80%) had dyslipidaemia, 
whilst 9 ACS patients (45%) presented with hypertension and 14 (70%) with dyslipidaemia on 
index admission.  Table 4-4 lists the cardiovascular medications that the stable CAD and ACS 
patients were on at the time of enrolment in the study.  
 
Table 4-3  Baseline characteristics of patient groups. 
 Healthy Group 
N=20 
Stable Group 
N=20 
ACS Group 
N=20 
Male 15 (75) 17 (85) 16 (80) 
Age (years) 57.1 ± 6.5 59.4 ± 5.0 59.0 ± 6.6 
BMI 24.1 ± 2.8 28.0 ± 4.8*** 30 ± 5.1*** 
Ethnicity    
European 20 (100) 20 (100) 18 (90) 
Other 0 (0) 0 (0) 2 (20) 
Cardiovascular Risk 
Factors 
   
Prior MI 0 13 (65)**** 4 (20)*## 
Prior PCI 0 11 (55)**** 4 (20)*# 
Prior CABG 0 9 (45)*** 1 (5)## 
Prior Stroke 0 3 (15) 1 (5) 
Hypertension 0 13 (65)**** 9 (45)*** 
Dyslipidaemia 0 16 (80)**** 14 (70)**** 
Continuous variables expressed as mean ± SD, categorical variables expressed as frequencies (percentages).   
*denotes significance in relation to healthy group, #denotes significance in relation to stable group, *#p<0.05, 
##p<0.01, ***p<0.001, ****p<0.0001. 
 
 
Table 4-4 Cardiovascular medication profile of patient groups. 
 Healthy Group 
N=20 
Stable Group 
N=20 
ACS Group 
N=20 
ACE Inhibitor 0 7 (35) 9 (45) 
Beta-Blocker 0 15 (75) 14 (70) 
Ca Channel Antagonist 0 3 (15) 3 (15) 
Statin 0 16 (80) 18 (90) 
Nitrates 0 3 (15) 1 (5) 
Categorical variables expressed as frequencies (percentages). 
Abbreviations: ACE – angiotension converting enzyme.   
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4.3.2 Glutathione peroxidase measurements 
GPx activity was significantly higher in ACS patients (109 ± 7.7 U/mL) compared to activity 
levels in the stable CAD patients (95.2 ± 16.4 U/mL, p<0.01) and healthy subjects (87.6 ± 8.3 
U/mL, p<0.001) (Figure 4-3).  No difference was detected between the stable CAD patients 
and healthy volunteers. 
 
GPx3 protein concentrations were significantly higher in ACS patients (21.6 ± 9.5 µg/mL) 
compared to the stable CAD patients (16.5 ± 2.8 µg/mL, p<0.05) and healthy subjects (16.3 ± 
5.3 µg/mL, p<0.05) (Figure 4-4).  No difference was detected between the stable CAD patients 
and healthy volunteers. 
 
When examining the relationship between GPx activity and GPx3 protein levels, no significant 
correlation between the two measures was found in ACS patients (r2=0.02, p=0.56) or stable 
CAD patients (r2=0.02, p=0.58).  Although not statistically significant, there appeared to be a 
positive correlation between GPx activity and GPx3 protein levels in the healthy cohort 
(r2=0.17, p=0.071). 
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Figure 4-3 Levels of GPx activity 
Levels of GPx activity (U/mL) was measured in healthy subjects, stable CAD patients and ACS 
patients.  Data is plotted for all 20 patients in each cohort as mean ± SD, and one-way ANOVA 
with Tukey’s multiple comparison test was used to compare differences, **p<0.01, 
****p<0.0001.  Healthy subjects are represented as Healthy, stable CAD patients as Stable 
and ACS patients as Acute. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4 Levels of GPx3 protein concentration 
Levels of GPx3 protein concentration (µg/mL) was measured in healthy subjects, stable CAD 
patients and ACS patients.  Data is plotted for all 20 patients in each cohort as mean ± SD, and 
one-way ANOVA with Tukey’s multiple comparison test was used to compare differences, 
*p<0.05.  Healthy subjects are presented as Healthy, stable CAD patients as Stable and ACS 
patients as Acute. 
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4.3.2.1 qPCR 
4.3.2.1.1 Trace images and melt curve analysis 
Figure 4-5 shows representative trace images of the amplification data for GPx1, GPx3, GPx4 
and GAPDH.  The corresponding melt-curve analysis conducted after amplification for each 
primer set is shown under each trace image.  Distinct single peaks can be seen for GPx1 
(82.5˚C), GPx3 (82.35˚C), GPx4 (82.60˚C) and GAPDH (79.85˚C).  Negative control samples 
containing H2O or RNA in place of cDNA template were run with each experiment, and melt-
curve analysis, as expected, showed no specific products for these samples (Figure 4-5). 
4.3.2.1.2 GPx mRNA expression levels 
GPx1, GPx3 and GPx4 mRNA expressions were measured from whole blood samples collected 
from 19 healthy volunteers, 20 stable CAD patients and 20 ACS patients.  One sample from a 
healthy volunteer could not be used for qPCR analysis due to degradation, and it was 
therefore excluded from analysis.   
 
GPx1 mRNA expression was significantly higher in ACS patients, with a 1.6 fold increase 
compared to healthy controls (p<0.0001).  No difference was detected between ACS and 
stable CAD patients (1.3 vs 1.1 fold change, respectively, p=0.12).   Stable CAD patients had a 
1.4 fold increase in GPx1 mRNA levels when compared to healthy controls (p<0.01) (Figure 4-
6A). 
 
GPx3 mRNA expression was significantly higher in ACS patients, with a 1.9 fold increase when 
compared to stable CAD patients (p<0.01).  Although the difference was not significant, the 
fold change in GPx3 expression was higher in ACS patients compared to healthy controls (2.6 
vs 1.8 fold change, respectively, p=0.09).  No difference was detected between the stable CAD 
and healthy cohorts in GPx3 mRNA expression (1.4 vs 1.8 fold change, respectively, p=0.42) 
(Figure 4-6B). 
 
GPx4 mRNA expression was significantly higher in ACS patients, with a 1.4 fold increase 
compared to both stable CAD patients and healthy controls (p<0.01).  No significant 
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differences were detected between the stable CAD and the healthy cohorts (1.02 vs 1.03 fold 
change, respectively, p=0.99) (Figure 4-6C) 
 
Pearson’s correlation tests did not demonstrate any significant relationships between GPx3 
mRNA and GPx3 concentration levels in ACS patients (r2=0.01, p=0.65), stable CAD patients 
(r2=0.06, p=0.31) and the healthy controls (r2=0.04, p=0.43).  Again no significant correlations 
were observed when comparing GPx3 mRNA and GPx activity levels in ACS patients (r2=0.02, 
p=0.55), stable CAD patients (r2=0.04, p=0.42) and healthy controls (r2=0.003, p=0.83)  
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Figure 4-5 Representative data from real-time PCR experiments.  
(A-D) Representative trace images in left column (X axis ‘Norm Fluoro’, Y axis ‘cycle’) and 
corresponding melt curve profiles in right column (X axis ‘dF/dT’, Y axis ‘˚C’) for GPx1 (A), 
GPx3 (B), GPx4 (C) and GAPDH (D).  All samples were run in duplicate, and duplicates of RNA 
and H2O negative controls (samples that stay below the threshold line in the trace image) 
were run with every experiment.  The melt curves show a single distinct peak for each gene, 
indicating a single specific PCR product. (E) Representative melt curve profile analysis for 
negative controls show no specific PCR product.  
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Figure 4-6  GPx 1, 3 and 4 mRNA expression levels 
Levels of GPx1 (A), GPx3 (B) and GPx4 (C) mRNA expression were measured in healthy 
subjects, stable CAD patients and ACS patients.  D) Bar graph displays all three isoforms on 
the same y axis to compare the magnitude of change in each isoform for each cohort.  mRNA 
expression is presented as arbitrary values expressed as fold change relative to GAPDH and 
normalised to calibrator control.  Fold change is relative to the value 1.0.    Data is plotted for 
19 healthy subjects and 20 stable CAD and ACS patients as mean ± SD.  One-way ANOVA with 
Tukey’s multiple comparison test was used to compare differences, *p<0.05, **p<0.01, 
****p<0.0001. Healthy subjects are presented as Healthy, stable CAD patients as Stable and 
ACS patients as Acute. 
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4.3.3 Oxidative stress biomarkers 
OxLDL was significantly higher in the ACS patients (61.9 ± 22.2 U/L) compared to the stable 
CAD (47.8 ± 10.4 U/L, p<0.05) and healthy cohorts (48.9 ± 11.9 U/L, p<0.05) (Figure 4-7).  No 
significant difference was detected between the stable CAD and the healthy cohorts.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 Levels of oxLDL 
Levels of oxLDL (U/L) were measured in healthy subjects, stable CAD patients and ACS 
patients.  Data is plotted for all 20 patients in each cohort as mean ± SD, and one-way ANOVA 
with Tukey’s multiple comparison test was used to compare differences, *p<0.05.  Healthy 
subjects are presented as Healthy, stable CAD patients as Stable and ACS patients as Acute. 
 
 
4.3.4 Correlation between GPx and oxidative stress biomarkers 
Pearson’s correlation tests did not demonstrate any significant relationships between GPx 
activity and oxLDL levels in ACS patients (r2=0.02, p=0.51), stable CAD patients (r2=0.07, 
p=0.26) and the healthy controls (r2=0.02, p=0.55). ).  Again no significant correlations were 
observed when comparing GPx3 concentration and oxLDL levels in ACS patients (r2=0.03, 
p=0.47), stable CAD patients (r2=0.03, p=0.49) and the healthy controls (r2=0.03, p=0.47).   
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4.4 Discussion 
 
This study demonstrated that ACS patients had higher levels of GPx activity, with 
corresponding increases seen in both protein and mRNA expression levels, when compared 
to stable CAD patients and healthy controls.  Levels of oxLDL were also seen to be higher in 
ACS patients relative to the stable CAD patients and healthy controls.  Therefore these results 
suggest that the ACS cohort experience higher levels of oxidative stress, with a corresponding 
systemic increase in the GPx system.  It is unclear whether the relationship between increased 
oxLDL and the increased levels of the GPx system is a causal relationship or an associative 
one.   
4.4.1 GPx system 
4.4.1.1 GPx activity 
The increase in GPx activity we observed in this ACS cohort suggests that the GPx enzyme may 
be influenced during the acute event.  No difference was detected in GPx activity between 
the stable CAD patients and healthy controls, suggesting lower levels of GPx activity are found 
in healthy subjects and CAD patients who are clinically stable.   Our results are consistent with 
studies published by Kok et al. [185] and Bor et al. [197] who report increased levels of GPx 
activity in ACS patients.  Although these studies utilised erythrocyte lysates to measure GPx 
activity, a positive correlation has been reported between erythrocyte-GPx and plasma-GPx 
activity [198], allowing us to compare our results to these other studies.  Similarly Zachara et 
al. [171] found that plasma GPx activity was significantly higher at day 2 post-ACS compared 
to healthy controls.   
 
However, there are other studies that have reported no difference in GPx activity between 
ACS patients and healthy subjects [187, 199], and some studies that have reported that GPx 
activity is lower in ACS patients when compared to healthy subjects [186, 200].  It is not clear 
what accounts for these existing differences in the literature. Different studies utilise different 
methodologies in terms of when samples are taken in the course of an acute event, the type 
of ACS patients recruited, how samples are handled and whether GPx activity is examined in 
plasma, cell fractions, or whole blood. It is not known how these factors may influence 
measurement of GPx.  In addition, patient factors are not always adequately controlled.  
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Factors such as age, gender, smoking and diabetes, all of which may influence both oxidative 
stress levels and GPx activity [169, 189, 198, 201], have been variably controlled for in the 
literature.  Table 4-5 provides a summary of the studies examined in this discussion.   
 
Since the cause of variability in GPx activity between patients is not well understood, this adds 
to the challenge of understanding the role of GPx in coronary disease progression.  The 
influence that age, gender, lifestyle and environmental factors have on GPx activity is not well 
established.  GPx activity is thought to decrease with age [198], smoking [170], and diabetes 
[202] and is reported to be higher in women [189].  Without controlling for these factors, it is 
possible that some of the differences in GPx activity seen in previous studies may be due to 
confounding factors rather than an accurate reflection of the progression of CAD. Therefore 
this may contribute to the variable results as depicted in Table 4-5.  The current study has 
controlled for cardiovascular risk factors that have been reported to influence levels of GPx 
activity in order to minimise possible confounding factors.   
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Table 4-5  Summary of factors used in GPx activity studies  
First author, Year, 
Reference 
Enzyme/population Biological 
source 
Characteristics Conclusion 
Diabetes Age Gender Smoking 
Kok et al, 1989 [185] GPx/AMI & healthy Erythrocyte x   x GPx higher in AMI vs healthy. 
Jayakumari et al, 1992 
[203] 
GPx, SOD, CAT & LPx in 
UA, SA & healthy 
Erythrocyte x   x GPx & CAT unchanged.  SOD lower in SA vs 
healthy, higher in UA vs SA & healthy.  LPx 
higher in SA & UA vs healthy. 
Akyol et al, 1993 [186] GPx in AMI, UA & 
healthy 
Serum  x x NS Higher GPx in AMI vs UA, both lower than 
healthy. 
Bor et al, 1999 [197] GPx in AMI vs healthy Erythrocyte & 
plasma 
NS  NS NS Ery GPx higher in AMI vs healthy, no change 
in plasma GPx 
Dusinovic et al, 1998 
[187] 
GPx in AMI vs healthy Erythrocyte NS NS NS NS No significant change in GPx. 
Dwivedi et al, 2006 [204] Whole blood SOD, CAT 
& GR in AMI vs healthy 
Whole blood NS   NS Lower antioxidants in AMI vs healthy. 
Zachara et al, 2001 [171] GPx in AMI vs healthy Erythrocyte & 
plasma 
NS   NS Plasma GPx higher in AMI at day 2 vs healthy, 
no change in ery GPX 
Dubois-Rande et al, 1994 
[199] 
GPx in UA , SA & 
healthy 
Plasma NS  NS NS No significant change in GPx. 
Lafont et al, 1996 [200] GPx in AMI vs healthy Erythrocyte x x x x GPx lower in AMI vs healthy 
Gunaldi et al, 2012 [205] GPx in AMI vs healthy Serum  x x NS Non-significant rise in GPx in AMI vs healthy 
Cheng et al, 2009 [206] GPx in AMI vs healthy Erythrocyte x   x GPx lower in AMI vs healthy 
Motghare et al, 2001 
[207] 
GPx & LPx in AMI, SA 
& healthy, whole 
blood 
Whole blood    x GPx lower in AMI vs healthy,  LPx higher in 
AMI vs healthy. No change in SA vs healthy. 
*NS - not stated by study ;  - controlled factor; x - uncontrolled factor.  Abbreviations: AMI -acute myocardial infarction; Ery - erythrocyte; GPx - glutathione peroxidase; 
LPx - lipid peroxides; UA - unstable angina; SOD - superoxide dismutase; CAT - catalase; SA - stable angina; GR - glutathione reductase;  
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4.4.1.2 GPx protein 
The studies on GPx listed in Table 4-5 have all focused on quantifying the level of activity of 
GPx.  There is little or no attention to the changes in the corresponding GPx protein levels in 
coronary disease progression that can be seen in the wider clinical literature.  We utilised a 
commercially available ELISA kit (Adipogen®) that provided a polyclonal antibody specific for 
GPx3, and detected a significant increase in this protein in the ACS cohort, with no differences 
detected between the stable CAD and healthy cohorts.  While this implies some level of 
coupling between protein and activity levels, within each cohort we did not observe a 
significant correlation between GPx3 protein and GPx activity levels in the plasma.  We did 
detect a non-significant correlation in the healthy cohort (p=0.07).  Overall this implies the 
coupling is relatively weak.  However this was not surprising, as GPx requires several 
secondary enzymes and cofactors [208] that influence the performance of the protein as an 
active enzyme [209].  It was beyond the scope of this study to monitor these other enzymes 
and cofactors, such as glutathione and selenium, but such information in future studies may 
help explain the extent of changes seen in GPx activity.  In addition, it is possible that GPx3 is 
not the only isoform present within the plasma accounting for total GPx activity [210].     
4.4.1.3 GPx mRNA 
We observed higher levels of mRNA for each of the GPx isoforms in ACS patients relative to 
stable CAD patients and healthy controls, although these differences were not statistically 
significant in all cases. Levels of GPx3 mRNA showed the greatest variance of the three 
isoforms, and this limited our ability to detect GPx3 differences between groups.  What 
accounts for this variance cannot be determined from this study.  It may be that the study is 
underpowered to look for differences in these populations, as the cohorts are a moderate 
size of 20 subjects (study power was to determine differences in GPx activity rather than 
mRNA levels, see Section 4.2.5). This may account for why a significant difference was 
detected only between ACS patients and the stable CAD patients, and not between ACS 
patients and healthy subjects.   
 
What accounts for the differential upregulation seen across the GPx isoforms cannot be 
determined from the results of this study. The extent of transcriptional and translational 
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regulation of the GPx enzymes in the progression of CAD has not yet been fully determined.  
As these GPx isoforms are selenoproteins, their biosynthesis is dependent on the availability 
of selenium that is incorporated into the growing polypeptide chain [134].  Consequently, 
selenium is an essential cofactor for optimal GPx activity [211].  As mentioned above, GPx 
cofactors such as selenium were not measured in this study, however it would be interesting 
to determine the role they play in the level of GPx upregulation seen in this study.  
Transcription binding sites and promoter regions that are modulated through oxygen tension 
and levels of hypoxia have been described in GPx1 and GPx3 mRNA [209, 212] and may 
account for the increased GPx mRNA seen in ACS patients who present with greater levels of 
oxidative stress. 
 
Taken together, the mRNA data suggest that several isoforms of the GPx enzyme are 
upregulated in an ACS population.  A recent study carried out in a mouse model suggests that 
GPx1 may contribute a small proportion to the total plasma activity [210].  Since our 
methodology for determining GPx activity does not allow us to differentiate between GPx 
isoforms, it is not possible to determine which isoform is contributing the activity measured 
in human plasma in this study.  Although the literature reports that GPx3 is the predominant 
isoform responsible for ROS reduction in the plasma [145], it may be possible that several 
isoforms may be secreted into the circulation. Further studies to corroborate what isoforms 
contribute to overall activity levels, both in the plasma and in the erythrocyte would be both 
interesting and relevant to our understanding of the intricacies of the GPx system.  
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4.4.2 Oxidative stress status in coronary disease progression 
This study demonstrated that ACS patients have significantly higher levels of oxLDL compared 
to stable CAD patients and healthy controls.  As oxLDL is a biomarker for the level of oxidative 
stress, it suggests that there is an increase in the pro-oxidant environment that promotes 
oxLDL formation.  There are a number of studies that consistently demonstrates protein and 
lipid oxidation biomarkers [53, 55, 213-215] and other ROS markers [216] are increased in 
ACS. 
 
The stable CAD patients did not exhibit elevated levels of oxLDL compared to the healthy 
controls.  This result is consistent with some studies that report no difference between these 
two groups [53, 215]; however an equal number of studies report a significant increase in 
oxLDL in their stable CAD cohorts versus healthy controls [217, 218].  Similar to the reports 
with GPx activity, it is not clear what the cause of this difference between the two sets of 
studies is.  Medical therapy for CVD, such as statins, have been reported to indirectly lower 
oxLDL levels by reducing levels of oxLDL constituents, LDL-C [219] and apolipoprotein B [220].  
However this is a routine medication that the majority of patients take in all studies, therefore 
it cannot fully explain the discrepancies.  We have applied rigorous controls for conditions 
known to possess high levels of oxidative stress, such as diabetes [169], smoking [201] and 
heart failure [221].  Although this may not fully explain the discrepancy in the literature, it is 
possible that the absence of these risk factors have contributed to the lower levels seen in 
our stable CAD patients who are clinically stable.   
 
It is well accepted that an MI represents an acute oxidative stress state [55]; however we 
cannot determine if the elevated levels of oxidative stress are causing the increase seen in 
GPx in this study.  Although a causative link has been reported previously in the literature, in 
which ROS is the driving force behind the changes in GPx activity, most of these studies rely 
on surrogate lipid or protein oxidation markers for measuring oxidative stress [213].  This is 
due to the challenge ROS molecules present when quantified in a clinical setting.  ROS have 
an evanescent nature, and their short half-lives make them good signalling molecules but 
confounds their measurement in the circulation by standard approaches [222].  Instead the 
focus is normally on measuring stable markers in the circulation that may reflect systemic 
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oxidative stress.  A consequence of excessive ROS in vivo is the modification of the LDL particle 
that generates oxLDL [43].  OxLDL is a frequently used marker for levels of oxidative stress 
and it has been implicated in de novo GSH synthesis [223], the obligatory cofactor for GPx 
activity.  Accordingly GPx activity is thought to indirectly lower oxLDL levels by consumption 
of H2O2 therefore minimising the level of oxidative modifications on the LDL compound [78].  
Whilst there is evidence that these two factors are associated, how dynamic these changes 
are throughout an ACS event cannot be determined from this study. 
 
Taken together, increased GPx mRNA, protein and activity all support the view that the GPx 
system is upregulated in an ACS event. This is consistent with the view that antioxidant 
defence systems will tend to respond to some form of acute challenge [63].  In the context of 
an ACS event, this challenge could encompass an increase in ROS production [224] as well as 
the increase in the overall pro-inflammatory environment associated with an MI [225].  In the 
present study, we have not examined what factors are leading to the change in the GPx 
system in ACS, or when these changes occur, but such studies would be strongly considered 
in future investigations.   
4.4.3 Limitations 
This study was designed to examine changes in the plasma measures of GPx and the 
corresponding oxidative stress levels.  It is possible that some calculations were 
underpowered to detect differences between the groups due to the moderate study size.   
 
Although we employed frequently used commercially available kits for analytical detection of 
our markers, these methods still have limitations.  All the methods used to assess oxLDL and 
GPx are indirect, and there is conflicting evidence about how well these circulating markers 
reflect oxidative stress in vivo [56].  Analytical differences between laboratories make it 
difficult to compare the results obtained in different studies.  Although most laboratories use 
methods based on the same methodological principles, the specific assay, conditions with 
regard to concentration of reagents, recording time, and temperature differ.  Sample handling 
is also extremely important for accurate measuring of oxidative stress.  For example, if 
samples are not immediately centrifuged at 4˚C after collection and stored appropriately, 
lipids have been shown to auto-oxidise [226]. 
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We controlled for multiple cardiovascular risk factors that may influence oxidative stress 
status in our three cohorts.  This may partially explain why our results differ from some 
previous studies.  Other factors, such as the type of ACS recruited and the timing of blood 
samples may introduce an unknown variance to measures of GPx and oxLDL.  For example, in 
our study, we collected blood within a mean time of 2-3 days post-MI.  Another study 
collected blood from patients who were admitted with a history of 5 hours of chest pain [207].  
Intra-patient variance has been reported [227], but an exact quantification of oxidative stress 
is not yet known in an ACS population.  Further investigation into the dynamics of GPx and 
oxLDL are warranted to understand how they are affected throughout the course of an ACS 
event, and whether an optimal sampling time can be identified. 
4.5 Conclusion 
In conclusion, this study has demonstrated that patients with ACS have higher levels of 
plasma-borne GPx, and multiple isoforms of GPx are correspondingly upregulated.  In turn, 
patients with ACS have higher levels of oxidative stress, as demonstrated by increased oxLDL 
levels.  We conclude that ACS patients have an increased oxidant/antioxidant status that is 
distinct from stable CAD patients and healthy subjects. 
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Chapter 5 - The dynamics of glutathione peroxidase 
and oxidised low-density lipoprotein during ST-
segment elevation myocardial infarction (STEMI) 
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5.1 Introduction 
 
Our results from Chapter 4 demonstrate that the GPx system is increased in ACS patients 
compared to stable CAD patients and healthy controls.  However, what has not been 
examined is the time course over which this change occurs.  In both Chapter 2 and Chapter 4 
single samples for the measurement of GPx activity were collected prior to angiography.  This 
was after a mean time of 2-4 days of patients presenting to hospital. 
 
How dynamic the changes in GPx activity are over the immediate course of an ACS is an 
important area of investigation.  There is limited data on the dynamics of GPx activity between 
index admission and throughout the development of an ACS.  One study reports an increase 
in GPx activity [171], whilst another reports no change [200] following reperfusion therapy 
and throughout the hospital admission. It is possible that some of the variation in GPx activity 
observed in Chapter 2 may have been due to differences in the timing of the sampling. 
Whether this is an important contributor, and how this may influence the relationship 
between measured activity and clinical outcomes is not known.   The present study was 
therefore designed as an exploratory investigation into the temporal changes of GPx activity 
that occur throughout an ACS event.   
 
Along with examining the temporal changes in GPx activity, oxLDL levels were measured.  This 
allows for the examination of corresponding changes in measures of oxidative stress in ACS 
patients.  Based on the theory that GPx is a defensive antioxidant enzyme, and therefore 
driven by changes in pro-oxidant levels, we hypothesise that similar temporal changes will 
occur in these two parameters. 
 
Thus, the aims of this study were: 
 To investigate the temporal changes in GPx activity and oxLDL levels in a STEMI cohort. 
 To compare whether the temporal changes of GPx activity and oxLDL display a similar 
pattern. 
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5.2 Methods 
 
5.2.1 Study population 
Twenty patients presenting to Wellington Regional Hospital with STEMI within 12 hours of 
symptom onset between January 2015 and May 2015 were eligible for inclusion in this study.  
STEMI was defined as symptoms consistent with myocardial ischaemia lasting longer than 15 
min, and ECG changes demonstrating new ST-segment elevation at the J point in two 
contiguous leads with the following cut points:  ≥0.1 mV in all leads other than V2-V3, where 
the following cut points apply: ≥0.2 mV in men ≥40 years, ≥0.25 mV in men ˂ 40 years or, ≥0.15 
mV in women as per the third universal definition of myocardial infarction [24].  Exclusion 
criteria consisted of inability to give informed consent, cardiogenic shock and/or referral for 
emergency coronary artery bypass grafting (CABG).  This study was reviewed and approved 
by the Northern B Health and Disability Ethics Committee (14/NTB/198) (Appendix 1).  
Participation was voluntary, and each patient provided written informed consent at the time 
of recruitment. 
5.2.2 Data collection  
Baseline demographics, clinical characteristics and procedural variables were collected 
prospectively from review of the medical records and cardiac catheterisation database.  
GRACE scores were calculated as previously described in Section 2.2.3.2.   
5.2.3 Blood collection 
Blood collection was sampled at empirical time points. The first two blood samples were 
collected immediately prior to angiography (Pre) and immediately following revascularisation 
(Post) directly from the arterial sheath.  The rationale was to collect measurements as close 
to the STEMI onset as possible following admission.  This allowed for further blood samples 
to be collected from a peripheral vein using a 21-gauge needle at the following time intervals 
post angiography: 6 hr, 12 hr, 24 hr, 48 hr and 72 hr, or up until the time of discharge. A 
follow-up blood sample was collected when the patient returned for their cardiology 
outpatient clinic visit between 6-12 weeks post-hospital discharge.  The rationale was to 
collect measurements at a time remote from the event in order to assess the levels when the 
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patient was clinically stable. Whole blood samples were collected into tubes anticoagulated 
with sodium citrate (0.109 M, BD Vacutainer).  Citrated whole blood was centrifuged at 1500 
g for 12 min at 4˚C to extract plasma.  Plasma was aliquoted and stored at -80˚C for 
subsequent analysis of GPx activity and oxLDL levels. 
5.2.4 GPx activity and oxLDL measurements 
Glutathione peroxidase activity assay kits (Enzo Lifesciences) were used to calculate GPx 
activity in the plasma samples as described in Section 2.2.5.1.  GPx activity was defined as 
nanomoles of NADPH consumed per minute and expressed as units per mL plasma.  The intra-
assay coefficient of variance was 7.8%, and the inter-assay coefficient of variance was 10.7%. 
 
OxLDL ELISA kits (Mercodia) were used to calculate oxLDL levels in the plasma samples as 
described in Section 4.2.4.  Concentration of oxLDL was determined by the cubic spline 
regression curve and expressed as units per mL plasma.  The intra-assay coefficient of variance 
was 5.8%, and the inter-assay coefficient of variance was 10.4%. 
 
For ease of comparisons, values for GPx activity and oxLDL were normalised to the pre-
angiography time point and expressed as a percentage increase or decrease respective to this 
baseline. 
 
5.2.5 Statistical analysis 
Continuous variables were reported as mean ± SD, and categorical variables were reported 
as frequencies and percentages.  Statistical tests to compare GPx activity and oxLDL over the 
different time points were carried out using either a one-way ANOVA with Tukey’s multiple 
comparisons or a Student’s paired t-test.  Chi-square test and Student’s t-test were used to 
compare categorical and continuous variables respectively.  Differences in values 
corresponding to p˂0.05 were considered statistically significant.  All statistical analyses were 
carried out in either GraphPad Prism Software v.06 or SPSS v.22.   
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5.3 Results 
 
5.3.1 Demographics and clinical characteristics 
Of the 20 study patients that were enrolled, 4 were excluded on the basis that blood samples 
after 24 hr could not be obtained.  Of these 4 patients, 2 were discharged back to regional 
hospitals, 1 had extremely poor venous access, and 1 withdrew consent.  The demographics 
and clinical characteristics of the remaining 16 patients are shown in Table 5-1.  The study 
population was found to be predominantly male (81%), with an average age of 61.5 years, 
and a BMI of 27.2.  Dyslipidaemia was diagnosed in 81.3% of patients, 50% had hypertension 
and 18.8% of patients were current smokers. 
5.3.2 Angiographic characteristics 
The angiographic characteristics of the 16 study patients are presented in Table 5-2.  
Angiographic success was obtained in all patients.  The mean peak value for high sensitivity-
troponin (hs-TnT) was 4669 ng/L.  The mean time between symptom onset of ischaemia and 
collection of the first blood sample (Pre) was 230 min.   
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Table 5-1  Demographics and clinical characteristics of study population. 
Patient # Age, 
years 
Gender 
M=1, F=0 
BMI Prior MI Family 
Hx 
HTN Dyslip AF Stroke PVD Current 
Smoker 
GRACE 
Scores 
Mean±SD 61.5±13.5  27.2±3.7         108±28 
Sum, (%)  13 (81.3)  1 (6.3) 5 (31.3) 8 (50) 13(81.3) 1 (6.3) 2 (12.5) 1 (6.3) 3 (18.8)  
1 79 1 22.0 0 0 1 1 0 1 0 0 135 
2 53 1 24.5 0 0 0 1 0 0 0 0 102 
3 49 1 25.2 0 1 0 1 0 0 0 1 96 
4 59 1 33.6 0 0 1 0 0 0 0 0 98 
5 74 1 24.8 0 0 1 1 0 1 0 0 129 
6 54 1 21.4 0 1 0 1 0 0 0 0 89 
7 81 1 24.5 0 0 1 1 1 0 1 0 158 
8 59 1 22.3 1 0 0 1 0 0 0 0 133 
9 70 0 30.9 0 0 1 1 0 0 0 0 120 
10 58 0 27.9 0 1 1 1 0 0 0 0 106 
11 65 1 29.4 0 1 0 1 0 0 0 0 114 
13 49 1 31.9 0 0 0 1 0 0 0 1 70 
14 77 1 26.4 0 0 1 0 0 0 0 0 141 
17 48 1 29.3 0 0 0 1 0 0 0 0 76 
19 34 1 30.3 0 1 0 1 0 0 0 1 55 
20 75 0 29.8 0 0 1 1 0 0 0 0 119 
Abbreviations: BMI – body mass index; MI – myocardial infarction; Hx – history; HTN – hypertension; dyslip – dyslipidaemia; AF – atrial fibrillation; PVD – peripheral vascular 
disease; GRACE – global registry of acute coronary events. 
The value of 1 implies ‘yes’ whereas the value of 0 implies ‘no’. 
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Table 5-2  Angiographic characteristics of study population. 
Patient # Peak  
hs-TnT 
(ng/L) 
Culprit lesion Culprit 
lesion 
stenosis 
ACC/AHA lesion classification # stents Angio-
graphic 
success 
Symptom onset –  
(Pre) sample 
 (mins) 
  LM LAD Cx RCA  A B1 B2 C BMS DES   
Mean ± SD 4669±3055             232 ± 140 
Sum, (%)  0 (0) 9 (56.3) 3 (18.8) 5 (31.3)  0 (0) 7 (43.8) 9 (56.3) 0 (0) 1 21 16(100)  
1 5684 0 1 0 0 95 0 1 0 0 0 1 1 140 
2 11298 0 1 0 0 100 0 1 0 0 0 1 1 170 
3 6514 0 0 1 0 100 0 1 0 0 0 1 1 100 
4 3157 0 1 0 0 100 0 1 0 0 0 1 1 100 
5 6080 0 0 0 1 95 0 1 0 0 1 0 1 125 
6 3533 0 0 0 1 100 0 0 1 0 0 2 1 180 
7 8326 0 1 0 0 100 0 0 1 0 0 3 1 228 
8 2675 0 0 1 0 100 0 0 1 0 0 1 1 135 
9 298 0 0 1 0 90 0 0 1 0 0 1 1 265 
10 149 0 0 0 1 100 0 0 1 0 0 1 1 190 
11 7979 0 1 0 0 100 0 1 0 0 0 1 1 510 
13 1978 0 1 0 0 95 0 0 1 0 0 2 1 120 
14 3958 0 1 0 0 90 0 1 0 0 0 2 1 310 
17 6970 0 1 0 0 100 0 0 1 0 0 1 1 123 
19 3090 0 0 0 1 100 0 0 1 0 0 1 1 495 
20 3017 0 1 0 1 100  0 0 1 0 0 2 1 302 
Abbreviations: hs-TnT - high-sensitivity troponin; LM – left main artery; LAD – left ascending artery; Cx – circumflex artery; RCA – right coronary artery; ACC – American 
College of Cardiology; AHA – American Heart Association; BMS – bare metal stent; DES – drug eluting stent. 
*The value of 1 implies ‘yes’ whereas the value of 0 implies ‘no’. 
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5.3.3 Patterns of GPx activity over a 72-hour time period 
Of the 16 study patients, we observed that there were two distinct patterns of GPx activity 
over the of 72-hr period following hospital admission with STEMI.  The first pattern was that 
GPx activity appeared to peak early in the admission period, with 8 patients (50%) exhibiting 
higher levels before the 24 hr time point.  Figure 5-1A & B shows two representative examples 
of patients who demonstrated an early peak of GPx activity.  The corresponding oxLDL 
measures are shown as well.   
 
In 7 patients (43.8%) we observed a late peak of GPx activity with higher levels occurring after 
the 24 hr time point.  Figure 5-2A & B show two representative examples of patients who 
demonstrated a late peak of GPx activity.  The corresponding oxLDL measures are shown as 
well. 
 
The remaining 1 patient was unable to be classified due to the unclear pattern of their GPx 
activity.  This patient did not appear to have a distinct peak that clearly categorised them into 
either an early or a late group – (graph not shown). 
 
A closer examination of these two groups, shows that the patients who were classified into 
the early peak group, had significantly higher GPx activity immediately post PCI (Post time 
point), compared to subsequent time points.  This is shown in Figure 5-3.  GPx activity was 
found to be significantly higher at the Post time point compared to subsequent activity levels 
found at 24 hr (p<0.01), 48 hr (p<0.05), 72 hr (p<0.01) and follow-up (p<0.05). 
 
Examination of the patients who were classified as the late peak group shows they had 
significantly higher GPx activity after the 24 hr time point.  This is shown in Figure 5-4.  GPx 
activity was found to be significantly higher at the 48 hr time point compared to the activity 
levels found at Pre (p<0.01), Post (p<0.05), 6 hr (p<0.01), 12 hr (p<0.05), 24 hr (p<0.05) and 
follow-up (p<0.05) times. 
 
The descriptive statistics for the patients who have been classified into either an early peak 
or a late peak of GPx activity are shown in Table 5-3.  Levels of peak high-sensitivity troponin 
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(hs-TnT) were significantly higher in patients who were classified as having an early peak of 
GPx activity compared to the hs-TnT levels found in those classified as having a late peak 
(p<0.05) (Figure 5-5).  Remaining cardiovascular risk factors did not appear to influence 
whether GPx activity corresponded to levels defined as an early peak or a late peak. 
5.3.4 Comparison of GPx and oxLDL measures at Pre vs F/U times 
Of the 16 patients, 9 (56.3%) had follow-up (F/U) measures taken at a time remote from their 
index study admission (6-12 weeks post-hospital discharge).  Both GPx activity (p<0.01) and 
oxLDL levels (p<0.05) were found to be significantly lower at the F/U time point compared to 
the corresponding levels found at the pre-angiography (Pre) time point (Figure 5-6A & B 
respectively).   
5.3.5 Relationship between GPx activity and oxLDL levels 
The relationship between GPx activity and oxLDL appears to be complex. In 12 of the 15 
patients (80%), levels of oxLDL were found to be at their highest either at the same time 
(Figure 5-1A for representative example), or prior to (Figure 5-2A & B for representative 
examples) the highest level of GPx activity.  However in 3 of the 15 patients (20%), this was 
not observed.  Instead, oxLDL levels were at their highest at time points after the highest peak 
level of GPx activity (Figure 5-1B for representative example).  
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Figure 5-1 Representative graphs from ACS patients with an early peak of GPx activity. 
(A-B) Individual graphs from study patients representing an early peak in GPx activity (blue 
line), with the corresponding measures for oxLDL (red line) shown over the acute phase of a 
STEMI and the subsequent follow-up measure.  Data is normalised to the respective pre-
angiography measure (Pre), and expressed as a % increase or decrease respective to this 
baseline. 
 
 
       
 
 
 
 
 
 
 
 
 
 
Figure 5-2  Representative graphs from ACS patients with a late peak of GPx activity. 
(A-B) Individual graphs from study patients representing a late peak in GPx activity (blue line), 
with the corresponding measures for oxLDL (red line) shown over the acute phase of a STEMI 
and the subsequent follow-up measure.  Data is normalised to the respective pre-angiography 
measure (Pre), and expressed as a % increase or decrease respective to this baseline. 
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Figure 5-3  ACS patients with an early peak of GPx activity 
GPx activity was measured pre-angiography (Pre), post-angiography (Post) and subsequently 
at 6 hr, 12 hr, 48 hr, 72 hr and at a follow-up (F/U) time point.  Eight patients exhibited GPx 
activity that was higher before the 24 hr time point and therefore classified as having an early 
peak.  GPx activity was found to be significantly higher at the Post time point compared to 
activity levels found at 24 hr, 48 hr, 72 hr and (F/U).  GPx activity at each time point was 
normalised to the respective measure taken at the pre-angiography time (Pre) and expressed 
as a % increase or decrease respective to this baseline.  Data is plotted for all eight study 
patients and presented as mean ± SD, *p<0.05, **p<0.01, one-way ANOVA, Tukey’s multiple 
comparisons test. 
 
 
 Pre Post 6hr 12hr 24hr 48hr 72hr F/U 
Mean 100 110 90.3 96.4 77.4 79.0 75.5 70.6 
Std. Deviation 0.0 20.7 21.9 24.8 11.9 15.0 14.5 16.8 
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Figure 5-4  ACS patients with a late peak of GPx activity 
GPx activity was measured pre-angiography (Pre), post-angiography (Post) and subsequently 
at 6 hr, 12 hr, 48 hr, 72 hr and at a follow-up (F/U) time point.  Seven patients exhibited GPx 
activity that was higher after the 24 hr time point and classified as having a late peak.  GPx 
activity was found to be significantly higher at the 48 hr time point compared to activity levels 
found at Pre, Post, 6 hr, 12 hr, 24 hr and F/U.  GPx activity at each time point was normalised 
to the respective measure taken at the pre-angiography time (Pre) and expressed as a % 
increase or decrease respective to this baseline.  Data is plotted for all seven study patients 
and presented as mean ± SD, *p<0.05, **p<0.01, one-way ANOVA, Tukey’s multiple 
comparisons test. 
 
 
 
 Pre Post 6hr 12hr 24hr 48hr 72hr F/U 
Mean 100 119 97.4 133 143 347 196 79.6 
Std. Deviation 0.0 36.9 23.0 93.0 61.4 264 122 23.4 
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Table 5-3   Characteristics of the early vs late peak groups of GPx activity 
Variable Early peak group 
  (n=8) 
Late peak group 
(n=7) 
p value 
Age (years) 65 ± 15 58 ± 13 0.34a 
BMI  27 ± 3.3 27 ± 4.6 0.99a 
GRACE Scores 114 ± 31 104 ± 27 0.55a 
Peak hs-TnT (ng/L) 5553 ± 2338 2712 ± 2031 0.03a 
Symptom onset – Pre 
sample, (mins) 
252 ± 150 244 ± 150 0.82 a 
Male 7 (88) 5 (71) 0.44b 
Dyslipidaemia 7 (88) 6 (86) 0.92b 
Hypertension 4 (50) 4 (57) 0.60c 
Stroke 1 (13) 1 (14) 0.73c 
Family History of CAD 2 (25) 3 (43) 0.43c 
Current Smoker 2 (25) 1 (14) 0.27c 
Abbreviations: BMI – body mass index; GRACE – global registry of acute coronary events; hs-TnT – high-
sensitivity troponin. 
aStudent’s t-test, bchi-square test, cFisher’s exact test, continuous variables expressed as mean ± SD, categorical 
variables expressed as frequencies (percentages). 
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Figure 5-5  Troponin levels in ACS patients  
The peak troponin (TnT, ng/L) levels were recorded for each patient.  Patients were classified 
as either having an early peak of GPx activity (Early), or a late peak of GPx activity (Late).  Data 
is plotted for all 16 patients as mean ± SD, *p<0.05, Students unpaired t-test. 
 
 
 
         **             * 
 
 
 
 
 
 
 
 
Figure 5-6  GPx activity and oxLDL levels at follow-up vs pre-angiography 
(A) GPx activity (U/mL) and (B) oxLDL (U/L) were measured in nine study patients at follow-
up (F/U) time points remote from the initial admission (6-12 weeks post-hospital discharge).  
These values were compared to the values calculated at the pre-angiography (Pre) time point.  
Data is plotted for all 9 study patients, *p<0.05, **p<0.01, Student’s paired t-test. 
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5.4 Discussion 
 
In this study we examined the temporal changes that occur in GPx activity over the acute 
phase of a STEMI.  Corresponding measures of oxLDL were taken to assess whether the 
fluctuation in GPx activity was reflected in this biomarker of oxidative stress.  The results 
demonstrate that GPx activity is highly dynamic in STEMI patients, and that two distinct 
patterns of activity could be identified.  These were classified as an early peak group and a 
late peak group.  Patients in an early peak group of GPx activity were found to have 
significantly higher levels of hs-TnT compared to those patients in a late peak group of GPx 
activity.  Further observations concluded that oxLDL was found to be at its highest level either 
at the same time, or prior to, the GPx activity peak in the majority of patients.   
 
Our observation of two distinct patterns of change in GPx activity following a STEMI was not 
expected.  From this study cohort, 15 of the 16 patients could be characterised into either 
having an early peak of GPx activity or a late peak of GPx activity, with one patient not 
demonstrating any obvious GPx peak.  There has been no previous description of two distinct 
time courses of change in GPx activity prior to this, and it is unclear why there are two 
different patterns of response.  We observed that those patients in the early peak group had 
their highest level of GPx activity recorded within the first 24 hours of the study, whilst those 
patients in the late peak group had their highest level of GPx activity recorded after 24 hours, 
making the two groups significantly different from one another. 
 
Patients in an early peak group were found to have higher levels of hs-TnT than a late peak 
group.  This suggests that these patients in an early peak group experienced a larger 
myocardial infarct. Troponin is a surrogate marker of infarct size that correlates moderately 
to strongly with cardiac MRI-derived parameters [228].  The size of infarct is important as it 
correlates with factors such as left ventricular dysfunction [229], and is important for 
predicting MACE risk in ACS patients. 
 
The magnitude of change in GPx activity seen over time was different between the early and 
late peak groups.  Those in the early peak group had a mean GPx activity that was 10% higher 
than the pre-angiography value.  In contrast those in the late peak group had a mean GPx 
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activity that was 247% higher than the pre angiography value.  We do not know why the 
magnitude is so different between these two groups.  These changes have been calculated 
with reference to the initial measurement.  This measure most likely does not reflect the true 
baseline of the patient, and it is possible that the patients with a larger infarction had an 
earlier peak in GPx activity and/or in oxLDL which our initial measure did not capture.  
Alternatively, it is possible that patients with a larger infarction are not able to increase levels 
of GPx activity to the same extent as those with a smaller infarct.  Although a mechanism 
cannot be determined for this hypothesis from these studies, it can be speculated that 
patients with a larger MI may have a greater shift in the net balance of their redox state, 
predisposing them to greater ROS-mediated damage.  This hypothesis would need further 
investigation, but if this were found to be the case it could partially explain the inverse 
relationship between GPx activity and MACE observed in Chapter 2. 
 
The relationship between GPx activity and oxLDL appears to be quite complex.  Since the scale 
and magnitude of each measure have an unknown influence on the other, it is difficult to 
draw conclusions about the potential relationship.  In the majority of patients we observed 
that oxLDL reached its highest level either at the same time point, or prior to, the time point 
that GPx activity peaked; however, this was not consistent for all patients.  Three patients had 
high levels of oxLDL at time points after GPx activity was reached.  Nevertheless, it appears 
that in the majority of patients the increase in oxidative stress, reflected by the peak oxLDL 
measures, may be influencing the subsequent increase in GPx activity.  However it is entirely 
possible that the temporal increases seen in oxLDL and GPx are independent of each other 
and are being driven by other factors that have not been investigated in this study.  
 
Previous studies examining the temporal changes in GPx activity have been limited and have 
largely focused on patients receiving thrombolytic therapy.  To the best of our knowledge, 
this is the largest study to examine the temporal changes of GPx activity and oxLDL in an ACS 
cohort undergoing primary PCI.  We chose to conduct this study in a cohort of STEMI patients 
as this allowed us to minimise the time between symptom onset and initial blood collection.  
Patients presented to the angiography suite less than 12 hours post-symptom onset, and this 
meant that blood samples could be taken before and after PCI as well as over the course of 
the hospital admission.  
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Previous studies examining the temporal change in GPx activity after thrombolytic therapy 
have yielded variable results.  Consistent with our findings, Zachara et al [171] and Beard et 
al [172] showed a significant rise at 48 hr, and Pucheu et al [230] and Muzkova et al [213] 
observed a significant rise post thrombolytic therapy.  Other studies did not detect any 
significant differences in GPx activity over the course of an acute event [186, 199, 200].  
Previous studies have also examined the temporal changes in oxidative stress over the course 
of an acute event, using a range of lipid and protein oxidation markers.  Those that looked at 
oxLDL levels found a temporal increase following reperfusion [215, 231] with a decrease back 
to levels comparable to healthy controls at the time of discharge [214].  The increase in oxLDL 
is thought to be modulated by an oxidative burst that causes increased ROS production during 
myocardial ischaemia and subsequently released into the plasma from the injured plaque site 
[232, 233].  
 
Both GPx activity and oxLDL were found to be significantly lower at the follow-up time point 
when compared to the pre-angiography measure.  At this time point the patients are no 
longer in the acute stage of an MI, and are more likely to represent the levels seen chronically 
in stable CAD.  The significant difference we detected between these two time points 
supports the results seen in Chapter 4, in which stable CAD patients had significantly lower 
levels of both GPx activity and oxLDL compared to the ACS patients.  This result is also in 
accordance with previous literature on ACS patients, in which both GPx activity [186] and 
oxLDL [214] were reported to decrease back to levels comparable to healthy controls within 
30 days of discharge and before the point of hospital discharge.  
 
It has been suggested that GPx activity may be used as a biomarker to predict clinical 
prognosis [71, 166].  Our results suggest that utilising GPx activity as biomarker may be 
problematic.  Because of the large variability in the level of GPx activity throughout the time 
course of an ACS, the result obtained will be strongly influenced by sampling time.  If the 
pattern of response was consistent across all patients then it would be possible to estimate 
when peak levels occur and sample at that time.  However as our results demonstrate, there 
are at least two distinct time points when GPx activity levels peak.  This means there is an 
inability to select a set time point for optimal measurement.  Furthermore, the clinical 
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significance of the two patterns we observe in this study is unknown, and therefore 
interpreting GPx activity as a biomarker remains challenging.  Possibly measuring GPx activity 
at a time remote from the acute event may yield more consistent levels, but the clinical value 
of this would need further investigation.  
5.4.1 Limitations 
The ability to acquire a baseline measure prior to an ACS event occurring in human studies is, 
of course, not possible.  In an effort to overcome this limitation, we selected a sample time 
that was as close to an ACS admission as logistically possible, followed by a sample time that 
was remote from the acute event.  This allowed us to examine measurements of GPx activity 
and oxLDL that were likely to represent a level of a more chronic oxidant/antioxidant state 
and compare them to measures taken throughout an acute setting.  
 
Due to the exploratory and observational nature of the present study, it was not possible to 
investigate whether there was a causal relationship between GPx activity and levels of 
oxidative stress.  Although we do see similar patterns of temporal change between GPx 
activity and oxLDL, we are limited to assumptions that oxLDL represents the level of oxidative 
stress that may be influencing the level of GPx activity in our ACS cohort.  Further 
investigations into the mechanisms that modulate GPx activity in elevated levels of oxidative 
stress in ACS patients are necessary to determine how it is influenced during an ACS event. 
 
Due to the short follow-up period, it was not possible to examine the relationship between 
GPx activity, oxLDL levels and clinical events.  It would be interesting to determine whether 
the two patterns of response in GPx activity have a relationship with different clinical 
outcomes in a larger, and a longer duration study.   
 
Finally, there were issues with three patients being discharged or transferred to regional 
hospitals early on during the study period.  In one case, a patient withdrew consent due to 
the intrusive nature of repeated blood sampling.  Consequently this affected the final 
numbers in our study population for analysis of GPx activity and oxLDL measurements. 
 
125 
 
5.5 Conclusion 
 
In conclusion, GPx activity demonstrates considerable variability in the acute phase of an ACS, 
with two patterns of response identified.  Consistent with our findings from Chapter 4, the 
levels of GPx activity during an ACS admission are significantly higher than those taken at a 
time remote from the occurrence of an acute event.  The temporal changes in oxLDL appear 
to peak either at the same time, or prior to, the peak in GPx activity in the majority of ACS 
patients.  This finding raises the possibility that GPx activity is driven by changes in oxidative 
stress levels. 
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Chapter 6 - Summary and future directions 
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6.1 Summary 
In this thesis, the first aim was to examine the variability of GPx and SOD activity in an ACS 
population, and to determine whether this variability was associated with MACE at a 1-year 
follow-up.  To the best of our knowledge, this is the largest prospective cohort study to 
examine the relationship between GPx and SOD activity and the occurrence of MACE in ACS 
patients.  This study demonstrated a significant inverse relationship between GPx activity and 
the rate of MACE; however SOD activity was not associated with MACE rate.  These findings 
suggest that patients with lower levels of GPx may have reduced antioxidant defence, 
increasing their risk for oxidant-mediated damage and predisposing them to MACE.  ROC 
curve analysis found GPx to be a moderate predictor of MACE (AUC=0.62).  However the ROC 
curve did not identify a single cutoff value for GPx activity that predicted the occurrence of 
MACE, making its application as a biomarker in ACS patients challenging.   
 
The second study examined the hypothesis that low levels of GPx activity may be associated 
with high levels of platelet reactivity and ROS, therefore exploring a possible mechanism 
contributing to the higher rate of MACE experienced by a subset of patients.  Although GPx 
activity was not correlated with platelet reactivity in this study, this is possibly due to GPx only 
having a small effect in the setting of ACS, in which there are other more significant 
determinants of platelet reactivity overriding any effect of GPx activity. 
 
Increasing levels of GPx activity were found to be associated with a larger shift of inhibition 
of platelet aggregation mediated by SNO-Glu.  A large inhibition of platelet aggregation 
suggests a lower level of ROS is present due to SNO-Glu’s inhibitory properties being less 
impaired.  The inverse relationship observed between GPx activity and ROS levels is consistent 
with the hypothesis from Chapter 2 in that GPx activity plays a protective role in an ACS 
population by decreasing ROS-mediated damage that may predispose patients to MACE 
occurrence. 
 
In the third study, we observed ACS patients to have higher levels of GPx activity and higher 
GPx3 protein concentration, with corresponding increases in GPx1, GPx3 and GPx4 mRNA 
expression levels.  This compared to patients with stable CAD and healthy subjects, in which 
no statistically significant differences were detected in the GPx system.  Additionally, levels 
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of oxLDL were found to be higher in ACS patients compared to patients with stable CAD and 
healthy subjects.  Taken together, this study demonstrated that both the GPx system and 
levels of oxidative stress are elevated in ACS.  Whether this level is chronically elevated 
throughout the ACS could not be determined from this study. 
 
In the fourth set of experiments, GPx activity proved to be highly dynamic in a STEMI 
population, with no single consistent time point at which activity peaked.  Two distinct 
patterns of activity were observed, with some patients exhibiting an early peak in GPx activity 
(before 24 hr), whilst others exhibited a late peak (after 24 hr).  Patients with an early peak 
of GPx were found to have a smaller magnitude of change in their activity levels compared to 
those patients with a late peak of GPx.  Furthermore, patients with an early peak of GPx 
activity had higher peak levels of troponin, suggesting a larger myocardial infarction.  The 
relationship between levels of GPx activity and oxLDL appeared to be quite complex.  
However, in the majority of STEMI patients, peak levels of oxLDL occurred prior to, or at the 
same time, as the peak GPx activity level.  This suggests that the levels of GPx activity are 
modulated by increases in oxidative stress.  The clinical significance of the two response 
patterns of GPx activity requires further investigation. 
 
6.2 Limitations 
Throughout this thesis, there were unavoidable limitations that may have influenced our 
findings.  Our study populations were of a moderate size, and in some instances this reduced 
our ability to investigate relationships between GPx, oxidative stress measures, clinical factors 
and outcomes.  However, with time constraints of the thesis and factoring for follow-up time 
allowances, recruiting larger patient cohorts was not possible.   
 
One particular limitation that is still prevalent in the current literature is the lack of a 
standardised marker for ROS that reflects the levels of oxidative stress in vivo.  This thesis 
utilised both an indirect surrogate marker for ROS levels, SNO-Glu, and the frequently used 
oxidative stress marker, oxLDL.  However, neither measure are direct indicators of the oxidant 
environment in the vasculature therefore have limitations when quantifying oxidative stress 
levels.  A novel SNO-Glu oxidative status assay was developed in this research project.  SNO-
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Glu is based on platelet function measures, therefore highly dependent on the type of 
antiplatelet medication patients are treated with.  The variability of response to antiplatelet 
agents adds an additional unknown variance to the SNO-Glu assay that would need to be 
investigated more thoroughly.  Nonetheless, the SNO-Glu assay does have reasonable 
potential to be a useful measure for quantifying ROS in a clinical setting. 
 
OxLDL is a frequently used marker of oxidative stress that is widely published throughout the 
literature.  However it is a single marker representing the extent of lipid and protein oxidation. 
There is conflict in the literature surrounding its accuracy for quantifying the extent of 
oxidative stress in the vasculature and therefore a lack of understanding in its role in CAD 
progression [6, 232, 234].  Additionally, statin medication has been reported to variably affect 
the levels of oxLDL measured in CAD patients [235].  This thesis highlights that there still 
remains a clear need for an appropriate and accurate oxidative stress measure that can be 
sampled from the peripheral circulation and applied in a clinical setting.   
 
GPx activity is widely quantified using commercially available colourimetric activity kits.  
Although the particular kit used in our study was thoroughly validated and showed a high 
reproducibility, colourimetric analysis still has limitations.  Interferences with absorbance 
readings can arise from sample turbidity, bubbles in the samples, and similar colours from 
interfering substances adding an unknown variance.  Care must be taken when performing 
these tests to ensure precision and reproducibility in the results.  The measure of GPx activity 
is an indirect method, with the oxidation of NADPH to NAD+ accompanied by a decrease in 
absorbance at 340 nm that is proportional to the level of GPx activity.  A direct measure of 
GPx activity would be more reliable; however such a method is not yet available 
commercially.   
 
The biochemical assays used in this thesis were commercially sourced from reputable 
biomedical companies and their use has been widely published in the literature.  The aim of 
this thesis was not to develop new measurement tools for oxidative stress and the GPx 
enzyme.  Instead, it was to use the appropriate pre-existing tools and apply them in a clinical 
context. 
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One of the strengths of this thesis has been the recruitment of a high-risk patient cohort.  
Each cohort has been characterised in considerable detail, and as described in Chapter 2, 
carefully and thoroughly followed up. 
 
6.3 Clinical implications and future directions   
 
The findings from this thesis have several clinical implications and raise further avenues for 
investigation.  In addition, some of our observations may further explain why there has been 
such discrepancy in the literature examining the relationship between GPx activity and the 
risk of adverse clinical events.   
 
First, we observe that there is a distinct increase in the GPx system in ACS patients compared 
to stable CAD patients and healthy subjects. Additionally there is a corresponding increase in 
oxLDL levels in ACS patients compared to the stable CAD patients and healthy subjects.  This 
highlights the importance of identifying and distinguishing the stage of coronary artery 
disease of patients when studying the effects of GPx activity as the levels appear to be 
influenced by the disease state.   
 
Second, we identified that variability in levels of GPx activity between ACS patients was 
associated with the rate of MACE at 1-yr.  When examining the temporal changes in GPx 
activity over the acute phase of a STEMI we demonstrated that there was also significant 
variability both within and between patients.  The dynamic nature of the GPx activity 
observed meant that no consistent time point at which peak GPx activity occurred could be 
identified.  The marked variation in GPx activity that occurred with the different sampling 
times in those with ACS may help explain the divergent findings regarding the relationship 
between GPx activity and the risk of adverse clinical events, as GPx activity will be strongly 
influenced by sampling time.  As discussed in Chapter 5, there are only a handful of studies 
that have examined GPx activity over the time period similar to our design, with the majority 
carried out in patients who received thrombolytic agents.  This is in contrast to our study 
cohort who received primary PCI within 12 hours of ischaemic symptom onset.  It is possible 
the different reperfusion treatments contribute to the variable reports in the literature, 
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however further investigation would be needed to thoroughly answer this question. 
Additionally, the clinical significance of the novel finding of two distinct patterns of response 
we observed in GPx activity reported in Chapter 5 requires further investigation.   
 
What is driving the type of response as well as the magnitude of response in GPx activity over 
an ACS event is unknown.  We demonstrate significantly higher levels of troponin in patients 
with an early peak of GPx activity, suggesting these patients experience a larger myocardial 
infarction.  The magnitude of change in GPx activity at this time point was lower than the 
change observed in a late peak of GPx activity.  It is possible that ACS patients with lower 
levels of GPx activity experience a bigger infarct, therefore contributing to the relationship 
we observed between low levels of GPx activity and a higher rate of MACE.  Further 
investigations into this relationship would help to answer this hypothesis.   
 
Although we currently do not understand the cause of the variability in GPx levels, we noted 
that both GPx activity and oxLDL are elevated in those with ACS.  The temporal changes in 
oxLDL appear to coincide with the temporal changes in GPx activity in the majority of patients, 
suggesting that GPx activity may be responding to changes in oxidative stress. However the 
proportional changes that occur between these two parameters in an ACS event, or whether 
there is a causal relationship, cannot be determined from our studies. Determining the 
proportional change is important as oxidative stress is essentially the change in the redox 
balance that predisposes the patient to oxidative damage. So although we have 
demonstrated that both pro-oxidant and antioxidant measures are higher in an ACS event, 
from our oxLDL and GPx measures respectively, we cannot determine what the net redox 
balance between the two systems is in those with ACS.  Essentially our ROS marker from 
Chapter 3 can be used as a representation for the redox balance.  We demonstrated that high 
levels of ROS were correlated with lower levels of GPx activity in ACS patients, and suggested 
that this may partially contribute to the higher rates of MACE observed in this group in 
Chapter 2.  Even though all the ACS patients from the Chapter 2 study cohort may have had 
increased levels of GPx activity in response to the event, it is feasible to suggest that some 
ACS patients do not up-regulate their GPx activity in response to an oxidative challenge to the 
same extent as others.  Thus the net change in redox balance may differ within a population.  
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As our results demonstrated, it is those patients with low levels of GPx activity that are most 
at risk of MACE.  If there were indeed a group of patients in which GPx activity does not 
increase adequately during an ACS event, either due to infarct size, or to an as yet 
unestablished factor, then potentially this group of patients may benefit from an intervention 
strategy, such as supplemental antioxidant therapy.  We suggest that GPx activity has 
potential to identify this population who may benefit from targeted therapy. However the 
standardisation of measuring GPx activity as a biomarker remains problematic.  The 
Atherogene study prospectively studied GPx activity in a large population with suspected 
chronic coronary artery disease.  This study concluded that GPx activity was predictive of CVD 
events after a 5-yr follow-up [71], therefore it is possible that measurement of GPx activity at 
a time remote from an acute event may have merit.  In a clinically stable population, GPx 
activity may be more constant and exhibit less variance.  However, this may limit the ability 
to intervene in an ACS population with low levels of GPx activity who exhibit a higher risk of 
poorer outcomes.  Further investigation into the dynamics of GPx activity in a stable coronary 
disease population, and the clinical impact it has, is warranted to establish GPx as a risk 
biomarker or as a tool to direct intervention in individual patients. 
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Lower South Regional Ethics 
Committee 
Ministry of Health PO Box 5013 1 The 
Terrace Wellington  
Phone: (04) 816 2646 Email: 
lowersouth_ethicscommittee@moh.g
ovt.nz 
 
 
16 December 2011 
 
Dr Scott Harding  
Capital and Coast District Health Board 
Cardiology Department  
Wellington Hospital 
Private Bag 7902  
Wellington 
 
 
 
Dear Dr Harding   
Re:  Ethics ref: LRS/11/09/035 (please quote in all correspondence) 
Study title: Platelet reactivity and adverse outcomes in patients undergoing coronary 
 angiography  
Investigators: Dr Scott Harding, Dr Alexander Sasse, Associate Professor Peter Larsen, 
 Ms Anne Camille La Flamme, Mr Michael Chen-xu 
Approved site: Wellington Hospital - Capital and Coast District Health Board 
 
 
This study was given ethical approval by the Lower South Regional Ethics Committee on 16 
December 2011. A list of members of the Committee is attached. 
 
Approved Documents  
 National Application Form (with amendments) 
 Signed Part 4: Declaration for Dr Scott Harding, dated 17 August 2011 
 Completed Form A for Wellington Hospital, CCDHB dated 23 August 2011 
 Part 5: Use of Human Tissue 
 Part 6: Genetic Section 
 Participant Information Sheet - Platelet reactivity and adverse outcomes in patients 
undergoing coronary angiography: Version 2, dated 25 September 2011 
 Participant Consent Form - Platelet reactivity and adverse outcomes in patients 
undergoing coronary angiography: Version 2, dated 25 September 2011 
 Participant Information Sheet - Platelet reactivity and adverse outcomes in patients 
undergoing coronary angiography - Genetic Sub-Study: Version 2, dated 25 September 
2011 
 Participant Consent Form - Platelet reactivity and adverse outcomes in patients 
undergoing coronary angiography - Genetic Analysis Sub-Study: Version 2, dated 25 
September 2011 
 Platelet reactivity and adverse outcomes in patients undergoing coronary angiography - 
30 Day Follow-Up Data Form 
 Platelet reactivity and adverse outcomes in patients undergoing coronary 
angiography - 12-Month Follow-Up Data Form 
 Evidence of Maori Consultation - letter dated 27 November 2011 signed by Jack 
Rikihana on behalf of the Research Advisory Group - Maori 
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This approval is valid until 16 December 2016, provided that Annual Progress Reports are 
submitted (see below). 
 
Access to ACC  
For the purposes of section 32 of the Accident Compensation Act 2001, the Committee is 
satisfied that this study is not being conducted principally for the benefit of the manufacturer or 
distributor of the medicine or item in respect of which the trial is being carried out. Participants 
injured as a result of treatment received in this trial will therefore be eligible to be considered for 
compensation in respect of those injuries under the ACC scheme. 
 
Amendments and Protocol Deviations  
All significant amendments to this proposal must receive prior approval from the Committee. 
Significant amendments include (but are not limited to) changes to:  
 the researcher responsible for the conduct of the study at a study site 
 the addition of an extra study site 
 the design or duration of the study 
 the method of recruitment 
 information sheets and informed consent procedures. 
 
Significant deviations from the approved protocol must be reported to the Committee as soon 
as possible. 
 
Annual Progress Reports and Final Reports  
The first Annual Progress Report for this study is due to the Committee by 16 December 2012. 
The Annual Report Form that should be used is available at 
www.ethicscommittees.health.govt.nz. Please note that if you do not provide a progress report 
by this date, ethical approval may be withdrawn. 
 
A Final Report is also required at the conclusion of the study. The Final Report Form is also 
available at www.ethicscommittees.health.govt.nz. 
 
Requirements for the Reporting of Serious Adverse Events (SAEs)  
SAEs occurring in this study must be individually reported to the Committee within 7-15 days only 
where they:  
 are unexpected because they are not outlined in the investigator’s brochure, and 
 are not defined study end-points (e.g. death or hospitalisation), and 
 occur in patients located in New Zealand, and 
 if the study involves blinding, result in a decision to break the study code. 
 
There is no requirement for the individual reporting to ethics committees of SAEs that do not meet 
all of these criteria. However, if your study is overseen by a data monitoring committee, copies of 
its letters of recommendation to the Principal Investigator should be forwarded to the Committee 
as soon as possible. 
 
Please see www.ethicscommittees.health.govt.nz for more information on the reporting of SAEs, 
and to download the SAE Report Form. 
 
Statement of compliance  
The committee is constituted in accordance with its Terms of Reference. It complies with the 
Operational Standard for Ethics Committees and the principles of international good clinical 
practice. 
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The committee is approved by the Health Research Council’s Ethics Committee for the purposes 
of section 25(1)(c) of the Health Research Council Act 1990. 
 
We wish you all the best with your study. 
 
Yours sincerely 
 
 
 
 
 
 
Kirsten Forrest  
Administrator  
Lower South Ethics Committee  
Email: LowerSouth_ethicscommittee@MOH.govt.nz 
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INFORMATION SHEET 
Platelet reactivity and adverse outcomes in patients undergoing coronary 
angiography  
 
You are invited to take part in a study that is investigating how effective two drugs we 
commonly use to limit blood clot formation, aspirin and clopidogrel, are in patients who have 
an acute coronary syndrome (heart attack). We are interested in learning more about why 
these drugs are not as effective in some patients as they are in others, and examining whether 
having a less effective response to these drugs is associated with an increased risk of adverse 
events following coronary angiography. This study has received ethical approval from the 
Central Region Human Ethics Committee.  
 
Principal Investigator 
Dr Scott Harding, Cardiologist, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone No. 04 3855 999  
E-mail: Scott.Harding@ccdhb.org.nz 
 
How are people selected for this study, and who will select them? 
Patients who are undergoing coronary angiography after a heart attack will be invited to 
participate in this study by Ana Holley or Michael Chen-Xu.  
 
 
What will happen during the study? 
If you are happy to participate in the study you will have blood taken from you before you have 
your coronary angiogram. This blood will be taken by inserting a needle into a vein on your arm. 
When we do this we will be taking 30ml (about 6 teaspoons) in volume. Your blood will be tested 
for platelet function (how the blood clots) and serum will be extracted. The serum will be tested 
stored for later analysis of biological markers that will tell us about the state of your immune 
system. Any residual serum will be destroyed following this. Prior to tissue being disposed of 
(using the standard Hospital process) a Maori blessing will be performed.  
 
With your permission, data from this study may be used in future related studies, which have 
been given ethical approval from a Health & Disability Ethics Committee. 
 
As samples of human tissue will be taken during this study, there may be cultural issues 
associated with storing tissue that need to be discussed with your family/whanau. Some Iwi 
disagree with storage of human tissue citing whakapapa and advise their people to consult 
prior to participation in research where this occurs. To avoid problems at a later stage, we 
suggest your family/whanau is involved with you at all stages of the research. However, we 
also acknowledge that individuals have the right to choose to participate. 
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Confidentiality 
All data will be kept confidential. You will not be personally identified in any reports or 
publications that are developed throughout the course of this research. The data will appear 
grouped and include no markings that can be traced back to you.  
 
Participants Rights 
You do not have to accept this invitation to participate in this research. 
 If you agree to participate you have the right to: 
1. Ask any questions about the study anytime during your participation 
2. Withdraw from the study at anytime without any affect on your future health 
care/continuing health care at any time  
 
Participation in this study will be stopped should the investigators of this study feel it is not in 
your best interests to continue. 
 
What are the potential inconveniences of the study?   
Insertion of a needle into a vein can result in some swelling around the area, and this area may 
be a little tender after the needle is removed. It is possible that you could get an infection due to 
insertion of the needle, although this is not common and we will take standard precautions to 
minimise this risk. 
 
What are the benefits of this study? 
This study will provide significant knowledge about how well anti-clotting drugs are working in 
patients who have had a heart attack.  
 
There will be no direct benefit to you from participating in this study. 
 
Costs for the study 
It will not cost anything to take part in this study. 
 
Family or Whanau support 
You may have a friend, family or whanau support present. 
 
For Maori Health Support please contact Whanau Care Services on 04 3855 999 ext 80948 
 
If you have any questions or concerns about your rights as a participant in this research study 
you can contact an independent health and disability advocate. This is a free service provided 
under the Health and Disability Commissioner Act.  
Telephone: (NZ wide) 0800 555 050  
Free Fax (NZ wide):  0800 2787 7678 (0800 2 SUPPORT)  
Email (NZ wide):  advocacy@hdc.org.nz 
 
Results 
A written report of the study will be available to participants on request.  
 
Compensation  
In the unlikely event of a physical injury as a result of your participation in this study, you will 
be covered by the accident compensation legislation with its limitations. If you have any 
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questions about ACC please feel free to ask the researcher for more information before you 
agree to take part in this trial. 
 
If you have any questions about ACC, contact your nearest ACC office or the investigator. 
 
Please feel free to contact the Study Investigators if you have any questions about this study. 
Their contact details are listed above. 
 
Statement of Approval 
This project has been given ethical approval by the Lower South Regional Ethics Committee.  If 
you have any concerns about the ethics of this study, please contact the Lower South Regional 
Ethics Committee by email lowersouth_ethicscommittee@moh.govt.nz. 
 
 
Co-investigators 
Working with Dr Harding is the research team as follows: 
 
Dr Alexander Sasse, Cardiologist, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone No. 04 3855 999 
Email: Alexander.sasse@ccdhb.org.nz 
 
Assoc Prof Peter Larsen Clinical Physiologist, University of Otago, Wellington 
Work Phone 04 385 5999 extn 5103 
E-mail: Peter.Larsen@otago.ac.nz 
 
Assoc. Prof Anne La Flamme, Senior Lecturer, School of Biological Sciences, Victoria University 
of Wellington 
Work Ph: 04 463-6093   
E-mail: anne.laflamme@vuw.ac.nz 
 
Michael Chen-Xu, MBChB Student University of Otago, Wellington 
Work Phone 04 385 5999 extn 5103 
E-mail: chemi166@student.otago.ac.nz 
 
Ana Holley PhD Student, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone No: 04 3855999 
E-mail: Ana.Holley@vuw.ac.nz 
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Participant Consent Form 
 
Platelet reactivity and adverse outcomes in patients undergoing coronary 
angiography  
 
 
 
 I have read and I understand the information sheet dated 22nd August 2011 for volunteers 
taking part in the study designed to study platelet reactivity in coronary angiography. I 
have had the opportunity to discuss this study. I am satisfied with the answers I have been 
given. 
 I have had the opportunity to use whānau support or a friend to help me ask questions 
and understand the study. 
 I understand that taking part in this study is voluntary (my choice), and that I may 
withdraw from the study at any time, and this will in no way affect my future health 
care/continuing health care. 
 I understand that my participation in this study is confidential and that no material that 
could identify me will be used in any reports on this study or in any subsequent study that 
may use the aggregated results. 
 I understand the compensation provisions for this study. 
 I have had time to consider whether to take part in the study. 
 I know who to contact if I have any side effects from the study. 
 I consent to the use of my data for future related studies, which have been given ethical 
approval from a Health & Disability Ethics Committee. 
 
 
I wish to receive a copy of the results.  Yes      No    
 
If yes, please include a postal or e-mail address to which you would like the summary report to 
be sent when the study has been completed. 
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I __________________________ hereby consent to take part in this study. 
 
Date: 
Signature: 
Full names of researchers: 
Contact phone number for researchers: 
Project explained by: 
Project role: 
Signature: 
Date: 
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Platelet reactivity and adverse outcomes in patients undergoing coronary 
angiography – Genetic Sub-Study  
 
Principal Investigator 
Dr Scott Harding, Cardiologist, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone No. 04 3855 999  
E-mail: Scott.Harding@ccdhb.org.nz 
 
  
Introduction 
You have already agreed to take part in the main research study, and have signed the consent 
form. In the main study we will investigate the relationship between high on treatment 
residual platelet reactivity and rise in cardiac enzymes during coronary angiography. In 
addition, we will examine the factors associated with an increased risk of high on treatment 
platelet reactivity in acute coronary syndromes 
We do not know exactly why some individuals are more likely to respond to the antiplatelet 
medications than other individuals. However, it has been suggested that there may be a 
genetic reason for the differences in response to the drugs. 
 
Purpose of the Sub-Study 
The purpose of this study is to find out to what extend the differences in response to 
clopidogrel are due to genes, which are found in your DNA. It has been suggested that some 
people have an alteration in the gene that metabolises clopidogrel, and that this could 
contribute to the variable response to this drug. By studying the DNA from your blood 
samples, researchers can try to understand how much of the high on treatment platelet 
reactivity is due to genetics. 
 
Explanation of Study 
This study involves obtaining a single blood sample for DNA 10 ml (about 2 teaspoons) which 
will be used for research purposes only.  The blood sample will be taken at the same time that 
you require blood samples for the main research study. Your blood will be taken to the 
Clinical Research Laboratory in Wellington Hospital, where DNA will be extracted from your 
blood. This DNA will be stored in the Laboratory under strict supervision in a limited access 
facility. 
As samples of human tissue will be taken during this study, there may be cultural issues 
associated with storing tissue that need to be discussed with your family/whanau. Some Iwi 
disagree with storage of human tissue citing whakapapa and advise their people to consult 
prior to participation in research where this occurs. To avoid problems at a later stage, we 
suggest your family/whanau is involved with you at all stages of the research. However, we 
also acknowledge that individuals have the right to choose to participate. 
 
The DNA samples will be used to study various genetic causes for how patients may respond to 
clopidogrel and aspirin. The DNA samples will be stored to provide a resource for future studies 
that we will conduct  on the genes responsible for how these drugs are processed by the body, 
how the drugs work, and other pathways that the drugs may interact with. Your blood cells will 
not be made to grow forever in the laboratory. Any future use of the genetic samples outside 
of this project will first be reviewed by a Health & Disability Ethics Committee. 
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The DNA samples will be stored for future testing for up to 10 years from the time the sample 
is taken, or until the sample is gone. When this 10 year period ends, any remaining DNA will 
be destroyed, and the destruction will be documented.  
If any future testing is performed using your sample, and is within the scope of this consent 
form, no additional informed consent will be obtained from you, and you will not be notified. 
 
Disclosure of Research Results 
Many genetic studies are exploratory research studies, and may not yield information that will 
be clinically useful to patients for some time. Therefore, no information obtained from these 
studies will be disclosed to you, your family or your doctors. Research from this sub-study will 
not become part of your medical records. 
 
Risks of Participation 
The blood sample will be taken at the same time as a routine blood test is obtained, and 
therefore will not represent an additional risk for you. The amount of blood taken is small, 
and will not be harmful.  
 
Benefits of Participation 
You will receive no direct benefit from participating in this study. However, patients treated in 
the future with these drugs may benefit from information learned from your participation. 
 
Confidentiality 
All identifying information collected in this study will be kept strictly confidential. If any 
publication arises from this research, you will not be identified in by name.  It is possible that 
if people who are not involved in this research knew your genetic information, this may cause 
problems with your employment or insurance. The chance that taking part in this research will 
harm you is very small.  
To protect your privacy we will only use a subject number, instead of your name, on your 
blood sample. Your name will not be disclosed outside of the research clinic, where your 
information will be treated as strictly confidential. No genetic information will be entered into 
your medical record.  
 
Participants Rights 
You do not have to accept this invitation to participate in this research. 
 If you agree to participate you have the right to ask any questions about the study anytime 
during your participation. 
 
Termination of Participation 
If, at any time, you should choose to withdraw from participation in this study, all DNA 
samples from you will be removed from storage and destroyed. However, data obtained from 
your DNA prior to withdrawal of consent will not be deleted. 
Costs for the study 
It will not cost anything to take part in this study. 
 
Family or Whanau support 
You may have a friend, family or whanau support present. 
For Maori Health Support please contact Whanau Care Services on 04 3855 999 ext 80948 
 
If you have any questions or concerns about your rights as a participant in this research study 
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you can contact an independent health and disability advocate. This is a free service provided 
under the Health and Disability Commissioner Act.  
Telephone: (NZ wide) 0800 555 050  
Free Fax (NZ wide):  0800 2787 7678 (0800 2 SUPPORT)  
Email (NZ wide):  advocacy@hdc.org.nz 
 
Results 
A written report of the study will be available to participants on request.  
 
Compensation  
In the unlikely event of a physical injury as a result of your participation in this study, you will 
be covered by the accident compensation legislation with its limitations. If you have any 
questions about ACC please feel free to ask the researcher for more information before you 
agree to take part in this trial. 
 
If you have any questions about ACC, contact your nearest ACC office or the investigator. 
Please feel free to contact the Study Investigators if you have any questions about this study. 
Their contact details are listed below. 
 
Statement of Approval 
This project has been given ethical approval by the Lower South Regional Ethics Committee.  If 
you have any concerns about the ethics of this study, please contact the Lower South Regional 
Ethics Committee by email lowersouth_ethicscommittee@moh.govt.nz. 
 
Co-investigators 
Working with Dr Harding is the research team as follows: 
 
Dr Alexander Sasse, Cardiologist, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone No. 04 3855 999 
Email: Alexander.sasse@ccdhb.org.nz 
 
Assoc Prof Peter Larsen Clinical Physiologist, University of Otago, Wellington 
Work Phone 04 385 5999 extn 5103 
E-mail: Peter.Larsen@otago.ac.nz 
 
Assoc. Prof Anne La Flamme, Senior Lecturer, School of Biological Sciences, Victoria University 
of Wellington 
Work Ph: 04 463-6093   
E-mail: anne.laflamme@vuw.ac.nz 
 
Michael Chen-Xu, MBChB Student University of Otago, Wellington 
Work Phone 04 385 5999 extn 5103 
E-mail: chemi166@student.otago.ac.nz 
 
Ana Holley PhD Student, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone No: 04 3855999 
E-mail: Ana.Holley@vuw.ac.nz 
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Participant Consent Form 
 
Platelet reactivity and adverse outcomes in patients undergoing coronary 
angiography – Genetic Analysis Sub Study 
 
 
 
 I have read and I understand the information sheet dated 22nd August 2011 for 
volunteers taking part in the sub-study designed to investigate genetic variants 
associated with high platelet reactivity. I have had the opportunity to discuss this study. 
I am satisfied with the answers I have been given. 
 I have had the opportunity to use whānau support or a friend to help me ask questions 
and understand the study. 
 I understand that taking part in this study is voluntary (my choice), and that I may 
withdraw from the study at any time, and this will in no way affect my future health 
care/continuing health care. 
 I understand that my participation in this study is confidential and that no material that 
could identify me will be used in any reports on this study or in any subsequent study 
that may use the aggregated results. 
 I understand the compensation provisions for this study. 
 I have had time to consider whether to take part in the study. 
 I know who to contact if I have any side effects from the study. 
 I consent to the use of my data for future related studies, which have been given 
ethical approval from a Health & Disability Ethics Committee. 
 
 
 
 
 
I give consent to have my blood stored for analysis of DNA for this study, and understand that 
following 10 years any remaining sample will be destroyed:   
Yes      No    
 
 
I wish to receive a copy of the results.  Yes      No    
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If yes, please include a postal or e-mail address to which you would like the summary report 
to be sent when the study has been completed. 
 
          
          
          
       
 
 
 
I __________________________ hereby consent to take part in this study. 
 
Date: 
Signature: 
Full names of researchers: 
Contact phone number for researchers: 
Project explained by: 
Project role: 
Signature: 
Date: 
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Health and Disability Ethics Committees  
1 The Terrace  
PO Box 5013 Wellington 6011 0800 4 ETHICS  
hdecs@moh.govt.nz 
 
07 March 2013 
 
 
Dr Scott Harding 
Cardiology 
Research 
Wellington Hospital 
Newtown/Wellington 
6023 
 
 
Dear Dr Harding 
 
 
Re: Ethics ref: 13/CEN/29  
 
 Study title: Investigation of the glutathione peroxidase system in stable coronary  
 
  
disease and healthy controls 
  
   
 
    
 
 
 
I am pleased to advise that this application has been approved by the Central Health 
and Disability Ethics Committee. This decision was made through the HDEC-Expedited 
Review pathway. 
 
Conditions of HDEC approval 
 
HDEC approval for this study is subject to the following conditions being met prior to 
the commencement of the study in New Zealand. It is your responsibility, and that of 
the study’s sponsor, to ensure that these conditions are met. No further review by the  
Central Health and Disability Ethics Committee is required. 
 
Standard conditions: 
 
· Before the study commences at any locality in New Zealand, all relevant 
regulatory approvals must be obtained.  
 
· Before the study commences at a given locality in New Zealand, it must be 
authorised by that locality in Online Forms. Locality authorisation confirms 
that the locality is suitable for the safe and effective conduct of the study, and 
that local research governance issues have been addressed.  
 
After HDEC review 
 
Please refer to the Standard Operating Procedures for Health and Disability Ethics 
Committees (available on www.ethics.health.govt.nz) for HDEC requirements relating 
to amendments and other post-approval processes. 
 
Participant access to ACC 
The Central Health and Disability Ethics Committee is satisfied that your study is not a clinical trial 
that is to be conducted principally for the benefit of the manufacturer or distributor of the medicine 
or item being trialled. Participants injured as a result of treatment received as part of your study 
may therefore be eligible for publicly-funded compensation through the Accident Compensation 
Corporation (ACC) 
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Please don’t hesitate to contact the HDEC secretariat for further information. We wish 
you all the best for your study. 
 
Yours sincerely, 
 
 
 
 
Helen Walker 
Chairperson  
Central Health and Disability Ethics Committee 
 
 
Encl: appendix A: documents submitted 
appendix B: statement of compliance and list of members
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PARTICIPANT INFORMATION SHEET 
Investigation of the glutathione peroxidise system in stable 
coronary disease and healthy subjects 
 
Principal Investigator 
Dr Scott Harding, Cardiologist, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone No. 04 3855999 
E-mail: scott.harding@ccdhb.org.nz 
 
You are invited to take part in a study that is investigating the levels of antioxidants in the blood stream.  
Oxidative stress is involved in the onset and progression of atherosclerosis (the build up of fatty 
deposits in the blood vessels), angina and heart attacks.  Antioxidants in the blood stream such as 
glutathione peroxidase (GPx) provide a protective defence against high levels of oxidative stress and 
may slow the progression of atherosclerosis. We aim to investigate whether levels of GPx and other 
antioxidants vary in healthy volunteers and those with stable coronary disease. We will also aim to 
investigate how such variations are related to measures of oxidative stress and disease state. 
How are people selected for this study, and who will select them? 
Patients who have confirmed stable coronary disease will be invited to partake in this study.  Healthy 
volunteers will also be invited to participate and will be invited to partake in this study through poster 
advertisement distributed throughout Wellington Hospital and Otago Medical School. 
What will happen during the study? 
If you are happy to participate in this study then you will have a single blood test.  This blood will be 
taken by inserting a needle into a vein in your arm.  When we do this we will be taking 30 mL (about 
6 teaspoons) in volume.  Your blood will be tested for platelet function (how the blood clots) and 
various components of the blood will be tested for GPx and markers of oxidative stress and 
inflammation.  Any residual blood or components of blood will be destroyed following this.  Prior to 
tissue being disposed of, (using the standard Hospital process) a Maori blessing will be performed. 
As samples of human tissue will be taken during this study, there may be cultural issues associated 
with storing tissue that need to be discussed with your family/whanau.  Some Iwi disagree with 
storage of human tissue citing whakapapa and advise their people to consult prior to participation in 
research where this occurs.  To avoid problems at a later stage, we suggest your family/whanau is 
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involved with you at all stages of the research.  However, we also acknowledge that individuals have 
the right to choose to participate. 
Confidentiality 
All data will be kept confidential.  You will not be personally identified in any reports or publications 
that are developed throughout the course of this research.  The data will appear grouped and include 
no markings that can be traced back to you. 
Participant Rights 
You do not have to accept this invitation to participate in this research.  If you agree to participate you 
have the right to: 
1. Ask any questions about the study anytime during your participation 
2. Withdraw from the study at anytime without any affect on your future health care/continuing 
health care at anytime. 
Participation in this study will be stopped should the investigators of this study feel it not in your best 
interests to continue. 
What are the potential inconveniences of this study?  
Insertion of a needle into a vein can result in some swelling around the area, and this area may be a 
little tender after the needle is removed.  It is possible that you could get an infection due to insertion 
of the needle. However this is very rare and we will take standard precautions to minimise this risk. 
What are the benefits of this study? 
This study will provide significant knowledge about the variation in the GPx system and oxidative stress 
in a healthy population, and those with stable coronary artery disease. We believe that those with low 
levels of GPx will have higher levels of oxidative stress. If this is confirmed then the effect of targeted 
antioxidant therapies in those with low levels of GPx could be explored. 
There will be no direct benefit to you from participating in this study. 
Costs for the study 
It will not cost anything to take part in the study. 
Family or Whanau support 
You may have a friend, family or whanau support present. 
For Maori Health Support please contact Whanau Care Services: 
Trish Heuser - Speciality Clinical Nurse Cardiology 04 3855 999 ext 80948 
If you any questions or concerns about your rights as a participant in this research study you can 
contact an independent health and disability advocate.  This is a free service provided under the 
Health and Disability Commissioner Act: 
Telephone: (NZ wide) 0800 555 050 
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Free Fax: (NZ wide) 0800 2787 7678 (0800 2 SUPPORT) 
Email: (NZ wide) advocacy@hdc.org.nz 
Results 
A written report of the study will be available to participants on request. 
Compensation 
In the unlikely event of a physical injury as a result of participation in this study, you will be covered 
by the accident compensation legislation with its limitations.  If you have any questions about ACC 
please feel free to ask the researcher for more information before you agree to take part in this trial. 
If you have any questions about ACC, contact your nearest ACC office or the investigator. 
Please feel free to contact the Study Investigators if you have any questions about this study.  Their 
contact details are listed above and below. 
Statement of Approval 
This project is awaiting ethical approval by the Central Health and Disability Ethics Committee. 
Co-investigators 
Working with Dr Harding is the research team as follows: 
Assoc. Prof Peter Larsen, Clinical Physiologist, University of Otago, Wellington 
Work phone 04 385 5999 extn 5103 
E-mail: Peter.larsen@otago.ac.nz 
Prof John Miller, Physiologist, Victoria University of Wellington 
Work phone 04 463 6082 
Email: john.h.miller@vuw.ac.nz 
Ana Holley, PhD Student, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone 04 385 5999 
Email: Ana_holley@hotmail.com 
Lisa Johnston, PhD Student, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone 04 385 5999 
Email: lisa.johsnton@vuw.ac.nz 
Richard Portch, Masters Student, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone 04 385 5999 
Email: Richard.portch@hotmail.com 
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Participant Consent Form 
Investigation of the glutathione peroxidase system in stable coronary disease 
and healthy subjects 
 Request for interpreter:        Circle one 
English I wish to have an interpreter Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 
Māori E hiahia ana ahau ki tetahi kaiwhaka 
Māori/kaiwhaka pakeha korero 
Ae  Kao 
Cook Island 
Māori 
Ka inangaro au i tetai tangata uri reo Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata 
fakahokohoko kupu 
E Nakai 
Sāmoan Ou te mana’o ia i ai se fa’amatala upu Ioe Leai 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana 
Peletania ki na gagana o na motu o te Pahefika 
Ioe Leai 
Tongan Oku ou fiema’u ha fakatonulea Io Ikai 
 
 I have read and I understand the information sheet dated 11th February 2013 for volunteers 
taking part in the study designed to study the glutathione peroxidase system in 
atherosclerosis.  I have had the opportunity to discuss this study.  I am satisfied with the 
answers I have been given. 
 I have had the opportunity to use whanau support or a friend to help me ask questions and 
understand the study. 
 I understand that taking part in this study is voluntary (my choice), and that I may withdraw 
from the study at any time, and this will no way affect my future health care/continuing 
health care. 
 I understand that my participation in this study is confidential and that no material that 
could identify me will be used in any reports on this study. 
 I understand the compensation provisions for this study. 
 I have had time to consider whether to take part in the study. 
 I know who to contact if I have any side effects from the study. 
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I wish to receive a copy of the results.  Yes  No 
 
I       (Participant’s full name) hereby consent to take 
part in this study and have received a copy of the signed consent form for my own records. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If applicable: 
 
Printed name of Interpreter 
 
Signature of Interpreter    Date 
  
Participant’s 
Signature 
Investigator/Researcher who explained 
study 
Investigator/Researcher Signature  
Date 
Date 
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Health and Disability Ethics Committees  
Ministry of Health 
C/- MEDSAFE, Level 6, Deloitte House  
10 Brandon Street 
PO Box 5013  
Wellington 
6011 
 
 
hdecs@moh.govt.nz 
 
10 December 2014 
 
 
Dr Scott Harding  
Cardiology Research  
Wellington Hospital 
Newtown/Wellington 6023 
 
 
Dear Dr Harding 
 
 
Re: Ethics ref: 14/NTB/198 
 Study title: Investigation of the Dynamic Relationship of Antioxidant Enzymes in 
  Myocardial infarction. 
   
 
 
I am pleased to advise that this application has been approved by the Northern B 
Health and Disability Ethics Committee. This decision was made through the HDEC-
Full Review pathway. 
 
Conditions of HDEC approval 
 
HDEC approval for this study is subject to the following conditions being met prior to 
the commencement of the study in New Zealand. It is your responsibility, and that of 
the study’s sponsor, to ensure that these conditions are met. No further review by 
the  
Northern B Health and Disability Ethics Committee is required. 
 
Standard conditions: 
 
· Before the study commences at any locality in New Zealand, all 
relevant regulatory approvals must be obtained.  
 
· Before the study commences at a given locality in New Zealand, it must be 
authorised by that locality in Online Forms. Locality authorisation confirms 
that the locality is suitable for the safe and effective conduct of the study, 
and that local research governance issues have been addressed.  
 
After HDEC review 
 
Please refer to the Standard Operating Procedures for Health and Disability Ethics 
Committees (available on www.ethics.health.govt.nz) for HDEC requirements 
relating to amendments and other post-approval processes. 
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Your next progress report is due by 10 December 2015. 
 
Participant access to ACC 
 
The Northern B Health and Disability Ethics Committee is satisfied that your study is not 
a clinical trial that is to be conducted principally for the benefit of the manufacturer or 
distributor of the medicine or item being trialled. Participants injured as a result of 
treatment received as part of your study may therefore be eligible for publicly-
funded compensation through the Accident Compensation Corporation (ACC). 
 
Please don’t hesitate to contact the HDEC secretariat for further information. We 
wish you all the best for your study. 
 
Yours sincerely, 
 
 
 
Mrs Raewyn Sporle  
Chairperson 
Northern B Health and Disability Ethics Committee 
 
 
Encl: appendix A: documents submitted  
appendix B: statement of compliance and list of members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175 
 
PARTICIPANT INFORMATION SHEET 
The DREAM Study   
Dynamic Relationship of antioxidant Enzymes in Acute Myocardial infarction 
Principal Investigator 
Dr Scott Harding, Cardiologist, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone No. 04 3855999 E-mail: scott.harding@ccdhb.org.nz 
You are invited to take part in a study that is investigating the levels of oxidative stress in the 
blood stream.  High levels of oxidative stress are found in patients experiencing heart attacks, and 
are known to cause damage to the blood vessels.  The antioxidant enzyme glutathione peroxidase 
(GPx) is known to protect against oxidative stress and may slow the progression of damage.  We 
aim to investigate how GPx and oxidative stress increase during a heart attack, as this is not well 
understood. 
Who is selected and what will happen in this study? 
Patients who present to Wellington Hospital diagnosed with a ST-segment elevation myocardial 
infarction (STEMI), commonly known as a heart attack, will be invited by one of the study 
investigators to participate in this study.  If you are happy to take part, we will initially take a 10 
mL blood sample prior to and immediately after your angiogram.  This will be done through a 
sheath that is inserted for the procedure. After the procedure, you will be given the full 
information sheet. You will then be able to ask further questions before continuing in this study. 
If you choose to participate in this study, your blood will be tested for GPx activity and markers 
of oxidative stress.  If you choose to not participate further at this time, then any blood samples 
will be destroyed. None of your personal information will be used.  
Confidentiality 
All data will be kept confidential. You will not be personally identified in any reports or 
publications throughout the course of this research. The data will appear grouped with no 
markings that can be traced back to you. 
Participant Rights 
You do not have to accept this invitation to participate in this research. If you agree to participate, 
you have the right to: 
1. Ask any questions about the study anytime during your participation  
2. Withdraw from the study at anytime without any affect on your future healthcare/continuing 
health care at anytime. 
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Participation in this study will be stopped should the study investigators feel it not in your best 
interests to continue. 
Participant Consent Form 
“The DREAM Study” 
 
 Request for interpreter:        Circle one 
English I wish to have an interpreter Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 
Māori E hiahia ana ahau ki tetahi kaiwhaka Māori/kaiwhaka pakeha 
korero 
Ae  Kao 
Cook Island 
Māori 
Ka inangaro au i tetai tangata uri reo Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata fakahokohoko kupu E Nakai 
Sāmoan Ou te mana’o ia i ai se fa’amatala upu Ioe Leai 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana Peletania ki na 
gagana o na motu o te Pahefika 
Ioe Leai 
Tongan Oku ou fiema’u ha fakatonulea Io Ikai 
 
 I have read and I understand the information sheet dated 9th December 2014 for volunteers 
taking part in the study designed to study the glutathione peroxidase system.  
 
 I understand that taking part in this study is voluntary (my choice), and that I may withdraw 
from the study at any time, and this will no way affect my future health care/continuing health 
care. 
 
 I understand that my participation in this study is confidential and that no material that could 
identify me will be used in any reports on this study. 
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I       (Participant’s full name) hereby consent to take part 
in this study and have received a copy of the signed consent form for my own records. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date Participant’s Signature 
Investigator/Researcher who explained 
study 
Date Investigator/Researcher Signature  
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INFORMATION SHEET 
The DREAM Study   
Dynamic Relationship of antioxidant Enzymes in Acute Myocardial infarction 
Principal Investigator 
Dr Scott Harding, Cardiologist, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital 
Work phone No. 04 3855999 
E-mail: scott.harding@ccdhb.org.nz 
YAn abbreviated consent has been given to you prior to your angiogram due to the time 
constraints at the beginning of the procedure.  You now have the opportunity to discuss this study 
fully and decide whether or not you wish to participate.  If you no longer wish to participate in 
this study then all samples and clinical data collected at this point will be destroyed with no affect 
on your provision of healthcare.   
This study is investigating the levels of oxidative stress in the blood stream.  High levels of 
oxidative stress are found in patients experiencing heart attacks and this is known to cause 
damage to the blood vessels.  Antioxidants in the blood stream, such as glutathione peroxidase 
(GPx), provide a protective defense against high levels of oxidative stress and may slow the 
progression of damage.  We have previously shown that a low level of GPx increases the risk of 
worse outcomes after a heart attack.  What is not clear is how the levels of these enzymes change 
over time in a person experiencing a heart attack.  We aim to investigate how levels of GPx and 
markers of oxidative stress increase during a heart attack. 
How are people selected for this study, and who will select them? 
Patients who present to the Cardiology Angiography Suite who have been diagnosed as 
experiencing ST-segment elevation myocardial infarction, commonly know as a heart attack, will 
be invited by a study investigator to participate in this study. 
What will happen during the study? 
If you are happy to participate in this study then you will have up to 7 blood samples taken from 
you over a period of up to 72 hours during your admission.  A further blood sample will be taken 
6 weeks later when you attend your follow-up appointment in Cardiology Outpatients.   The blood 
will be taken by inserting a needle into a vein in your arm.  When we do this we will be taking 10 
mL (2 teaspoonful) in volume.  Your blood will be tested for GPx activity and markers for oxidative 
stress.  Any residual blood or components of blood will be destroyed following this.  Prior to tissue 
being disposed of, (using the standard Hospital process) a Maori blessing will be performed. We 
will also collect information about your medical history and treatment during your hospital 
admission.  
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As samples of human tissue will be taken during this study, there may be cultural issues 
associated with storing tissue that need to be discussed with your family/whanau.  Some Iwi 
disagree with storage of human tissue citing whakapapa and advise their people to consult prior 
to participation in research where this occurs.  To avoid problems at a later stage, we invite you 
to involve your family/whanau at all stages of the research.  However, we also acknowledge that 
individuals have the right to choose to participate. 
Confidentiality 
All data will be kept confidential. You will not be personally identified in any reports or 
publications that are developed throughout the course of this research. The data will appear 
grouped and include no markings that can be traced back to you. 
Participant Rights 
You do not have to accept this invitation to participate in this research. If you agree to participate 
you have the right to: 
1. Ask any questions about the study anytime during your participation  
2. Withdraw from the study at anytime without any affect on your future healthcare/continuing 
health care at anytime. 
Participation in this study will be stopped should the investigators of this study feel it not in your 
best interests to continue. 
What are the potential inconveniences of this study? 
Insertion of a needle into a vein can result in some swelling around the area.  This area may be a 
little tender after the needle is removed. It is possible that you could get an infection due to 
insertion of the needle. However this is very rare and we will take standard precautions to 
minimise this risk. 
What are the benefits of this study? 
This study will provide significant knowledge about the upregulation and variation of the GPx 
system and oxidative stress over a time period where a person is undergoing a heart attack.  We 
believe these systems are very dynamic and that the ability of the GPx system to increase will 
influence the levels of oxidative stress.  Understanding the dynamic relationship of these 
biomarkers will help us to identify those patients who have low levels of GPx and who may benefit 
from the effect of targeted antioxidant therapies in the future.  
There will be no direct benefit to you from participating in this study. 
Costs for the study 
It will not cost anything to take part in the study. 
Family or Whanau support 
You may have a friend, family or whanau support present.  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or Maori Health Support please contact Whanau Care Services: Trish Heuser - Specialty Clinical 
Nurse Cardiology 04 3855 999 ext 80948 
If you any questions or concerns about your rights as a participant in this research study you can 
contact an independent health and disability advocate. This is a free service provided under the 
Health and Disability Commissioner Act: Telephone: (NZ wide) 0800 555 050 
Free Fax: (NZ wide) 0800 2787 7678 (0800 2 SUPPORT) Email: (NZ wide) advocacy@hdc.org.nz 
Results 
A written report of the study will be available to participants on request. 
Compensation 
In the unlikely event of a physical injury as a result of participation in this study, you may be 
covered by the accident compensation legislation with its limitations. If you have any questions 
about ACC please feel free to ask the researcher for more information before you agree to take 
part in this trial. 
If you have any questions about ACC, contact your nearest ACC office or the investigator. 
Please feel free to contact the Study Investigators if you have any questions about this study. Their 
contact details are listed above and below. 
Statement of Approval 
This project is awaiting ethical approval by the Northern B Health and Disability Ethics 
Committee. 
Co-investigators 
Working with Dr Harding is the research team as follows: 
Assoc. Prof Peter Larsen, Clinical Physiologist, University of Otago, Wellington, Work phone 04 
385 5999 extn 5103 E-mail: Peter.larsen@otago.ac.nz 
Prof John Miller, Physiologist, Victoria University of Wellington, Work phone 04 463 6082 Email: 
john.h.miller@vuw.ac.nz 
Sarah Fairley, Interventional Cardiology Fellow, Cardiac Care Unit, Capital & Coast LTD, 
Wellington Hospital, Work Phone 0274995099 Email: sarah.fairly@ccdhb.org.nz 
Ana Holley, PhD Student, Cardiac Care Unit, Capital & Coast LTD, Wellington Hospital, Work 
phone 04 385 5999 Email: ana.holley@vuw.ac.nz 
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Participant Consent Form 
Investigation into the dynamics of the glutathione 
peroxidase system in STEMI patients 
 
 Request for interpreter:        Circle one 
English I wish to have an interpreter Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 
Māori E hiahia ana ahau ki tetahi kaiwhaka 
Māori/kaiwhaka pakeha korero 
Ae  Kao 
Cook 
Island 
Māori 
Ka inangaro au i tetai tangata uri reo Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata 
fakahokohoko kupu 
E Nakai 
Sāmoan Ou te mana’o ia i ai se fa’amatala upu Ioe Leai 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana 
Peletania ki na gagana o na motu o te 
Pahefika 
Ioe Leai 
Tongan Oku ou fiema’u ha fakatonulea Io Ikai 
 
 I have read and I understand the information sheet dated 9th December 2014 for 
volunteers taking part in the study designed to study the glutathione peroxidase system 
in STEMI patients.  I have had the opportunity to discuss this study.  I am satisfied with 
the answers I have been given. 
 I have had the opportunity to use whanau support or a friend to help me ask questions 
and understand the study. 
 I understand that taking part in this study is voluntary (my choice), and that I may 
withdraw from the study at any time, and this will no way affect my future health 
care/continuing health care. 
 I understand that my participation in this study is confidential and that no material that 
could identify me will be used in any reports on this study. 
 I understand the compensation provisions for this study. 
 I have had time to consider whether to take part in the study. 
 I know who to contact if I have any side effects from the study. 
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I wish to receive a copy of the results.  Yes  No 
 
I       (Participant’s full name) hereby consent to take 
part in this study and have received a copy of the signed consent form for my own records. 
 
 
 
 
 
 
 
 
 
 
 
Date Participant’s 
Signature 
Investigator/Researcher who explained 
study 
Date Investigator/Researcher Signature  
If applicable: 
 
Printed name of Interpreter 
 
Signature of Interpreter    Date 
  
